# Completeness, timing, and guidance of percutaneous coronary intervention for myocardial infarction and multivessel disease: a systematic review and network meta-analysis

Claudio Laudani, MD, MSc; Giovanni Occhipinti, MD; Antonio Greco, MD; Marco Spagnolo, MD; Daniele Giacoppo, MD, MSc, PhD; Davide Capodanno\*, MD, PhD

C. Laudani and G. Occhipinti contributed equally as first authors.

D. Giacoppo and D. Capodanno contributed equally as senior authors.

GUEST EDITOR: Franz-Josef Neumann, MD, PhD; Department of Cardiology and Angiology, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany

\*Corresponding author: Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "Rodolico – San Marco", University of Catania, via Santa Sofia 78, 95124, Catania, Italy. E-mail: dcapodanno@unict.it

This paper also includes supplementary data published online at: https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-24-00814

**BACKGROUND:** Trials assessing the prognostic influence of the completeness, timing, and guidance of percutaneous coronary intervention (PCI) for haemodynamically stable acute myocardial infarction (MI) and multivessel coronary artery disease (MV-CAD) have provided heterogeneous results.

**AIMS:** We aimed to comprehensively and simultaneously assess the available evidence on the completeness, timing, and guidance of PCI for acute MI and MV-CAD.

**METHODS:** Major electronic databases were screened to identify randomised trials comparing at least two PCI strategies for acute MI and MV-CAD. Recurrent MI and cardiac death were the primary and co-primary outcomes. Frequentist and Bayesian 5- and 3-node network meta-analyses were conducted along with complementary analyses to explore potential sources of heterogeneity.

**RESULTS:** Fourteen trials, including 14,433 patients, were pooled. In the frequentist 5-node analysis, angiography-guided immediate complete revascularisation (CR) reduced MI compared with infarct-related artery (IRA)-only revascularisation (hazard ratio [HR] 0.42, 95% confidence interval [CI]: 0.27-0.66), angiography-guided staged CR (HR 0.56, 95% CI: 0.36-0.87), and functionally guided staged CR (HR 0.37, 95% CI: 0.20-0.69). Functionally guided immediate CR was associated with reduced MI compared with IRA-only revascularisation (HR 0.53, 95% CI 0.34-0.82). The Bayesian analysis confirmed only an advantage of angiography-guided immediate CR over IRA-only revascularisation. In frequentist 3-node analysis, immediate CR reduced MI (HR 0.51, 95% CI: 0.37-0.70) and cardiac death (HR 0.68, 95% CI: 0.50-0.93) compared with IRA-only revascularisation and MI compared with staged CR (HR 0.55, 95% CI: 0.38-0.79). The Bayesian analysis did not confirm the reduction in cardiac death. CR, regardless of the type of guidance and especially when immediate, reduced the rate of any revascularisation compared with IRA-only revascularisation.

**CONCLUSIONS:** In haemodynamically stable patients with acute MI and non-complex MV-CAD undergoing PCI, immediate CR following successful culprit lesion treatment reduces recurrent MI compared with IRA-only revascularisation and staged CR. Whether CR is associated with reduced cardiovascular death remains uncertain.

KEYWORDS: complete revascularisation; coronary artery disease; multivessel coronary artery disease; myocardial infarction; percutaneous coronary intervention ultivessel coronary artery disease (MV-CAD) – defined as the presence of significant narrowing in multiple epicardial vessels – is observed in approximately 50% of patients presenting with acute coronary syndrome<sup>1</sup>. This condition is associated with worse clinical outcomes compared with single-vessel disease, especially in the context of ST-segment elevation myocardial infarction (STEMI)<sup>2-4</sup>. Complete revascularisation (CR) in patients with haemodynamically stable STEMI and MV-CAD undergoing primary percutaneous coronary intervention (PCI) has been associated with improved clinical outcomes compared with infarct-related artery (IRA)-only revascularisation<sup>5-9</sup>.

Nevertheless, in some pivotal trials, the improvement associated with CR compared with IRA-only revascularisation was primarily driven by recurrent revascularisation in the context of open-label designs, and only the COMPLETE and FIRE trials provided robust and unequivocal evidence on hard endpoints<sup>6-10</sup>. Yet, the FULL REVASC trial recently challenged previous conclusions, as no significant differences between CR and culprit lesion-only revascularisation were found, while relevant complementary questions about the optimal timing for non-IRA lesion revascularisation (i.e., during the index or staged PCI) and type of guidance (i.e., functional or exclusively angiographic) have remained underexplored for a long time<sup>6-8,11</sup>.

Over the last year, several trials comparing different PCI strategies in terms of completeness<sup>11</sup>, timing<sup>10,12-14</sup> and guidance<sup>11,15</sup> for the treatment of patients with acute MI and MV-CAD have yielded mixed results. Given the residual uncertainty surrounding this complex topic and the need for a comprehensive view accounting for the completeness of myocardial revascularisation, the timing of the intervention and the role of functional assessment in guiding PCI of non-IRA lesions, we decided to conduct comprehensive, updated, frequentist and Bayesian network meta-analyses comparing different revascularisation strategies for PCI in patients with acute MI and MV-CAD.

Editorial, see page e196

#### **Methods**

This meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements (**Supplementary Table 1**) and Cochrane Collaboration recommendations<sup>16,17</sup>. The protocol was registered with PROSPERO (CRD42023474321).

#### **ELIGIBILITY CRITERIA**

Studies satisfying the following criteria were included: (i) random allocation to at least two of the strategies among IRA-only revascularisation, angiography-guided immediate CR, angiography-guided staged CR, functionally guided

#### Impact on daily practice

In patients with haemodynamically stable acute myocardial infarction and non-complex multivessel coronary artery disease, immediate complete revascularisation (CR) reduces recurrent myocardial infarction and repeat revascularisation compared with infarct-related arteryonly revascularisation and staged CR, regardless of the type of guidance. These findings suggest that immediate angiography- or functionally guided CR should be pursued, when feasible, to improve long-term outcomes in this population.

immediate CR, and functionally guided staged CR; (ii) inclusion of patients with acute MI and MV-CAD; (iii) predominant implantation of drug-eluting stents; and (iv) clinical follow-up of at least 12 months.

## SEARCH, DATA EXTRACTION, AND QUALITATIVE ASSESSMENT

**Supplementary Table 2** illustrates the full search strategy. Randomised trials were systematically searched in PubMed/ Medline, Scopus, Web of Science and Cochrane. Reports were independently screened at the title and abstract levels and subsequently at the full-text level by three reviewers under the supervision of a senior reviewer. The quality of each trial was collegially evaluated by the Risk of Bias (RoB) 2 tool<sup>18</sup>. A list of included trials is provided in **Supplementary Appendix 1**.

#### OUTCOMES

The prespecified primary and co-primary outcomes of interest were MI and cardiac death, respectively. Secondary outcomes included all-cause death, definite or probable stent thrombosis, any revascularisation, ischaemia-driven revascularisation, a composite of major adverse cardiac events (MACE) as defined in the original trials, and periprocedural events, including stroke of any type, contrast-induced acute kidney injury and major bleeding.

#### STATISTICAL ANALYSIS

Categorical variables are reported as counts and proportions and continuous variables as means or medians.

The analyses were primarily conducted in a frequentist framework and secondarily replicated in a Bayesian framework to assess the robustness of conclusions<sup>17,19</sup>. Network meta-analyses allow the combination of evidence from both direct and indirect comparisons<sup>17</sup>. The analyses were based on a comprehensive 5-node network (i.e., IRA-only revascularisation, angiography-guided immediate CR, functionally guided immediate CR, angiography-guided

Abbreviations						
CR	complete revascularisation	MV-CAD	multivessel coronary artery disease			
Crl	credible interval	NSTEMI	non-ST-segment elevation myocardial infarction			
FFR	fractional flow reserve	PCI	percutaneous coronary intervention			
IRA	infarct-related artery	STEMI	ST-segment elevation myocardial infarction			
МІ	myocardial infarction	SUCRA	surface under the cumulative ranking curve			

staged CR, and functionally guided staged CR) and were subsequently replicated in a simplified 3-node closed-loop network (i.e., IRA-only revascularisation, immediate CR and staged CR) to gain statistical power.

Comparisons between the revascularisation strategies at the longest available follow-up, as defined in the original intention-to-treat analyses, were reported by hazard ratios (HR) and 95% confidence intervals (CI) or credible intervals (CrI), for frequentist and Bayesian frameworks, respectively, computed by hierarchical random-effects consistency models<sup>17</sup>. In-hospital outcomes were evaluated by using odds ratios (OR) and 95% CI or CrI, depending on the framework. For each outcome of interest, the network of evidence was visually and numerically assessed in terms of weights, comparisons, and individual trial influence<sup>20</sup>. Specifications on the priors used for Bayesian analyses, as well as the number of iterations, Gibbs sampling procedure, and assessment of chain convergence are reported in **Supplementary Appendix 2**.

The results are displayed by using relative-effect tables and forest plots. Each strategy was ranked according to its probability of having a certain rank (i.e., rankogram) and the surface under the cumulative ranking curve (SUCRA)<sup>21</sup>. Consistency between direct and indirect evidence within the network was assessed by node-splitting<sup>19,22</sup>. Between-trial heterogeneity was assessed by I<sup>2</sup> and  $\tau^2$  statistics<sup>17</sup>.

Sensitivity analyses were conducted by excluding the largest and most impactful trial (COMPLETE<sup>9</sup>), trials including non-STEMI (NSTEMI) patients, trials employing non-invasive guidance to achieve staged CR, trials deemed at high risk for bias according to the RoB 2 tool, trials aiming at culprit lesion-only instead of IRA-only revascularisation, trials with inconsistent revascularisation timing, and trials mostly contributing to heterogeneity based on common statistics. Meta-regression analyses were used to explore the influence of diabetes, 3-vessel disease and year of publication on outcomes.

Finally, the impact of small-study effects and publication bias were assessed by comparison-adjusted funnel plots complemented with Egger's tests<sup>17,22</sup>. Statistical analyses were conducted using R 4.3.2 (R Foundation for Statistical Computing) and Stata 18 (StataCorp).

#### Results

#### STUDY SELECTION AND NETWORK GEOMETRY

The selection process is summarised in **Supplementary Figure 1**. Fourteen eligible trials encompassing a total of 14,433 patients were included<sup>5-15,23-25</sup>. The FRAME-AMI<sup>15</sup>, FLOWER-MI<sup>24</sup>, and CROSS-AMI<sup>25</sup> trials were excluded from the complementary 3-node network meta-analysis (10 trials, 10,883 patients) as they did not compare strategies employed at different times.

**Figure 1** displays the geometry of the networks. The inclusion and exclusion criteria of each trial are reported in **Supplementary Table 3**. The definitions of CR used in each trial and the proportion of patients who eventually received a treatment strategy are reported in **Supplementary Table 4**.

#### STUDY CHARACTERISTICS

**Table 1** summarises the key trial characteristics. Nine trials included only patients with STEMI<sup>5-9,13,14,24,25</sup>, 4 trials included patients with acute MI undergoing emergency or urgent PCI of the culprit lesion<sup>10-12,15</sup>, and 1 trial included only patients with NSTEMI<sup>23</sup>. Overall, the mean age was 65.6 years, 20.8% were females, 19.7% had diabetes, and 25.1% had 3-vessel disease. The median time to revascularisation in trials



**Figure 1.** Network geometry. Network geometry of the 5- (A) and 3-node (B) analyses for the primary endpoint of myocardial infarction. Node size is proportional to the number of patients, and connection thickness is proportional to the number of trials contributing to the comparison. IRA: infarct-related artery

Table 1. Main characteristics of	of the	included	trials.
----------------------------------	--------	----------	---------

Trial (year)	Age, years	Female	Clinical presentation	Diabetes	Previous PCI	Previous myocardial infarction	Three- vessel disease	Chronic kidney disease	Follow-up, months
PRAMI (2013)⁵	62.0	102 (21.9)	STEMI: 465 (100)	83 (17.9)	NA	35 (7.5)	167 (35.9)	NA	23
CvLPRIT (2015) <sup>6,31</sup>	64.9	56 (18.9)	STEMI: 296 (100)	39 (13.2)	9 (3.0)	12 (4.1)	67 (22.6)	2 (0.7)	67ª
DANAMI-3- PRIMULTI (2015) <sup>7</sup>	63.5	121 (19.3)	STEMI: 627 (100)	71 (11.3)	NA	44 (7.0)	197 (31.4)	0 (0)	27ª
SMILE (2016) <sup>23</sup>	72.5	111 (20.5)	NSTEMI: 542 (100)	19 (4.1)	85 (15.7)	133 (24.5)	NA	NA	12 <sup>b</sup>
COMPARE- ACUTE (2017) <sup>8,32</sup>	62.5	202 (22.8)	STEMI: 885 (100)	137 (15.5)	69 (7.8)	70 (7.9)	285 (32.2)	10 (1.1)	36 <sup>b</sup>
CROSS-AMI (2019) <sup>24</sup>	62.0	48 (15.7)	STEMI: 306 (100)	44 (14.4)	NA	16 (5.3)	133 (43.5)	NA	12 <sup>b</sup>
COMPLETE (2019) <sup>9</sup>	62.0	816 (20.2)	STEMI: 4,041 (100)	787 (19.5)	283 (7.0)	302 (7.5)	901 (22.5)	81 (2.0)	36ª
FLOWER-MI (2021) <sup>25,33</sup>	61.5	205 (17.5)	STEMI: 1,171 (100)	189 (16.1)	103 (8.8)	76 (6.5)	266 (22.7)	23 (2.0)	42ª
FRAME-AMI (2023) <sup>15</sup>	63.3	88 (15.7)	STEMI: 265 (47.2) NSTEMI: 297 (52.8)	183 (32.6)	37 (6.6)	14 (2.5)	217 (38.6)	16 (2.8)	42ª
BIOVASC (2023) <sup>12</sup>	65.2	169 (22.2)	STEMI: 608 (39.9) NSTEMI: 790 (51.8) UA: 127 (8.3)	321 (21.0)	204 (13.4)	158 (10.4)	265 (17.4)	78 (5.1)	12 <sup>b</sup>
FIRE (2023) <sup>10</sup>	80.5	528 (36.5)	STEMI: 509 (35.2) NSTEMI: 936 (64.8)	463 (32.0)	257 (17.8)	220 (15.2)	432 (29.9)	662 (45.8)	12 <sup>b</sup>
COCUA (2023) <sup>14</sup>	62.7	41 (19.6)	STEMI: 209 (100)	79 (37.8)	2 (1.0)	2 (1.0)	39 (18.7)	NA	12ª
MULTISTARS AMI (2023) <sup>13</sup>	65.0	178 (21.2)	STEMI: 840 (100)	131 (15.6)	56 (6.7)	48 (5.7)	131 (15.6)	NA	12 <sup>b</sup>
FULL REVASC (2024) <sup>11</sup>	65.4	365 (23.7)	STEMI: 1,410 (91.4) NSTEMI: 132 (8.6)	249 (16.2)	134 (8.7)	125 (8.1)	487 (31.6)	NA	57ª

Data are presented as n (%) or mean value unless otherwise specified. <sup>a</sup>Median, <sup>b</sup>maximum. NA: not available; NSTEMI: non-ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; UA: unstable angina

of staged CR ranged from 1 to 37 days. Outcomes reported by each trial are illustrated in **Supplementary Table 5**, while trial-specific definitions of MI and MACE are reported in **Supplementary Table 6**.

#### **RISK OF BIAS**

**Supplementary Figure 2** and **Supplementary Figure 3** display the RoB 2 assessment, with detection of significant risk of bias in the outcomes assessment in two trials<sup>13,14</sup>. Some concerns surrounded the remaining trials, mostly because of the unfeasibility of a blinded design.

#### FIVE-NODE NETWORK META-ANALYSES: PRIMARY AND CO-PRIMARY OUTCOMES

Angiography-guided immediate CR significantly reduced MI compared with IRA-only revascularisation in both the frequentist (HR 0.42, 95% CI: 0.27-0.66) and Bayesian (HR 0.47, 95% CrI: 0.25-0.89) frameworks (Table 2, Central illustration, Supplementary Table 7). In the frequentist analysis, MI was also reduced by functionally guided immediate CR compared with IRA-only revascularisation (HR 0.53,

95% CI: 0.34-0.82), by angiography-guided immediate CR compared with angiography-guided staged CR (HR 0.56, 95% CI: 0.36-0.87) and functionally guided staged CR (HR 0.37, 95% CI: 0.20-0.69), and by functionally guided immediate CR compared with functionally guided staged CR (HR 0.47, 95% CI: 0.25-0.88) (Table 2, Central illustration). The overall heterogeneity was moderate (I<sup>2</sup>=39%,  $\tau^2$ =0.074) (Table 2, Central illustration). Angiography-guided immediate CR showed the highest probability of ranking first among all strategies (Supplementary Table 8). No sign of inconsistency was detected in either frequentist or Bayesian analysis (Figure 2, Supplementary Table 9).

The co-primary outcome of cardiovascular death did not significantly differ between revascularisation strategies in either the frequentist analysis or the Bayesian analysis **(Table 2, Central illustration, Supplementary Table 7)**, and moderate heterogeneity was detected ( $I^2=42\%$ ,  $\tau^2=0.166$ ). Functionally guided immediate CR ranked first in both the frequentist and Bayesian frameworks **(Supplementary Table 9)**. Significant inconsistency was detected for the comparisons of angiography-guided immediate CR versus IRA-only

Myocardial infarction							
	IRA only	Angio immediate CR	Angio staged CR	Functional immediate CR	Functional staged CR		
IRA only	-	2.36 [1.51-3.71]*	1.32 [0.85-2.03]	1.89 [1.22-2.92]*	0.88 [0.55-1.41]		
Angio immediate CR	0.42 [0.27-0.66]*	-	0.56 [0.36-0.87]*	0.80 [0.49-1.30]	0.37 [0.20-0.69]*		
Angio staged CR	0.76 [0.49-1.18]	1.80 [1.15-2.82]*	-	1.43 [0.82-2.50]	0.67 [0.37-1.20]		
Functional immediate CR	0.53 [0.34-0.82]*	1.25 [0.77-2.04]	0.70 [0.40-1.21]	_	0.47 [0.25-0.88]*		
Functional staged CR	1.14 [0.71-1.83]	2.69 [1.44-5.03]*	1.50 [0.84-2.68]	2.15 [1.14-4.05]*	-		
Heterogeneity: I <sup>2</sup> =39%; τ <sup>2</sup> =0.074							
Cardiac death							

	IRA only	Angio immediate CR	Angio staged CR	Functional immediate CR	Functional staged CR
IRA only	-	1.29 [0.65-2.57]	1.30 [0.67-2.52]	1.82 [0.92-3.62]	1.25 [0.60-2.59]
Angio immediate CR	0.77 [0.39-1.54]	-	1.01 [0.56-1.80]	1.41 [0.60-3.34]	0.97 [0.36-2.57]
Angio staged CR	0.77 [0.40-1.50]	0.99 [0.56-1.78]	-	1.41 [0.58-3.42]	0.96 [0.37-2.48]
Functional immediate CR	0.55 [0.28-1.09]	0.71 [0.30-1.67]	0.71 [0.29-1.73]	_	0.68 [0.25-1.85]
Functional staged CR	0.80 [0.39-1.67]	1.04 [0.39-2.76]	1.04 [0.40-2.69]	1.46 [0.54-3.97]	-
11 12 12 1000/ 2 0	100				

Heterogeneity: I²=42%;  $\tau^{2}$ =0.166

Death							
	IRA only	Angio immediate CR	Angio staged CR	Functional immediate CR	Functional staged CR		
IRA only	-	1.21 [0.86-1.71]	1.17 [0.85-1.61]	1.47 [1.07-2.04]*	0.82 [0.57-1.18]		
Angio immediate CR	0.83 [0.58-1.17]	-	0.97 [0.69-1.36]	1.22 [0.83-1.79]	0.68 [0.41-1.12]		
Angio staged CR	0.85 [0.62-1.18]	1.03 [0.73-1.46]	-	1.26 [0.83-1.91]	0.70 [0.43-1.13]		
Functional immediate CR	0.68 [0.49-0.94]*	0.82 [0.56-1.21]	0.79 [0.52-1.21]	_	0.56 [0.34-0.91]*		
Functional staged CR	1.22 [0.85-1.76]	1.48 [0.89-2.44]	1.43 [0.88-2.31]	1.80 [1.10-2.93]*	-		
Heterogeneity: $I^2=34\%$ ; $\tau^2=0.018$							

Definite or probable stent thrombosis							
	IRA only	Angio immediate CR	Angio staged CR	Functional immediate CR	Functional staged CR		
IRA only	-	0.81 [0.37-1.79]	0.72 [0.41-1.26]	1.39 [0.67-2.87]	0.18 [0.03-0.96]*		
Angio immediate CR	1.24 [0.56-2.74]	-	0.89 [0.46-1.72]	1.72 [0.71-4.14]	0.22 [0.04-1.23]		
Angio staged CR	1.39 [0.80-2.43]	1.13 [0.58-2.18]	-	1.93 [0.84-4.43]	0.25 [0.05-1.21]		
Functional immediate CR	0.72 [0.35-1.49]	0.58 [0.24-1.40]	0.52 [0.23-1.18]	-	0.13 [0.02-0.77]*		
Functional staged CR	5.57 [1.05-29.66]*	4.50 [0.81-24.89]	4.00 [0.83-19.35]	7.73 [1.30-45.89]*	-		

Heterogeneity: I<sup>2</sup>=0%;  $\tau^2$ =0

Any revascularisation							
IRA only	Angio immediate CR	Angio staged CR	Functional immediate CR	Functional staged CR			
-	2.99 [1.70-5.27]*	1.97 [1.06-3.69]*	2.40 [1.29-4.46]*	2.27 [1.15-4.45]*			
0.33 [0.19-0.59]*	-	0.66 [0.39-1.12]	0.80 [0.42-1.52]	0.76 [0.34-1.70]			
0.51 [0.27-0.95]*	1.51 [0.89-2.58]	-	1.21 [0.57-2.59]	1.15 [0.52-2.52]			
0.42 [0.22-0.78]*	1.25 [0.66-2.37]	0.82 [0.39-1.76]	_	0.95 [0.39-2.29]			
0.44 [0.22-0.87]*	1.32 [0.59-2.96]	0.87 [0.40-1.92]	1.06 [0.44-2.56]	-			
	IRA only  0.33 [0.19-0.59]* 0.51 [0.27-0.95]* 0.42 [0.22-0.78]* 0.44 [0.22-0.87]*	IRA only         Angio immediate CR           -         2.99 [1.70-5.27]*           0.33 [0.19-0.59]*         -           0.51 [0.27-0.95]*         1.51 [0.89-2.58]           0.42 [0.22-0.78]*         1.25 [0.66-2.37]           0.44 [0.22-0.87]*         1.32 [0.59-2.96]	IRA only         Angio immediate CR         Angio staged CR           -         2.99 [1.70-5.27]*         1.97 [1.06-3.69]*           0.33 [0.19-0.59]*         -         0.66 [0.39-1.12]           0.51 [0.27-0.95]*         1.51 [0.89-2.58]         -           0.42 [0.22-0.78]*         1.25 [0.66-2.37]         0.82 [0.39-1.76]           0.44 [0.22-0.87]*         1.32 [0.59-2.96]         0.87 [0.40-1.92]	IRA only         Angio immediate CR         Angio staged CR         Functional immediate CR           -         2.99 [1.70-5.27]*         1.97 [1.06-3.69]*         2.40 [1.29-4.46]*           0.33 [0.19-0.59]*         -         0.66 [0.39-1.12]         0.80 [0.42-1.52]           0.51 [0.27-0.95]*         1.51 [0.89-2.58]         -         1.21 [0.57-2.59]           0.42 [0.22-0.78]*         1.25 [0.66-2.37]         0.82 [0.39-1.76]         -           0.44 [0.22-0.87]*         1.32 [0.59-2.96]         0.87 [0.40-1.92]         1.06 [0.44-2.56]			

Heterogeneity: I<sup>2</sup>=81%;  $\tau^2$ =0.263 Ischaemia-driven revascularisation Functional immediate CR | Functional staged CR **IRA** only Angio immediate CR Angio staged CR IRA only 3.00 [1.36-6.64]\* 2.42 [1.10-5.36]\* 2.06 [0.97-4.39] 3.02 [1.13-8.08]\* 1.01 [0.33-3.08] Angio immediate CR 0.33 [0.15-0.74]\* 0.81 [0.39-1.67] 0.69 [0.28-1.69] Angio staged CR 1.24 [0.6-2.56] 0.85 [0.32-2.29] 1.25 [0.46-3.39] 0.41 [0.19-0.91]\* Functional immediate CR 0.49 [0.23-1.03] 1.46 [0.59-3.59] 1.18 [0.44-3.16] 1.47 [0.44-4.85] 0.68 [0.21-2.26] Functional staged CR 0.33 [0.12-0.88] 0.99 [0.32-3.04] 0.80 [0.29-2.18]

Heterogeneity: I<sup>2</sup>=84%;  $\tau^2$ =0.331

i viajor adverse cardiac events								
	IRA only	Angio immediate CR	Angio staged CR	Functional immediate CR	Functional staged CR			
IRA only	-	2.02 [1.38-2.96]*	1.51 [1.00-2.29]	2.08 [1.37-3.15]*	1.37 [0.87-2.17]			
Angio immediate CR	0.49 [0.34-0.72]*	-	0.75 [0.53-1.06]	1.03 [0.67-1.59]	0.68 [0.39-1.18]			
Angio staged CR	0.66 [0.44-1.00]	1.34 [0.94-1.90]	-	1.38 [0.83-2.29]	0.91 [0.53-1.56]			
Functional immediate CR	0.48 [0.32-0.73]*	0.97 [0.63-1.50]	0.73 [0.44-1.21]	-	0.66 [0.36-1.20]			
Functional staged CR	0.73 [0.46-1.15]	1.47 [0.85-2.56]	1.10 [0.64-1.90]	1.52 [0.83-2.76]	-			
Heterogeneity, $l^2 - 76\%$ , $\tau^2 - 0$	112							

Values are HRs [95% CIs]. \*Indicates a significant result when comparing treatment 1 (row) vs treatment 2 (column). CI: confidence interval; CR: complete revascularisation; HR: hazard ratio; IRA: infarct-related artery

#### EuroIntervention

#### Central Illustration

#### Comparison between CR strategies and IRA-only revascularisation.



timing (immediate or staged) and guidance (angiographic or functional) for achieving CR revascularisation were considered. In the three-node analyses, the timing for achieving CR was considered. CI: confidence interval; CR: complete revascularisation; CrI: credible interval; HR: hazard ratio; ID: ischaemia-driven; IRA: infarct-related artery; MACE: major adverse cardiac events

revascularisation (frequentist: p=0.028, Bayesian: p=0.040), functionally guided immediate CR versus IRA-only revascularisation (frequentist: p=0.021, Bayesian: p=0.025), and angiography-guided immediate CR versus functionally guided immediate CR (frequentist: p=0.027, Bayesian: p=0.025) (Figure 2, Supplementary Table 9).

#### FIVE-NODE NETWORK META-ANALYSES: SECONDARY OUTCOMES

Functionally guided immediate CR was the only strategy that reduced mortality compared to IRA-only revascularisation in the frequentist analysis (HR 0.68, 95% CI: 0.49-0.94), but this was not observed in the Bayesian analysis (Table 2, Central

illustration, Supplementary Table 7). Moderate heterogeneity was detected (I<sup>2</sup>=34%,  $\tau^2$ =0.018).

The incidence of stent thrombosis increased with functionally guided staged CR compared with IRA-only revascularisation (HR 5.57, 95% CI: 1.07-29.66) and functionally guided immediate CR (HR 7.73, 95% CI: 1.30-45.89) (Table 2). However, these effects were not detected in the Bayesian framework (Central illustration, Supplementary Table 7).

In the frequentist framework, compared with IRA-only revascularisation, any revascularisation was significantly lower with each of the four CR strategies (Central illustration, Table 2). Ischaemia-driven revascularisation was reduced



**Figure 2.** Node-splitting analysis for different revascularisation strategies compared with IRA-only revascularisation. Relative estimates for direct and indirect comparisons of revascularisation strategies compared with IRA-only revascularisation. CI: confidence interval; CR: complete revascularisation; CrI: credible interval; HR: hazard ratio; IRA: infarct-related artery;  $P_{inc}$ : P for inconsistency

by angiography-guided immediate CR, angiography-guided staged CR, and functionally guided staged CR (Table 2, Central illustration). In the Bayesian framework, angiographyguided and functionally guided immediate revascularisation reduced any revascularisation when compared with IRA-only revascularisation, and no significant differences were detected for ischaemia-driven revascularisation (Supplementary Table 7). High heterogeneity was detected for any revascularisation (I<sup>2</sup>=81%,  $\tau^2$ =0.263) and ischaemia-driven revascularisation (I<sup>2</sup>=84%,  $\tau^2$ =0.331). Significant inconsistency was detected for any revascularisation in the comparisons of angiography-guided staged CR versus IRA-only revascularisation (frequentist: p=0.008, Bayesian: p=0.007) and angiography-guided immediate versus angiography-guided staged CR (frequentist: p=0.011, Bayesian: p=0.002), as well as for ischaemia-driven revascularisation in the comparisons of angiography-guided staged CR versus IRA-only revascularisation (frequentist: p=0.029, Bayesian: p=0.049) and angiography-guided immediate versus angiography-guided staged CR (frequentist: p=0.002, Bayesian: p=0.022) (Supplementary Table 9). MACE was reduced with angiography-guided and functionally guided immediate CR (Table 2, Central illustration). In the Bayesian framework, the results in terms of MACE were consistent (Supplementary Table 7). High heterogeneity was detected for MACE (I<sup>2</sup>=76%,  $\tau^2$ =0.112).

## THREE-NODE NETWORK ANALYSES: PRIMARY AND CO-PRIMARY OUTCOMES

In the 3-node analysis, immediate CR significantly reduced MI incidence compared with both IRA-only revascularisation (HR 0.51, 95% CI: 0.37-0.70) and staged CR (HR 0.55, 95% CI: 0.38-0.79) (Table 3, Central illustration). Heterogeneity was low (I<sup>2</sup>=28%,  $\tau^2$ =0.046) (Table 3). Bayesian analysis reported consistent results for immediate CR versus IRA-only revascularisation (HR 0.59, 95% CrI: 0.37-0.89) (Supplementary Table 10). Immediate CR was associated with the highest probability of ranking first (Supplementary Table 11), and no evidence of inconsistency was detected (Figure 2, Supplementary Table 12).

Immediate CR significantly reduced the incidence of cardiac death compared with IRA-only revascularisation in the frequentist analysis (HR 0.68, 95% CI: 0.50-0.93), but not in the Bayesian analysis, with undetectable heterogeneity (I<sup>2</sup>=0%,  $\tau^2$ <0.001) (Table 3, Central illustration, Supplementary Table 10). Regardless of the statistical framework, immediate CR had the highest probability

#### Table 3. Frequentist random-effects network meta-analysis – 3-node analysis.

Myocardial infarction	Myocardial infarction						
	IRA only	Immediate CR	Staged CR				
IRA only	_	1.97 [1.43-2.73]*	1.08 [0.80-1.45]				
Immediate CR	0.51 [0.37-0.70]*	_	0.55 [0.38-0.79]*				
Staged CR	0.93 [0.69-1.25]	1.83 [1.27-2.63]*	_				
Heterogeneity: $I^2=28\%$ ; $\tau^2=0.046$							
Cardiac death							
	IRA only	Immediate CR	Staged CR				
IRA only	_	1.46 [1.08-1.99]*	1.21 [0.94-1.55]				
Immediate CR	0.68 [0.50-0.93]*	_	0.82 [0.59-1.16]				
Staged CR	0.83 [0.65-1.06]	1.21 [0.86-1.70]	-				
Heterogeneity: I <sup>2</sup> =2%; τ <sup>2</sup> <0.001							
Death							
	IRA only	Immediate CR	Staged CR				
IRA only	_	1.30 [1.04-1.63]*	1.03 [0.85-1.24]				
Immediate CR	0.77 [0.61-0.96]*	_	0.79 [0.61-1.02]				
Staged CR	0.97 [0.80-1.17]	1.26 [0.98-1.63]	-				
Heterogeneity: I <sup>2</sup> =31%; τ <sup>2</sup> =0.001							
Definite or probable stent thrombo	osis						
	IRA only	Immediate CR	Staged CR				
IRA only	_	1.10 [0.59-2.04]	0.81 [0.48-1.37]				
Immediate CR	0.91 [0.49-1.69]	_	0.74 [0.41-1.34]				
Staged CR	1.23 [0.73-2.08]	1.35 [0.75-2.44]	_				
Heterogeneity: I <sup>2</sup> =0%; $\tau^2$ =0							
Any revascularisation							
	IRA only	Immediate CR	Staged CR				
IRA only	_	2.82 [1.71-4.64]*	2.00 [1.18-3.38]*				
Immediate CR	0.35 [0.22-0.58]*	_	0.71 [0.42-1.19]				
Staged CR	0.50 [0.30-0.84]*	1.41 [0.84-2.36]	-				
Heterogeneity: I <sup>2</sup> =84%; $\tau^2$ =0.296							
Ischaemia-driven revascularisation	on						
	IRA only	Immediate CR	Staged CR				
IRA only	_	2.53 [1.30-4.95]*	2.34 [1.12-4.91]*				
Immediate CR	0.39 [0.20-0.77]*	_	0.92 [0.44-1.93]				
Staged CR	0.43 [0.20-0.90]*	1.08 [0.52-2.26]	-				
Heterogeneity: I <sup>2</sup> =89%; $\tau^2$ =0.400							
Major adverse cardiac events							
	IRA only	Immediate CR	Staged CR				
IRA only	_	2.01 [1.53-2.63]*	1.45 [1.11-1.91]*				
Immediate CR	0.50 [0.38-0.65]*	-	0.72 [0.55-0.96]*				
Staged CR	0.69 [0.52-0.91]*	1.38 [1.05-1.83]*	-				
Heterogeneity: I <sup>2</sup> =77%; $\tau^2$ =0.072							

Values are HRs [95% CIs]. \*Indicates a significant result when comparing treatment 1 (row) vs treatment 2 (column). CI: confidence interval; CR: complete revascularisation; HR: hazard ratio; IRA: infarct-related artery

of ranking first (Supplementary Table 11). No significant inconsistency was detected (Figure 2, Supplementary Table 12).

**THREE-NODE NETWORK ANALYSES: SECONDARY OUTCOMES** Consistently with MI and cardiac death, immediate CR was associated with a significant reduction in mortality compared with IRA-only revascularisation in the frequentist framework (**Table 3, Supplementary Table 10**). While stent thrombosis was comparable between strategies, both immediate and staged CR reduced ischaemia-driven revascularisation compared with IRA-only revascularisation in the frequentist analysis but not in the Bayesian framework (**Table 3, Supplementary Table 10**).

High between-trial heterogeneity was detected for any (I<sup>2</sup>=84%,  $\tau^2$ =0.296) and ischaemia-driven revascularisation (I<sup>2</sup>=89%,  $\tau^2$ =0.400). Significant inconsistency was detected for both outcomes (**Supplementary Table 12**). Immediate CR reduced MACE compared with both IRA-only revascularisation and staged CR, and staged CR reduced MACE compared to IRA-only revascularisation.

#### PERIPROCEDURAL OUTCOMES

No significant differences between strategies in terms of periprocedural stroke, major bleeding, or contrast-induced acute kidney injury were detected in either the 5- or 3-node analysis, independently of the framework adopted, with no sign of heterogeneity or inconsistency (Supplementary Table 13-Supplementary Table 18).

#### SENSITIVITY ANALYSES

The leave-one-out analysis revealed that most of the heterogeneity for MI, cardiac death and all-cause mortality was introduced by the FRAME-AMI trial (Supplementary Table 19-Supplementary Table 38). Sensitivity analyses, after excluding the largest trial, trials with NSTEMI patients, the only trial employing non-invasive guidance, trials deemed at high risk of bias, trials comparing CR with culprit lesion-only revascularisation, trials with inconsistent revascularisation timing and the trial introducing most heterogeneity, were generally consistent with the main analysis, and only limited variations in estimates were observed (Supplementary Table 39-Supplementary Table 64). Meta-regressions showed no significant influence of key variables on treatment effects (Supplementary Table 65-Supplementary Table 70). Pairwise comparisons of trials focusing on CR versus IRA-only revascularisation showed significant reductions in MI, any revascularisation and MACE, with consistent results between the frequentist and Bavesian frameworks (Supplementary Table 71-Supplementary Table 74).

#### Discussion

This meta-analysis of randomised clinical trials comparing different PCI-based revascularisation strategies in patients with acute MI and MV-CAD without haemodynamic instability consistently shows that CR is associated with a significant reduction in recurrent MI compared with IRAonly revascularisation. In a 5-node analysis attempting to simultaneously address questions about the optimal timing and guidance to achieve CR, both angiography-guided and functionally guided immediate CR were associated with 58% and 47% relative risk reductions in MI, respectively, compared with IRA-only revascularisation. Conversely, no decrease in MI was found with staged CR, regardless of the type of guidance. A 3-node analysis not only confirmed a reduction in MI after immediate CR compared with IRAonly revascularisation but also showed a 45% relative risk reduction after immediate CR compared with staged CR.

Based on these results, it is reasonable to hypothesise that preventive treatment of significant non-culprit lesions reduces the occurrence of spontaneous MI compared with IRA-only revascularisation, though evidence from available trials has yielded mixed results<sup>5-9,13,14,24,25</sup>. In particular, the large-scale randomised COMPLETE trial showed

that CR reduces cardiovascular death or recurrent MI compared with culprit lesion-only revascularisation (HR 0.74, 95% CI: 0.60-0.91), primarily driven by a reduced incidence of recurrent MI (HR 0.68, 95% CI: 0.53-0.86), as cardiovascular death did not significantly differ between groups<sup>9</sup>. Later, in the FIRE trial<sup>10</sup>, patients assigned to CR exhibited a lower incidence of MACE as a result of consistent reductions in mortality (HR 0.70, 95% CI: 0.51-0.96), recurrent MI (HR 0.62, 95% CI: 0.40-0.97), and ischaemia-driven revascularisation (HR 0.63, 95% CI: 0.40-0.98). However, in the DANAMI-3-PRIMULTI and COMPARE-ACUTE trials, the significant reductions in MACE after CR compared with IRA-only revascularisation were essentially due to reduced repeat revascularisation, which is a softer endpoint (HR 0.31, 95% CI: 0.18-0.53 and HR 0.32, 95% CI: 0.20-0.54, respectively)7,8. More importantly, the large-scale FULL REVASC trial did not find significant benefits with functionally guided staged CR compared with IRA-only revascularisation, apart from a reduction in repeat revascularisation (HR 0.59, 95% CI: 0.45-0.78), at the expense of higher risk of stent thrombosis (HR 2.80, 95% CI: 1.18-6.67)<sup>11</sup>.

The timing for achieving CR may partially explain the differences across trials, and immediate CR seems to align with the mechanisms of acute MI, wherein the improved collateral circulation provided by CR reduces the extent of myocardial tissue transitioning into necrosis in areas supplied by the culprit lesion. In this regard, the present meta-analysis not only indicates a significant reduction in recurrent MI associated with immediate CR but also reveals that staged CR may be associated with fewer benefits compared with IRA-only revascularisation. Yet there is heterogeneity surrounding this result, and some considerations are required. In particular, the MULTISTARS AMI and BIOVASC trials specifically designed to address the question of CR timing have indicated advantages of immediate compared to staged CR in patients presenting with acute MI and MV-CAD<sup>12,13</sup>. However, in both trials the primary composite endpoints were composed of a broad number of outcomes with mixed specificity, and the conclusions in terms of MI and repeat revascularisation were associated with some areas of uncertainty. More specifically, in MULTISTARS AMI, 56.7% of non-fatal MIs in the two groups were periprocedural, only 31.8% of non-fatal MIs in the staged CR group occurred before achieving CR, and the difference in non-fatal MIs did not significantly differ between CR strategies after excluding periprocedural events (HR 0.62, 95% CI: 0.20-1.89)13. In the BIOVASC trial, there was a significant reduction in MI in patients assigned to immediate CR compared to those assigned to staged CR12. However, the difference was driven by an excess of periprocedural events in the staged CR group compared with the immediate CR group (0.1% vs 1.4%), and in the staged CR group only 44.1% of events occurred in the time window between the index and staged revascularisations<sup>12</sup>. Adjudicating periprocedural MI associated with immediate CR performed in the context of acute MI, primarily STEMI, may be challenging as the diagnosis relies on the definition used, and the index event may mask recurrences<sup>26</sup>. In this context, the difference in MI between immediate and complete CRs may reflect the

dissimilar preprocedural troponin levels between the index and staged revascularisation times. This uncertainty is further amplified by a prespecified mechanistic substudy of the CvLPRIT trial showing that CR not only failed to show significant reductions in total (12.6% vs 13.5%; p=0.57) and IRA infarct size (12.1% vs 12.2%; p=0.68) on 48- to 72-hour cardiac magnetic resonance imaging, compared with IRA-only revascularisation, but was also associated with increased periprocedural MI (22.4% vs 10.5%; p=0.02)<sup>27</sup>. For these reasons, considering the limited statistical power for hard individual endpoints of BIOVASC and MULTISTARS AMI as well as the heterogeneity in the population of interest and some inconsistent findings between the two trials, larger trials and high-quality mechanistic studies are still required to draw more robust conclusions on the benefits of different timings to achieve CR.

Against this background, demonstrating a significant reduction in cardiac death associated with different CR strategies is essential. Our 3-node meta-analysis showed that immediate CR is associated with a 32% relative risk reduction in cardiac death compared with IRA-only revascularisation, without signals of inconsistency, but the Bayesian 3-node analysis showed less marked effects, and the 5-node analysis did not reveal significant differences between strategies. Importantly, signs of network inconsistency were found in the 5-node analyses. In network meta-analyses, direct and indirect comparisons between treatments are assumed to derive from studies with reasonable similarity, ensuring the transitivity of information across the network<sup>16,20</sup>. When direct and indirect evidence show significant disagreement for a given comparison, the transitivity is locally violated<sup>16,20</sup>. In light of the inconsistency observed, there are conflicting conclusions, possibly deriving from trials employing functionally guided CR. Indeed, the COMPARE-ACUTE, FULL REVASC, FLOWER-MI, and FRAME-AMI trials showed conflicting results for functionally guided CR. Specifically, functionally guided immediate CR reduced repeat revascularisation compared with IRA-only revascularisation in the COMPARE-ACUTE trial<sup>8</sup>. FULL REVASC showed no benefit of predominantly staged functionally guided CR compared with culprit lesion-only revascularisation<sup>11</sup>. While FLOWER-MI showed no benefit of functionally guided staged CR compared with angiography-guided CR, FRAME-AMI indicated reduced cardiovascular mortality and MI by functionally guided revascularisation compared with angiography-guided CR15,25. The absence of uniform and objective methods to define the significance of non-culprit disease, with some trials using angiographic (essentially visual) and others functional assessment, has introduced heterogeneity across studies and influenced the identification of lesions requiring treatment<sup>28</sup>.

The present meta-analysis also indicates a substantial reduction in repeat revascularisation associated with CR compared with IRA-only revascularisation. The 5-node analysis revealed that these results occur regardless of the timing and type of guidance of CR, with relative risk reductions ranging from 49% to 67%, no significant differences between CR strategies, and consistent results in the 3-node and pairwise analyses. However, the amount of heterogeneity detected was not negligible. In the context of

trials with unblinded treatment allocation, the awareness of residual non-culprit lesions may have magnified the incidence of repeat revascularisation over time in patients assigned to IRA-only revascularisation compared with those assigned to CR. Consistently, the results in terms of ischaemia-driven revascularisation were less marked compared with those in terms of any revascularisation. In addition, although the similar trends in terms of MI and ischaemia-driven revascularisation support an increased occurrence of MI in patients assigned to IRA-only revascularisation compared to CR, other results across analyses revealed inconsistency between the two outcomes due to significant reductions in MI without a concomitant reduction in ischaemia-driven revascularisation. These findings require more analysis, as they cannot be further properly inspected at the aggregate level.

Finally, the increased incidence of stent thrombosis associated with functionally guided staged CR was driven by the observation of a significant excess of events in the FULL REVASC trial. However, this finding has no clear procedureor strategy-related explanation.

#### Limitations

Some considerations are required when interpreting the results of this meta-analysis. First, the absence of individual patient data did not allow for an evaluation of confounders on the overall results, though sensitivity analyses and meta-regressions mitigated some concerns. Second, some approximations were required in the definition of the strategies employed across trials. Indeed, the proportions of immediate and staged revascularisation across trials that did not impose a specific timing showed some heterogeneity. However, this condition influenced only the 5-node analysis, and, except for FRAME-AMI, it was possible in all the other trials to identify a clearly predominant timing of CR. Similarly, per-protocol analyses reported across trials did not present overall sufficient granularity to account for the patients who eventually did not receive the allocated strategy in the context of a per-protocol sensitivity analysis. Third, the timing for achieving CR was physician driven and was dissimilar across trials. Individual patient data would be necessary to properly address these latter two points. Fourth, the use of intravascular imaging was limited, with possible implications on procedural outcomes<sup>29</sup>. Lastly, the coronary artery disease patterns included across trials may not be representative of more complex conditions, limiting the generalisability of some results<sup>30</sup>.

#### Conclusions

In haemodynamically stable patients with non-complex MV-CAD undergoing urgent PCI for acute MI, immediate CR following successful culprit-lesion treatment, whether angiographically or functionally guided, reduces recurrent MI and repeat revascularisation compared with IRA-only revascularisation and staged CR. Staged CR is associated with reduced benefits compared with IRA-only revascularisation, generally limited to reduced repeat revascularisation. Although functionally guided immediate CR may reduce mortality compared with IRA-only revascularisation, this conclusion was highly inconsistent across analyses.

#### Authors' affiliation

Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "Rodolico - San Marco", University of Catania, Catania, Italy

#### **Guest Editor**

This paper was guest edited by Franz-Josef Neumann, MD, PhD; Department of Cardiology and Angiology, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany.

#### Funding

The study was supported by the Department of General Surgery and Surgical-Medical Specialties of the University of Catania, Catania, Italy.

#### Conflict of interest statement

The authors have no conflicts of interest relevant to the contents of this paper to declare. The Guest Editor reports consultancy fees from Novartis and Meril Life Sciences; speaker honoraria from Boston Scientific, Amgen, Daiichi Sankyo, and Meril Life Sciences; reports speaker honoraria paid to his institution from BMS/Pfizer, Daiichi Sankyo, Boston Scientific, Siemens, and Amgen; and research grants paid to his institution from Boston Scientific and Abbott.

#### References

- 1. Faro DC, Laudani C, Agnello FG, Ammirabile N, Finocchiaro S, Legnazzi M, Mauro MS, Mazzone PM, Occhipinti G, Rochira C, Scalia L, Spagnolo M, Greco A, Capodanno D. Complete Percutaneous Coronary Revascularization in Acute Coronary Syndromes With Multivessel Coronary Disease: A Systematic Review. JACC Cardiovasc Interv. 2023;16:2347-64.
- 2. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, Stone GW. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28:1709-16.
- 3. Jensen LO, Terkelsen CJ, Horváth-Puhó E, Tilsted HH, Maeng M, Junker A, Lassen JF, Thuesen L, Sørensen HT, Thayssen P. Influence of multivessel disease with or without additional revascularization on mortality in patients with ST-segment elevation myocardial infarction. Am Heart J. 2015;170:70-8.
- 4. Park DW, Clare RM, Schulte PJ, Pieper KS, Shaw LK, Califf RM, Ohman EM, Van de Werf F, Hirji S, Harrington RA, Armstrong PW, Granger CB, Jeong MH, Patel MR. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014;312:2019-27.
- 5. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG; PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369: 1115-23.
- 6. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015:65:963-72.
- 7. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemmensen P, De Backer O, Ravkilde J, Tilsted HH, Villadsen AB, Aarøe J, Jensen SE, Raungaard B, Køber L; DANAMI-3-PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease

(DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015:386:665-71.

- 8. Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Ong PJ, Hambrecht R, Angerås O, Richardt G, Omerovic E; Compare-Acute Investigators. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med. 2017;376:1234-44.
- 9. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B, Di Pasquale G, López-Sendón J, Faxon DP, Mauri L, Rao SV, Feldman L, Steg PG, Avezum Á, Sheth T, Pinilla-Echeverri N, Moreno R, Campo G, Wrigley B, Kedev S, Sutton A, Oliver R, Rodés-Cabau J, Stanković G, Welsh R, Lavi S, Cantor WJ, Wang J, Nakamya J, Bangdiwala SI, Cairns JA; COMPLETE Trial Steering Committee and Investigators. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019;381:1411-21.
- 10. Biscaglia S, Guiducci V, Escaned J, Moreno R, Lanzilotti V, Santarelli A, Cerrato E, Sacchetta G, Jurado-Roman A, Menozzi A, Amat Santos I, Díez Gil JL, Ruozzi M, Barbierato M, Fileti L, Picchi A, Lodolini V, Biondi-Zoccai G, Maietti E, Pavasini R, Cimaglia P, Tumscitz C, Erriquez A, Penzo C, Colaiori I, Pignatelli G, Casella G, Iannopollo G, Menozzi M, Varbella F, Caretta G, Dudek D, Barbato E, Tebaldi M, Campo G; FIRE Trial Investigators. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction. N Engl J Med. 2023;389:889-98.
- 11. Böhm F, Mogensen B, Engstrøm T, Stankovic G, Srdanovic I, Lønborg J, Zwackman S, Hamid M, Kellerth T, Lauermann J, Kajander OA, Andersson J, Linder R, Angerås O, Renlund H, Erglis A, Menon M, Schultz C, Laine M, Held C, Rück A, Östlund O, James S; FULL REVASC Trial Investigators. FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. N Engl J Med. 2024;390:1481-92.
- 12. Diletti R, den Dekker WK, Bennett J, Schotborgh CE, van der Schaaf R, Sabaté M, Moreno R, Ameloot K, van Bommel R, Forlani D, van Reet B, Esposito G, Dirksen MT, Ruifrok WPT, Everaert BRC, Van Mieghem C, Elscot JJ, Cummins P, Lenzen M, Brugaletta S, Boersma E, Van Mieghem NM; BIOVASC Investigators. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, noninferiority, randomised trial. Lancet. 2023;401:1172-82.
- 13. Stähli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, Kesterke R, Nordbeck P, Witzenbichler B, Lang IM, Kessler M, Valina C, Dibra A, Rohla M, Moccetti M, Vercellino M, Gaede L, Bott-Flügel L, Jakob P, Stehli J, Candreva A, Templin C, Schindler M, Wischnewsky M, Zanda G, Quadri G, Mangner N, Toma A, Magnani G, Clemmensen P, Lüscher TF, Münzel T, Schulze PC, Laugwitz KL, Rottbauer W, Huber K, Neumann FJ, Schneider S, Weidinger F, Achenbach S, Richardt G, Kastrati A, Ford I, Maier W, Ruschitzka F; MULTISTARS AMI Investigators. Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2023;389:1368-79.
- 14. Park S, Rha SW, Choi BG, Cho JH, Park SH, Lee JB, Kim YH, Park SM, Choi JW, Park JY, Shin ES, Lee JB, Suh J, Chae JK, Choi YJ, Jeong MH, Cha KS, Lee SW, Kim U, Kim GC, Choi WG, Cho YH, Cho DK, Ahn J, Suh SY, Choi SY, Byun JK, Cha JA, Hyun SJ, Kim JB, Choi CU, Park CG. Immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: results from a prematurely discontinued randomized multicenter trial. Am Heart J. 2023;259:58-67.
- 15. Lee JM, Kim HK, Park KH, Choo EH, Kim CJ, Lee SH, Kim MC, Hong YJ, Ahn SG, Doh JH, Lee SY, Park SD, Lee HJ, Kang MG, Koh JS, Cho YK, Nam CW, Koo BK, Lee BK, Yun KH, Hong D, Joh HS, Choi KH, Park TK, Yang JH, Song YB, Choi SH, Gwon HC, Hahn JY; FRAME-AMI Investigators. Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial. Eur Heart J. 2023;44:473-84.
- 16. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis IP, Straus S, Thorlund K, Jansen IP, Mulrow C, Catalá-López F. Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777-84.
- 17. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester, UK: John Wiley & Sons, 2019.

- 18. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:14898.
- 19. Sadeghirad B, Foroutan F, Zoratti MJ, Busse JW, Brignardello-Petersen R, Guyatt G, Thabane L. Theory and practice of Bayesian and frequentist frameworks for network meta-analysis. *BMJ Evid Based Med.* 2023;28:204-9.
- **20.** Efthimiou O, Debray TP, van Valkenhoef G, Trelle S, Panayidou K, Moons KG, Reitsma JB, Shang A, Salanti G; GetReal Methods Review Group. GetReal in network meta-analysis: a review of the methodology. *Res Synth Methods*. 2016;7:236-63.
- Salanti G, Nikolakopoulou A, Efthimiou O, Mavridis D, Egger M, White IR. Introducing the Treatment Hierarchy Question in Network Meta-Analysis. *Am J Epidemiol.* 2022;191:930-8.
- 22. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. *PLoS One.* 2014;9:e99682.
- 23. Sardella G, Lucisano L, Garbo R, Pennacchi M, Cavallo E, Stio RE, Calcagno S, Ugo F, Boccuzzi G, Fedele F, Mancone M. Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The SMILE Trial. J Am Coll Cardiol. 2016;67:264-72.
- 24. Calviño-Santos R, Estévez-Loureiro R, Peteiro-Vázquez J, Salgado-Fernández J, Rodríguez-Vilela A, Franco-Gutiérrez R, Bouzas-Mosquera A, Rodríguez-Fernández JÁ, Mesías-Prego A, González-Juanatey C, Aldama-López G, Piñón-Esteban P, Flores-Ríos X, Soler-Martín R, Seoane-Pillado T, Vázquez-González N, Muñiz J, Vázquez-Rodríguez JM. Angiographically Guided Complete Revascularization Versus Selective Stress Echocardiography-Guided Revascularization in Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Disease: The CROSS-AMI Randomized Clinical Trial. Circ Cardiovasc Interv. 2019;12:e007924.
- 25. Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, le Bras A, Gallet R, Khalife K, Morelle JF, Motreff P, Lemesle G, Dillinger JG, Lhermusier T, Silvain J, Roule V, Labèque JN, Rangé G, Ducrocq G, Cottin Y, Blanchard D, Charles Nelson A, De Bruyne B, Chatellier G, Danchin N; FLOWER-MI Study Investigators. Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. N Engl J Med. 2021;385:297-308.
- **26.** Spagnolo M, Occhipinti G, Laudani C, Greco A, Capodanno D. Periprocedural myocardial infarction and injury. *Eur Heart J Acute Cardiovasc Care.* 2024;13:433-45.
- 27. McCann GP, Khan JN, Greenwood JP, Nazir S, Dalby M, Curzen N, Hetherington S, Kelly DJ, Blackman DJ, Ring A, Peebles C, Wong J, Sasikaran T, Flather M, Swanton H, Gershlick AH. Complete Versus Lesion-Only Primary PCI: The Randomized Cardiovascular MR CvLPRIT Substudy. J Am Coll Cardiol. 2015;66:2713-24.
- 28. Escaned J, Berry C, De Bruyne B, Shabbir A, Collet C, Lee JM, Appelman Y, Barbato E, Biscaglia S, Buszman PP, Campo G, Chieffo A, Colleran R, Collison D, Davies J, Giacoppo D, Holm NR, Jeremias A, Paradies V, Piróth Z, Raposo L, Roguin A, Rudolph T, Sarno G, Sen S, Toth GG, Van Belle E, Zimmermann FM, Dudek D, Stefanini G, Tarantini G. Applied coronary physiology for planning and guidance of percutaneous coronary interventions. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology. EuroIntervention. 2023;19:464-81.
- 29. Giacoppo D, Laudani C, Occhipinti G, Spagnolo M, Greco A, Rochira C, Agnello F, Landolina D, Mauro MS, Finocchiaro S, Mazzone PM, Ammirabile N, Imbesi A, Raffo C, Buccheri S, Capodanno D. Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis. *Circulation.* 2024;149:1065-86.
- 30. Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, Wiebe J, Joner M, Hochholzer W, Laugwitz KL, Schunkert H, Kastrati A, Kufner S. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. *Eur Heart J.* 2023;44:1343-57.

- 31. Gershlick AH, Banning AS, Parker E, Wang D, Budgeon CA, Kelly DJ, Kane PO, Dalby M, Hetherington SL, McCann GP, Greenwood JP, Curzen N. Long-Term Follow-Up of Complete Versus Lesion-Only Revascularization in STEMI and Multivessel Disease: The CvLPRIT Trial. J Am Coll Cardiol. 2019;74:3083-94.
- 32. Smits PC, Laforgia PL, Abdel-Wahab M, Neumann FJ, Richardt G, Boxma-de Klerk B, Lunde K, Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Frederix GW, Omerovic E. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction: three-year follow-up with cost benefit analysis of the Compare-Acute trial. *EuroIntervention*. 2020;16:225-32.
- 33. Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, Ngaleu Siaha F, Gallet R, Khalife K, Morelle JF, Motreff P, Lemesle G, Dillinger JG, Lhermusier T, Silvain J, Roule V, Labèque JN, Rangé G, Ducrocq G, Cottin Y, Blanchard D, Charles Nelson A, Djadi-Prat J, Chatellier G, Danchin N; FLOWER-MI Study Investigators. Three-Year Outcomes With Fractional Flow Reserve-Guided or Angiography-Guided Multivessel Percutaneous Coronary Intervention for Myocardial Infarction. *Circ Cardiovasc Interv.* 2024;17:e013913.

#### Supplementary data

Supplementary Appendix 1. List of included trials.

**Supplementary Appendix 2.** Supplementary methods: Bayesian models.

Supplementary Table 1. PRISMA-NMA checklist.

Supplementary Table 2. Search strategy.

**Supplementary Table 3.** Inclusion and exclusion criteria across trials.

**Supplementary Table 4.** Definition of complete revascularisation in intervention and control arms and percentages of crossover.

Supplementary Table 5. Available endpoints across trials.

**Supplementary Table 6.** Myocardial infarction and MACE definitions across trials.

**Supplementary Table 7.** Bayesian random-effects network meta-analysis – 5-node analysis.

**Supplementary Table 8.** Frequentist and Bayesian randomeffects network meta-analysis rank probabilities and SUCRA – 5-node analysis.

**Supplementary Table 9.** Node-splitting analysis for the frequentist and Bayesian frameworks – 5-node analysis.

**Supplementary Table 10.** Bayesian random-effects network meta-analysis – 3-node analysis.

**Supplementary Table 11.** Frequentist and Bayesian rank probabilities and SUCRA – 3-node analysis.

**Supplementary Table 12.** Frequentist and Bayesian network node-splitting analysis – 3-node analysis.

**Supplementary Table 13.** Frequentist random-effects network meta-analysis for periprocedural outcomes – 5-node analysis. **Supplementary Table 14.** Bayesian random-effects network meta-analysis for periprocedural outcomes – 5-node analysis. **Supplementary Table 15.** Node-splitting analysis for periprocedural outcomes – 5-node analysis.

Supplementary Table 16. Frequentist random-effects network meta-analysis for periprocedural outcomes – 3-node analysis.
 Supplementary Table 17. Bayesian random-effects network meta-analysis for periprocedural outcomes – 3-node analysis.
 Supplementary Table 18. Node-splitting analysis for periprocedural outcomes – 3-node analysis.

**Supplementary Table 19.** Influence analysis for myocardial infarction – 5-node analysis.

**Supplementary Table 20.** Influence analysis for cardiac death – 5-node analysis.

**Supplementary Table 21.** Influence analysis for all-cause death – 5-node analysis.

**Supplementary Table 22.** Influence analysis for definite or probable stent thrombosis – 5-node analysis.

**Supplementary Table 23.** Influence analysis for MACE – *5*-node analysis.

**Supplementary Table 24.** Influence analysis for any revascularisation – 5-node analysis.

**Supplementary Table 25.** Influence analysis for ischaemiadriven revascularisation – 5-node analysis.

**Supplementary Table 26.** Influence analysis for stroke – 5-node analysis.

**Supplementary Table 27.** Influence analysis for contrastinduced acute kidney injury – 5-node analysis.

**Supplementary Table 28.** Influence analysis for major bleeding – 5-node analysis.

**Supplementary Table 29.** Influence analysis for myocardial infarction – 3-node analysis.

**Supplementary Table 30.** Influence analysis for cardiac death – 3-node analysis.

**Supplementary Table 31.** Influence analysis for all-cause death – 3-node analysis.

**Supplementary Table 32.** Influence analysis for definite or probable stent thrombosis – 3-node analysis.

**Supplementary Table 33.** Influence analysis for any revascularisation – 3-node analysis.

**Supplementary Table 34.** Influence analysis for ischaemiadriven revascularisation – 3-node analysis.

**Supplementary Table 35.** Influence analysis for MACE – 3-node analysis.

**Supplementary Table 36.** Influence analysis for stroke – 3-node analysis.

**Supplementary Table 37.** Influence analysis for contrastinduced acute kidney injury – 3-node analysis.

**Supplementary Table 38.** Influence analysis for major bleeding – 3-node analysis.

**Supplementary Table 39.** Frequentist random-effects network meta-analysis after excluding the COMPLETE trial – 5-node analysis.

**Supplementary Table 40.** Bayesian random-effects network meta-analysis after excluding the COMPLETE trial – 5-node analysis.

**Supplementary Table 41.** Frequentist random-effects network meta-analysis after excluding the COMPLETE trial – 3-node analysis.

**Supplementary Table 42.** Bayesian random-effects network meta-analysis after excluding the COMPLETE trial – 3-node analysis.

**Supplementary Table 43.** Frequentist random-effects network meta-analysis after excluding trials with NSTEMI – 5-node analysis.

**Supplementary Table 44.** Bayesian random-effects network meta-analysis after excluding trials with NSTEMI – 5-node analysis.

**Supplementary Table 45.** Frequentist random-effects network meta-analysis for periprocedural outcomes after excluding trials with NSTEMI – 5-node analysis.

**Supplementary Table 46.** Bayesian random-effects network meta-analysis for periprocedural outcomes after excluding trials with NSTEMI – 5-node analysis.

**Supplementary Table 47.** Frequentist random-effects network meta-analysis after excluding trials with NSTEMI – 3-node analysis.

**Supplementary Table 48.** Bayesian random-effects network meta-analysis after excluding trials with NSTEMI – 3-node analysis.

**Supplementary Table 49.** Frequentist random-effects network meta-analysis after excluding the CROSS-AMI trial – 5-node analysis.

**Supplementary Table 50.** Bayesian random-effects network meta-analysis after excluding the CROSS-AMI trial – 5-node analysis.

**Supplementary Table 51.** Frequentist random-effects network meta-analysis after excluding trials at high risk for bias – 5-node analysis.

**Supplementary Table 52.** Bayesian random-effects network meta-analysis after excluding trials at high risk for bias – *5*-node analysis.

**Supplementary Table 53.** Frequentist random-effects network meta-analysis after excluding trials at high risk for bias – 3-node analysis.

**Supplementary Table 54.** Bayesian random-effects network meta-analysis after excluding trials at high risk for bias – 3-node analysis.

**Supplementary Table 55.** Frequentist random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation – *5*-node analysis.

**Supplementary Table 56.** Bayesian random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation – 5-node analysis.

**Supplementary Table 57.** Frequentist random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation – 3-node analysis.

**Supplementary Table 58.** Bayesian random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation – 3-node analysis.

**Supplementary Table 59.** Frequentist random-effects network meta-analysis after excluding trials with mixed revascularisation timing – *5*-node analysis.

**Supplementary Table 60.** Bayesian random-effects network meta-analysis after excluding trials with mixed revascularisation timing – *5*-node analysis.

**Supplementary Table 61.** Frequentist random-effects network meta-analysis after excluding trials with mixed revascularisation timing – 3-node analysis.

**Supplementary Table 62.** Bayesian random-effects network meta-analysis after excluding trials with mixed revascularisation timing – 3-node analysis.

**Supplementary Table 63.** Frequentist random-effects network meta-analysis after excluding the FRAME-AMI trial – 5-node analysis.

**Supplementary Table 64.** Bayesian random-effects network meta-analysis after excluding the FRAME-AMI trial – 5-node analysis.

**Supplementary Table 65.** Random-effects network meta-regression for diabetes – 5-node analysis.

**Supplementary Table 66.** Random-effects network meta-regression for 3-vessel disease – 5-node analysis.

**Supplementary Table 67.** Random-effects network metaregression for the year of publication – 5-node analysis.

**Supplementary Table 68.** Random-effects network meta-regression for diabetes – 3-node analysis.

**Supplementary Table 69.** Random-effects network metaregression for 3-vessel disease – 3-node analysis.

**Supplementary Table 70.** Random-effects network meta-regression for the year of publication – 3-node analysis.

**Supplementary Table 71.** Frequentist random-effects pairwise meta-analysis for complete versus IRA-only revascularisation. **Supplementary Table 72.** Bayesian random-effects pairwise meta-analysis for complete versus IRA-only revascularisation. **Supplementary Table 73.** Frequentist random-effects pairwise meta-analysis for periprocedural outcomes for complete versus IRA-only revascularisation.

**Supplementary Table 74.** Bayesian random-effects pairwise meta-analysis for periprocedural outcomes for complete versus IRA-only revascularisation.

 $\label{eq:supplementary Figure 1. Screening and selection process.$ 

Supplementary Figure 2. Individual trial risk of bias.

Supplementary Figure 3. Cumulative risk of bias.

The supplementary data are published online at: https://eurointervention.pcronline.com/ doi/10.4244/EIJ-D-24-00814



## SUPPLEMENTARY DATA

## Completeness, timing, and guidance of percutaneous coronary intervention for myocardial infarction and multivessel disease: a systematic review and network meta-analysis

#### Laudani et al. EuroIntervention 2025;21:e1-e14 DOI: 10.4244/EIJ-D-24-00814

#### **TABLE OF CONTENTS**

#### SUPPLEMENTARY APPENDIX 1. LIST OF INCLUDED TRIALS (page 5).

#### SUPPLEMENTARY APPENDIX 2. METHODS: BAYESIAN MODELS (page 8).

#### SUPPLEMENTARY TABLES (page 9).

- Supplementary Table 1. PRISMA-NMA checklist (page 9).
- Supplementary Table 2. Search strategy (page 13).
- Supplementary Table 3. Inclusion and exclusion criteria across trials (page 14).
- **Supplementary Table 4.** Definition of complete revascularisation in intervention and control arms and percentages of crossover. (page 20).
- Supplementary Table 5. Available endpoints across trials (page 22).
- Supplementary Table 6. Myocardial infarction and MACE definitions across trials (page 23).
- Supplementary Table 7. Bayesian random-effects network meta-analysis 5-node analysis (page 26).
- **Supplementary Table 8.** Frequentist and Bayesian random-effects network meta-analysis rank probabilities and SUCRA- 5-node analysis (page 28).
- **Supplementary Table 9.** Node-splitting analysis for the frequentist and Bayesian frameworks 5-node analysis. (page 31).
- Supplementary Table 10. Bayesian random-effects network meta-analysis 3-node analysis (page 42).
- Supplementary Table 11. Frequentist and Bayesian rank probabilities and SUCRA 3-node analysis (page 43).
- **Supplementary Table 12.** Frequentist and Bayesian network node-splitting analysis 3-node analysis (page 45).
- Supplementary Table 13. Frequentist random-effects network meta-analysis for periprocedural outcomes 5node analysis (page 48).
- Supplementary Table 14. Bayesian random-effects network meta-analysis for periprocedural outcomes 5node analysis (page 49).
- Supplementary Table 15. Node-splitting analysis for periprocedural outcomes 5-node analysis (page 50).

- Supplementary Table 16. Frequentist random-effects network meta-analysis for periprocedural outcomes 3node analysis (page 55).
- **Supplementary Table 17.** Bayesian random-effects network meta-analysis for periprocedural outcomes 3- node analysis (page 56).
- Supplementary Table 18. Node-splitting analysis for periprocedural outcomes 3-node analysis (page 57).
- Supplementary Table 19. Influence analysis for myocardial infarction 5-node analysis (page 59).
- Supplementary Table 20. Influence analysis for cardiac death 5-node analysis (page 60).
- Supplementary Table 21. Influence analysis for all-cause death 5-node analysis (page 61).
- **Supplementary Table 22.** Influence analysis for definite or probable stent thrombosis 5-node analysis (page 62).
- Supplementary Table 23. Influence analysis for MACE 5-node analysis (page 63).
- Supplementary Table 24. Influence analysis for any revascularisation 5-node analysis. (page 64).
- Supplementary Table 25. Influence analysis for ischaemia-driven revascularisation 5-node analysis (page 65).
- Supplementary Table 26. Influence analysis for stroke 5-node analysis (page 66).
- **Supplementary Table 27.** Influence analysis for contrast-induced acute kidney injury 5-node analysis (page 67).
- Supplementary Table 28. Influence analysis for major bleeding 5-node analysis (page 68).
- Supplementary Table 29. Influence analysis for myocardial infarction 3-node analysis. (page 69).
- Supplementary Table 30. Influence analysis for cardiac death 3-node analysis (page 70).
- Supplementary Table 31. Influence analysis for all-cause death 3-node analysis (page 71).
- **Supplementary Table 32.** Influence analysis for definite or probable stent thrombosis 3-node analysis (page 72).
- Supplementary Table 33. Influence analysis for any revascularisation 3-node analysis (page 73).
- Supplementary Table 34. Influence analysis for ischaemia-driven revascularisation 3-node analysis (page 74).
- Supplementary Table 35. Influence analysis for MACE 3-node analysis (page 75).
- Supplementary Table 36. Influence analysis for stroke 3-node analysis (page 76).
- **Supplementary Table 37.** Influence analysis for contrast-induced acute kidney injury 3-node analysis (page 77).
- Supplementary Table 38. Influence analysis for major bleeding 3-node analysis (page 78).
- Supplementary Table 39. Frequentist random-effects network meta-analysis after excluding the COMPLETE trial 5-node analysis. (page 79).
- **Supplementary Table 40.** Bayesian random-effects network meta-analysis after excluding the COMPLETE trial 5-node analysis (page 81).
- **Supplementary Table 41.** Frequentist random-effects network meta-analysis after excluding the COMPLETE trial 3-node analysis (page 83).
- **Supplementary Table 42.** Bayesian random-effects network meta-analysis after excluding the COMPLETE trial 3-node analysis (page 84).

- **Supplementary Table 43.** Frequentist random-effects network meta-analysis after excluding trials with NSTEMI 5-node analysis (page 85).
- Supplementary Table 44. Bayesian random-effects network meta-analysis after excluding trials with NSTEMI 5-node analysis (page 87).
- Supplementary Table 45. Frequentist random-effects network meta-analysis for periprocedural outcomes after excluding trials with NSTEMI 5-node analysis (page 89).
- Supplementary Table 46. Bayesian random-effects network meta-analysis for periprocedural outcomes after excluding trials with NSTEMI 5-node analysis (page 90).
- **Supplementary Table 47.** Frequentist random-effects network meta-analysis after excluding trials with NSTEMI 3-node analysis (page 91)
- Supplementary Table 48. Bayesian random-effects network meta-analysis after excluding trials with NSTEMI 3-node analysis (page 92).
- **Supplementary Table 49.** Frequentist random-effects network meta-analysis after excluding the CROSS-AMI trial 5-node analysis (page 93).
- Supplementary Table 50. Bayesian random-effects network meta-analysis after excluding the CROSS-AMI trial 5-node analysis (page 95).
- **Supplementary Table 51.** Frequentist random-effects network meta-analysis after excluding trials at high risk for bias 5-node analysis (page 97).
- Supplementary Table 52. Bayesian random-effects network meta-analysis after excluding trials at high risk for bias 5-node analysis (page 99).
- Supplementary Table 53. Frequentist random-effects network meta-analysis after excluding trials at high risk for bias 3-node analysis (page 101).
- Supplementary Table 54. Bayesian random-effects network meta-analysis after excluding trials at high risk for bias 3-node analysis (page 102).
- **Supplementary Table 55.** Frequentist random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion -only revascularisation 5-node analysis (page 103).
- **Supplementary Table 56.** Bayesian random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation 5-node analysis (page 105).
- **Supplementary Table 57.** Frequentist random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation 3-node analysis (page 107).
- **Supplementary Table 58.** Bayesian random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation 3-node analysis (page 108).
- Supplementary Table 59. Frequentist random-effects network meta-analysis after excluding trials with mixed revascularisation timing 5-node analysis (page 109).
- **Supplementary Table 60.** Bayesian random-effects network meta-analysis after excluding trials with mixed revascularisation timing 5-node analysis (page 111).
- Supplementary Table 61. Frequentist random-effects network meta-analysis after excluding trials with mixed revascularisation timing 3-node analysis (page 113).
- **Supplementary Table 62.** Bayesian random-effects network meta-analysis after excluding trials with mixed revascularisation timing 3-node analysis (page 114).

- **Supplementary Table 63.** Frequentist random-effects network meta-analysis after excluding the FRAME-AMI trial 5-node analysis (page 115).
- **Supplementary Table 64.** Bayesian random-effects network meta-analysis after excluding the FRAME-AMI trial 5-node analysis (page 117).
- **Supplementary Table 65.** Random-effects network meta-regression for the percentage for diabetes 5-node analysis (page 119).
- **Supplementary Table 66.** Random-effects network meta-regression for the percentage of patients for 3-vessel disease 5-node analysis (page 121).
- **Supplementary Table 67.** Random-effects network meta-regression for the year of publication 5-node analysis (page 123).
- **Supplementary Table 68.** Random-effects network meta-regression for the percentage for diabetes 3-node analysis (page 125).
- Supplementary Table 69. Random-effects network meta-regression for the percentage of patients with 3-vessel disease 3-node analysis (page 126).
- **Supplementary Table 70.** Random-effects network meta-regression for year of publication 3-node analysis (page 127).
- **Supplementary Table 71.** Frequentist random-effects pairwise meta-analysis for complete versus IRA-only revascularisation (page 128).
- **Supplementary Table 72.** Bayesian random-effects pairwise meta-analysis for complete versus IRA-only revascularisation (page 129).
- **Supplementary Table 73.** Frequentist random-effects pairwise meta-analysis for periprocedural outcomes for complete versus IRA-only revascularisation (page 130).
- **Supplementary Table 74.** Bayesian random-effects pairwise meta-analysis for periprocedural outcomes for complete versus IRA-only revascularisation (page 131).

#### SUPPLEMENTARY FIGURES (page 131).

- Supplementary Figure 1. Screening and selection process (page 132).
- Supplementary Figure 2. Individual trial risk of bias (page 133).
- Supplementary Figure 3. Cumulative risk of bias (page 134).

#### Supplementary Appendix 1. List of the included trials.

#### • FULL REVASC (2024)<sup>11</sup>

Felix Böhm, Brynjölfur Mogensen, Thomas Engstrøm, Goran Stankovic, Ilija Srdanovic, Jacob Lønborg, Sammy Zwackman, Mehmet Hamid, Thomas Kellerth, Jörg Lauermann, Olli A Kajander, Jonas Andersson, Rikard Linder, Oskar Angerås, Henrik Renlund, Andrejs Ērglis, Madhav Menon, Carl Schultz, Mika Laine, Claes Held, Andreas Rück, Ollie Östlund, Stefan James.

#### FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.

N Eng J Med 2024; 390:1481-1492. doi: 10.1056/NEJMoa2314149.

#### • BIOVASC (2023)<sup>12</sup>

Roberto Diletti, Wijnand K den Dekker, Johan Bennett, Carl E Schotborgh, Rene van der Schaaf, Manel Sabaté, Raúl Moreno, Koen Ameloot, Rutger van Bommel, Daniele Forlani, Bert van Reet, Giovanni Esposito, Maurits T Dirksen, Willem P T Ruifrok, Bert R C Everaert, Carlos Van Mieghem, Jacob J Elscot, Paul Cummins, Mattie Lenzen, Salvatore Brugaletta, Eric Boersma, Nicolas M Van Mieghem.

## Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.

Lancet 2023;401:1172-1182. doi: 10.1016/S0140-6736(23)00351-3.

#### • COCUA (2023)<sup>14</sup>

Soohyung Park, Seung-Woon Rha, Byoung Geol Choi, Jang Hyun Cho, Sang Ho Park, Jin Bae Lee, Yong Hoon Kim, Sang Min Park, Jae Woong Choi, Ji Young Park, Eun-Seok Shin, Jae Beom Lee, Jon Suh, Jei Keon Chae, Young Jin Choi, Myung Ho Jeong, Kwang soo Cha, Seung Wook Lee, Ung Kim, Gi Chang Kim, Woong-Gil Choi, Yun-Hyeong Cho, Deok-kyu Cho, Jihun Ahn, Soon-Yong Suh, Se Yeon Choi, Jae Kyeong Byun, Jin Ah Cha, Soo Jin Hyun, Ji Bak Kim, MD, Cheol Ung Choi, Chang Gyu Park.

# Immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease: results from a prematurely discontinued randomized multicenter trial.

Am Heart J 2023:259:58-67. doi: 10.1016/j.ahj.2023.01.020.

#### • COMPARE-ACUTE (2017)<sup>8</sup>

Pieter C. Smits, Mohamed Abdel-Wahab, Franz-Josef Neumann, Bianca M. Boxma de Klerk, Ketil Lunde, Carl E. Schotborgh, Zsolt Piroth, David Horak, Adrian Wlodarczak, Paul J. Ong, Rainer Hambrecht, Oskar Angerås, Gert Richardt, Elmir Omerovic.

#### Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction.

N Engl J Med 2017;376:1234-1244. doi: 10.1056/NEJMoa1701067.

#### • COMPLETE (2019)<sup>9</sup>

Shamir R. Mehta, David A. Wood, Robert F. Storey, Roxana Mehran, Kevin R. Bainey, Helen Nguyen, Brandi Meeks, Giuseppe Di Pasquale, Jose López-Sendón, David P. Faxon, Laura Mauri, Sunil V. Rao, Laurent Feldman, P. Gabriel Steg, Álvaro Avezum, Tej Sheth, Natalia Pinilla-Echeverri, Raul Moreno, Gianluca Campo, Benjamin Wrigley, Sasko Kedev, Andrew Sutton, Richard Oliver, Josep Rodes-Cabau, Goran Stanković, Robert Welsh, Shahar Lavi, Warren J. Cantor, Jia Wang, Juliet Nakamya, Shrikant I. Bangdiwala, John A. Cairns.

#### Complete Revascularization with Multivessel PCI for Myocardial Infarction.

N Engl J Med 2019;381:1411-1421. doi: 10.1056/NEJMoa1907775.

#### • CROSS-AMI (2019)<sup>24</sup>

Ramón Calviño-Santos, Rodrigo Estévez-Loureiro, Jesús Peteiro-Vázquez, Jorge Salgado-Fernández, Alejandro Rodríguez-Vilela, Raúl Franco-Gutiérrez, Alberto Bouzas-Mosquera, José Ángel Rodríguez-Fernández, Alejandro Mesías-Prego, Carlos González-Juanatey, Guillermo Aldama-López, Pablo Piñón-Esteban, Xacobe Flores-Ríos, Rita Soler-Martín, Teresa Seoane-Pillado, Nicolás Vázquez-González, Javier Muñiz, José Manuel Vázquez-Rodríguez.

# Angiographically Guided Complete Revascularization Versus Selective Stress Echocardiography-Guided Revascularization in Patients With ST-Segment-Elevation Myocardial Infarction and Multivessel Disease: The CROSS-AMI Randomized Clinical Trial.

Circ Cardiovasc Interv 2019;12:e007924. doi: 10.1161/CIRCINTERVENTIONS.119.007924.

#### • CvLPRIT (2015)<sup>6</sup>

Anthony H. Gershlick, Jamal Nasir Khan, Damian J. Kelly, John P. Greenwood, Thiagarajah Sasikaran, Nick Curzen, Daniel J. Blackman, Miles Dalby, Kathryn L. Fairbrother BA, Winston Banya, Duolao Wang, Marcus Flather, Simon L. Hetherington, Andrew D. Kelion, Suneel Talwar, Mark Gunning, Roger Hall, Howard Swanton, Gerry P. McCann.

# Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease: The CvLPRIT Trial.

J Am Coll Cardiol 2015;65:963-72. doi: 10.1016/j.jacc.2014.12.038.

#### • **DANAMI-3-PRIMULTI** (2015)<sup>7</sup>

Thomas Engstrøm, Henning Kelbæk, Steffen Helqvist, Dan Eik Høfsten, Lene Kløvgaard, Lene Holmvang, Erik Jørgensen, Frants Pedersen, Kari Saunamäki, Peter Clemmensen, Ole De Backer, Jan Ravkilde, Hans-Henrik Tilsted, Anton Boel Villadsen, Jens Aarøe, Svend Eggert Jensen, Bent Raungaard, Lars Køber.

# Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial.

Lancet 2015;386:665-71. doi: 10.1016/s0140-6736(15)60648-1.

#### • FIRE (2023)<sup>10</sup>

Simone Biscaglia, Vincenzo Guiducci, Javier Escaned, Raul Moreno, Valerio Lanzilotti, Andrea Santarelli, Enrico Cerrato, Giorgio Sacchetta, Alfonso Jurado-Roman, Alberto Menozzi, Ignacio Amat Santos, José Luis Díez Gil, Marco Ruozzi, Marco Barbierato, Luca Fileti, Andrea Picchi, Veronica Lodolini, Giuseppe Biondi-Zoccai, Elisa Maietti, Rita Pavasini, Paolo Cimaglia, Carlo Tumscitz, Andrea Erriquez, Carlo Penzo, Iginio Colaiori, Gianluca Pignatelli, Gianni Casella, Gianmarco Iannopollo, Mila Menozzi, Ferdinando Varbella, Giorgio Caretta, Dariusz Dudek, Emanuele Barbato, Matteo Tebaldi, Gianluca Campo.

#### Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.

N Engl J Med 2023;389:889-898. doi: 10.1056/NEJMoa2300468.

#### • FLOWER-MI (2021)<sup>25</sup>

Etienne Puymirat, Guillaume Cayla, Tabassome Simon, Philippe G. Steg, Gilles Montalescot, Isabelle Durand-Zaleski, Alicia le Bras, Romain Gallet, Khalife Khalife, Jean-François Morelle, Pascal Motreff, Gilles Lemesle, Jean-Guillaume Dillinger, Thibault Lhermusier, Johanne Silvain, Vincent Roule, Jean-Noel Labèque, Grégoire Rangé, Grégory Ducrocq, Yves Cottin, Didier Blanchard, Anaïs Charles Nelson, N.D., Bernard De Bruyne, Gilles Chatellier, Nicolas Danchin.

#### Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction.

N Engl J Med 2021;385:297-308. doi: 10.1056/NEJMoa2104650.

#### • FRAME-AMI (2022)<sup>15</sup>

Joo Myung Lee, Hyun Kuk Kim, Keun Ho Park, Eun Ho Choo, Chan Joon Kim, Seung Hun Lee, Min Chul Kim, Young Joon Hong, Sung Gyun Ahn, Joon-Hyung Doh, Sang Yeub Lee, Sang Don Park, Hyun-Jong Lee, Min Gyu Kang, Jin-Sin Koh, Yun-Kyeong Cho, Chang-Wook Nam, Bon-Kwon Koo, Bong-Ki Lee, Kyeong Ho Yun, David Hong, Hyun Sung Joh, Ki Hong Choi, Taek Kyu Park, Jeong Hoon Yang, Young Bin Song, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Joo-Yong Hahn.

## Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial.

Eur Heart J 2023;44:473-484. doi: 10.1093/eurheartj/ehac763.

#### • MULTISTARS AMI (2023)<sup>13</sup>

Barbara E. Stähli, Ferdinando Varbella, Axel Linke, Bettina Schwarz, Stephan B. Felix, Moritz Seiffert, Rahel Kesterke, Peter Nordbeck, Bernhard Witzenbichler, Irene M Lang, Mirjam Kessler, Christian Valina, Alban Dibra, Miklos Rohla, Marco Moccetti, Matteo Vercellino, Luise Gaede, Lorenz Bott-Flügel, Philipp Jakob, Julia Stehli, Alessandro Candreva, Christian Templin, Matthias Schindler, Manfred Wischnewsky, Greca Zanda, Giorgio Quadri, Norman Mangner, Aurel Toma, Giulia Magnani, Peter Clemmensen, Thomas F. Lüscher, Thomas Münzel, P Christian Schulze, Karl-Ludwig Laugwitz, Wolfgang Rottbauer, Kurt Huber, Franz-Josef Neumann, Steffen Schneider, Franz Weidinger, Stephan Achenbach, Gert Richardt, Adnan Kastrati, Ian Ford, Willibald Maier, Frank Ruschitzka.

#### Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction.

N Engl J Med 2023;389:1368-1379. doi: 10.1056/NEJMoa2307823.

#### • PRAMI (2013)<sup>5</sup>

David S. Wald, Joan K. Morris, Nicholas J. Wald, Alexander J. Chase, Richard J. Edwards, Liam O. Hughes, Colin Berry, Keith G. Oldroyd.

#### Randomized Trial of Preventive Angioplasty in Myocardial Infarction.

N Engl J Med 2013;369:1115-23. doi: 10.1056/NEJMoa1305520.

#### • SMILE (2013)<sup>23</sup>

Gennaro Sardella, MD, Luigi Lucisano, Roberto Garbo, Mauro Pennacchi, Erika Cavallo, Rocco Edoardo Stio, Simone Calcagno, Fabrizio Ugo, MD, Giacomo Boccuzzi, Francesco Fedele, Massimo Mancone.

#### Single-Staged Compared With Multi-Staged PCI in Multivessel NSTEMI Patients: The Smile Trial.

J Am Coll Cardiol 2016;67:264-72. doi: 10.1016/j.jacc.2015.10.082.

#### Supplementary Appendix 2. Methods: Bayesian models.

In Bayesian analyses, overdispersed vague priors for a common distribution mean effect  $[\theta \sim N(0, 10^3)]$  and uniform between-trial heterogeneity random-effects parameters  $[\tau \sim \text{uniform } (0, 5)]$  were given. Models were computed by Markov chain Monte Carlo simulations, using four chains with over-dispersed initial values, and Gibbs sampling was based on 100,000 iterations after a burn-in phase of 50,000 iterations. Convergence was evaluated through visual assessment and according to Brooks-Gelman-Rubin statistics, assuming convergence when the latter was inferior to 1.1.

## Supplementary Table 1. PRISMA-NMA checklist.

Section / Topic	Item #	Checklist Item	Page #
TITLE			
Title	1	Identify the report as a systematic review <i>incorporating a</i> network meta-analysis (or related form of meta-analysis)	1
ABSTRACT		network meta analysis (or retaica form of meta analysis).	
Structured summary	2	<ul> <li>Provide a structured summary including, as applicable:</li> <li>Background: main objectives</li> <li>Methods: data sources; study eligibility criteria, participants, and interventions; study appraisal; and synthesis methods, such as network meta-analysis.</li> <li>Results: number of studies and participants identified; summary estimates with corresponding confidence/credible intervals; treatment rankings may also be discussed. Authors may choose to summarize pairwise comparisons against a chosen treatment included in their analyses for brevity.</li> <li>Discussion/Conclusions: limitations; conclusions and implications of findings.</li> <li>Other: primary source of funding; systematic review registration number with registry name.</li> </ul>	2-3
INTRODUCTION		8	
Rationale	3	Describe the rationale for the review in the context of what is already known, <i>including mention of why a network</i> <i>meta-analysis has been conducted</i> .	6
Objectives	4	Provide an explicit statement of questions being addressed, with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists and if and where it can be accessed (e.g., Web address); and, if available, provide registration information, including registration number.	6-7
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. <i>Clearly describe eligible treatments included in the treatment network, and note whether any have been clustered or merged into the same node (with justification)</i>	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	7; S14
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from	7

Data items Geometry of the network Risk of bias within individual studies Summary measures	11 <b>S1</b> 12 13	<ul> <li>investigators.</li> <li>List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.</li> <li>Describe methods used to explore the geometry of the treatment network under study and potential biases related to it. This should include how the evidence base has been graphically summarized for presentation, and what characteristics were compiled and used to describe the evidence base to readers.</li> <li>Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.</li> <li>State the principal summary measures (e.g., risk ratio, difference in means). Also describe the use of additional summary measures assessed, such as treatment rankings and surface under the cumulative ranking curve (SUCRA) values, as well as modified approaches used to present</li> </ul>	7 <b>8</b> 7 8
Planned methods of analysis	14	<ul> <li>summary findings from meta-analyses.</li> <li>Describe the methods of handling data and combining results of studies for each network meta-analysis. This should include, but not be limited to: <ul> <li>Handling of multi-arm trials;</li> <li>Selection of variance structure;</li> <li>Selection of prior distributions in Bayesian analyses; and</li> </ul> </li> </ul>	8
Assessment of Inconsistency	S2	• Assessment of model fit. Describe the statistical methods used to evaluate the agreement of direct and indirect evidence in the treatment network(s) studied. Describe efforts taken to address its presence when found	8-9
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies)	9
Additional analyses	16	Describe methods of additional analyses if done, indicating which were pre-specified. This may include, but not be limited to, the following: • Sensitivity or subgroup analyses; • Meta-regression analyses:	٥
		<ul> <li>Meta-regression analyses,</li> <li>Alternative formulations of the treatment network; and</li> <li>Use of alternative prior distributions for Bayesian analyses (if applicable).</li> </ul>	9
<b>RESULTS</b> †			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Presentation of network structure Summary of	S3 S4	Provide a network graph of the included studies to enable visualization of the geometry of the treatment network. Provide a brief overview of characteristics of the treatment	9
network geometry	57	network. This may include commentary on the abundance of trials and randomized patients for the different interventions and pairwise comparisons in the network, gaps of evidence in the treatment network, and potential	9

		biases reflected by the network structure.	
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and	9-10: \$122
		provide the citations.	<i>y</i> =10. 5122
Risk of bias within	19	Present data on risk of bias of each study and, if available,	10; S123-
Results of individual	20	For all outcomes considered (benefits or harms) present	5124
studies	20	for each study: 1) simple summary data for each intervention group, and 2) effect estimates and confidence intervals. <i>Modified approaches may be needed to deal with</i> <i>information from larger networks</i>	14-17
Synthesis of results	21	Present results of each meta-analysis done, including confidence/credible intervals. <i>In larger networks, authors</i> <i>may focus on comparisons versus a particular comparator</i> <i>(e.g. placebo or standard care), with full findings</i> <i>presented in an appendix. League tables and forest plots</i> <i>may be considered to summarize pairwise comparisons.</i> If additional summary measures were explored (such as treatment rankings), these should also be presented. Describe results from investigations of inconsistency. This	10-13
inconsistency	55	may include such information as measures of model fit to compare consistency and inconsistency models, <i>P</i> values from statistical tests, or summary of inconsistency estimates from different parts of the treatment network.	10-13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies for the evidence base being studied.	10
Results of additional analyses	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression analyses, <i>alternative network geometries studied, alternative choice of prior distributions for Bayesian analyses</i> , and so forth).	13-14
DISCUSSION			
Summary of evidence	24	Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy-makers).	14-18
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias). <i>Comment on the</i> <i>validity of the assumptions, such as transitivity and</i> <i>consistency. Comment on any concerns regarding network</i> <i>geometry (e.g., avoidance of certain comparisons).</i>	18-19
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future	19
FUNDING			
Funding	27	Describe sources of funding for the systematic review and	
č		other support (e.g., supply of data); role of funders for the systematic review. This should also include information regarding whether funding has been received from manufacturers of treatments in the network and/or whether some of the authors are content experts with professional conflicts of interest that could affect use of treatments in the network.	1

\_

PICOS= Population, Intervention, Comparators, Outcomes, Study Design.

\* Text in italics indicates wording specific to reporting of network meta-analyses that has been added to guidance from the PRISMA statement.

<sup>†</sup> Authors may wish to plan for use of appendices to present all relevant information in full detail for items in this section.

## Supplementary Table 2. Search strategy.

	Search String	Results
MedLine	e via PubMed	
#1	(((((((((((((((((((((((((((((((()))))))	6,888,948
	(preventive)) OR (1-stage)) OR (staged)) OR (culprit lesion)) OR (multi-	
	stag*)) OR (lesion-only)) OR (culprit-only)) OR ("infarct-related artery-	
	only")) OR (infarct-artery)) OR (physiology-guided)) OR ("fractional flow	
	reserve")) OR (FFR)) OR (FFR-guided)) OR (conservative)	
#2	multivessel* OR "multi vessel"	8,164
#3	#1 AND #2	2,797
#4	(2009:2024[pdat])	-
#5	#3 AND #4	1,799
Cochran	e Library	
#1	Immediate OR complete OR single-staged OR preventive OR stage* OR	648,360
	culprit lesion OR multi-stage OR lesion-only OR culprit-Only OR "infarct-	
	related artery-only" OR infarct-artery OR physiology-guided OR	
	"fractional flow reserve" OR "FFR" OR "FFR-guided" OR conservative	
#2	multivessel* OR "multi vessel"	1,462
#3	#1 AND #2	683
Web of S	cience	
#1	(ALL= (Immediate OR Complete OR single-staged OR preventive OR	2,337
	stage* OR "culprit lesion" OR multi-Stage OR lesion-only OR culprit-only	
	OR "infarct-related artery-only" OR infarct-artery OR physiology-guided	
	OR "fractional flow reserve" OR FFR OR FFR-guided OR conservative))	
	AND ALL= (multivessel* OR "multi vessel")	
#2	Refined by Publication Years (from 2009 to 2024)	1,811
Scopus		
#1	Immediate OR complete OR single-staged OR preventive OR stage* OR	
	culprit lesion OR multi-Stage OR lesion-only OR culprit-Only OR "infarct-	
	related artery-only" OR infarct-artery OR physiology-guided OR	
	"fractional flow reserve" OR "FFR" OR "FFR-guided" OR conservative	
#2	multivessel* OR multi-vessel	
#3	#1 AND #2	2,342
#4	Refined by Publication Years (from 2009 to 2024)	1,634

## Supplementary Table 3. Inclusion and exclusion criteria across trials.

Study	Inclusion Criteria	Exclusion Criteria
PRAMI (2013)	• Patients with acute MI undergoing a therapeutic PCI to the infarct related artery	<ul><li>Cardiogenic shock</li><li>CABG</li></ul>
CvLPRIT (2015)	<ul> <li>Suspected or proven acute MI</li> <li>Significant ST segment elevation on ECG</li> <li>Less than 12 hours of symptom onset</li> <li>Scheduled for primary PCI for clinical reasons</li> <li>Provision of verbal assent followed by written informed consent</li> <li>MVD detected at time of angiography</li> </ul>	<ul> <li>Any contraindication to primary PCI or multi-vessel primary PCI</li> <li>Less than 18 years age</li> <li>Clear indication for or contraindication to multivessel primary PCI, according to operator judgement and the reasons will be documented</li> <li>Severe kidney impairment</li> </ul>
DANAMI-3-PRIMULTI (2015)	<ul> <li>Age ≥ 18 years</li> <li>Acute onset of chest pain with a duration of &lt; 12 hours</li> <li>ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads, signs of a true posterior infarction or documented newly developed left bundle branch block</li> <li>Culprit lesion in a major native vessel</li> <li>MVD</li> <li>Successful primary PCI</li> </ul>	<ul> <li>Pregnancy</li> <li>Known intolerance of acetylsalicylic acid, clopidogrel, heparin or contrast</li> <li>Inability to understand information or to provide informed consent</li> <li>Haemorrhagic diathesis or known coagulopathy</li> <li>Stent thrombosis</li> <li>Significant left main stem stenosis</li> <li>Cardiogenic shock at admittance</li> </ul>
SMILE (2016)	<ul> <li>Diagnosis of NSTEMI</li> <li>Presenting with MVD</li> </ul>	<ul> <li>Patients with cardiogenic shock at presentation</li> <li>Left main coronary disease (&gt; 50% diameter stenosis)</li> <li>Previous CABG surgery</li> <li>Patients with Syntax Score &gt; 32</li> <li>Candidate to by-pass surgery</li> <li>Severe valvular heart disease</li> <li>Unsuccessful procedures</li> </ul>
COMPARE-ACUTE (2017)	<ul> <li>All patients between 18-85 years presenting with STEMI who will be treated with primary PCI in &lt; 12 hours after symptoms onset* and have at least one stenosis of &gt; 50% in a non-IRA on quantitative coronary analysis or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator</li> <li>* Patients with symptoms for more than 12 hours but ongoing angina complaints could be randomized</li> </ul>	<ul> <li>Left main stem disease (stenosis &gt; 50%)</li> <li>STEMI due to in-stent thrombosis</li> <li>CTO of a non-IRA</li> <li>Severe stenosis with TIMI flow ≤ 2 of the non-IRA</li> <li>Non-IRA stenosis not amenable for PCI treatment (operators' decision)</li> <li>Complicated IRA treatment, with one or more of the following: (extravasation, permanent no reflow after IRA treatment [TIMI flow 0-1], inability to implant a stent)</li> <li>Known severe cardiac valve dysfunction that will require surgery in the follow-up period</li> </ul>

		<ul> <li>Killip class III or IV already at presentation or at the completion of culprit lesion treatment</li> <li>Life expectancy of &lt; 2 years</li> <li>Intolerance to medications or everolimus and known true anaphylaxis to prior contrast media of bleeding diathesis or known coagulopathy</li> <li>Gastrointestinal or genitourinary bleeding within the prior 3 months</li> <li>Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment</li> <li>Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period</li> <li>Pregnancy or planning to become pregnant any time after enrolment into this study</li> <li>Inability to obtain informed consent</li> <li>Expected lost to follow-up</li> </ul>
CROSS-AMI (2019)	<ul> <li>Typical chest pain lasting &gt; 30 minutes with ST-segment elevation ≥ 1 mm in ≥ 2 contiguous ECG leads or left bundle branch block and presentation &lt; 48 hours since symptom onset</li> <li>Patients undergoing rescue PCI</li> <li>Patients with effective lysis and coronary angiography in less than 24 hours</li> <li>Presence of other lesion ≥ 70% in a non-IRA</li> <li>Informed consent</li> </ul>	<ul> <li>Significant left main disease</li> <li>Lesions in vessels &lt; 2.00 mm</li> <li>Lesions in branches of a main epicardial coronary artery and short irrigation territory</li> <li>Previous CABG</li> <li>Any coronary intervention in the previous month</li> <li>Cardiogenic shock</li> <li>Anatomic features no suitable for coronary intervention</li> <li>Pregnancy</li> </ul>
COMPLETE (2019)	<ul> <li>Both criteria must be present:</li> <li>Men and women within 72 hours after successful PCI to the culprit lesion for STEMI PCI for STEMI can be either primary PCI or rescue PCI for failed fibrinolysis or a combination strategy where PCI is performed routinely 3-12 hours after fibrinolysis</li> <li>MVD defined as at least 1 additional non-IRA lesion that is at least 2.50 mm in diameter that has not been stented as part of the primary PCI and that is amenable to successful treatment with PCI due to ≥ 70% diameter stenosis (visual estimation) and FFR ≤ 0.80</li> </ul>	<ul> <li>Planned revascularization of non- culprit lesion</li> <li>Planned surgical revascularization</li> <li>Non-cardiovascular co-morbidity reducing life expectancy to &lt; 5 years</li> <li>Any factor precluding 5-year follow-up</li> <li>Prior CABG Surgery</li> </ul>
FLOWER-MI (2021)	• STEMI patients ≥ 18 years old with successful culprit lesion PCI	• Patients with cardiogenic shock (systolic blood pressure < 90 mmHg

	<ul> <li>(primary, rescue or pharmaco- invasive) and ≥ 50% stenosis judged amenable to PCI in at least one additional non-culprit lesion</li> <li>Written informed consent</li> </ul>	<ul> <li>with clinical signs of low output or patients requiring inotropic agents)</li> <li>Patients with MVD referred to surgery for CABG or treatment of acute complications (e.g., ventricular septal rupture)</li> <li>Patients with one-vessel disease</li> <li>Previous CABG surgery</li> <li>Extremely tortuous, calcified coronary vessels or CTO</li> <li>Life expectancy &lt; 2 years</li> <li>Patients with known hypersensitivity to adenosine</li> <li>Pregnancy</li> <li>Participation in another interventional therapeutic study at the same time or within 3 months prior to the beginning of the present study</li> </ul>
FRAME-AMI (2023)	<ul> <li>Subject at least 19 years of age</li> <li>Acute STEMI defined as: ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads or documented newly developed left bundle-branch block</li> <li>Acute NSTEMI defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably highsensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following: i) Symptoms of ischaemia; ii) New or presumed new significant ST-T wave changes; iii) Development of pathological Q waves on ECG; iv) Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality; v) Intracoronary thrombus detected on angiography</li> <li>PCI within 12 hours after the onset of symptoms for STEMI patients (in case of NSTEMI, PCI should be performed within 72 hours of symptom onset)</li> <li>MVD (at least one stenosis of &gt; 50% in a non-culprit vessel ≥ 2.00 mm by visual estimation)</li> <li>Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure</li> </ul>	<ul> <li>Severe stenosis with TIMI How ≤ 2 of the non-IRA</li> <li>Unprotected left main coronary artery disease (stenosis &gt; 50% by visual estimation)</li> <li>Non-IRA stenosis not amenable for PCI treatment by operators' decision)</li> <li>CTO in non-IRA</li> <li>Cardiogenic shock (Killip class IV) already at presentation or the completion of IRA PCI</li> <li>Intolerance to aspirin, clopidogrel, prasugrel, ticagrelor, heparin, bivalirudin, everolimus, or zotarolimus</li> <li>Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)</li> <li>Pregnancy or breast feeding</li> <li>Non-cardiac co-morbid conditions are present with life expectancy &lt; 1 year or that may result in protocol non-compliance (per site investigator's medical judgment)</li> <li>Other primary valvular disease with severe degree: severe mitral regurgitation, mitral stenosis, severe aortic regurgitation, or aortic stenosis</li> <li>Patients with a history of CABG or treated with fibrinolytic therapy</li> <li>Unwillingness or inability to comply with the procedures described in this protocol</li> </ul>

	General inclusion criteria:	• Age < 18 years and > 85 years
BIOVASC (2023)	<ul> <li>Age ≥ 18 years ≤ 85 years</li> <li>Acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on PCI, manufacturer's Instructions for Use and the Declaration of Helsinki</li> <li>Patient indication, lesion length and vessel diameter of the target lesion(s) according to the 'Instructions for Use' that comes with every Orsiro system</li> <li>The patient is willing and able to cooperate with study procedures and the required follow up visits</li> <li>The subject or legal representative has been informed of the nature of the study and agrees to its provisions and has provided an Ethics Committee approved written informed consent, including data privacy authorization</li> <li>Inclusion criteria for STEMI (both must be present):</li> <li>Chest pain for more than 20 minutes with an ST-segment elevation of 1 mm or greater in two or more contiguous leads, or with a new left bundle-branch block</li> <li>Admission either within 12 hours of symptom onset or between 12 and 24 hours after onset with evidence of continuing ischaemia</li> </ul>	<ul> <li>Age &lt; 18 years and &gt; 85 years</li> <li>Single coronary vessel disease or multivessel disease without clear culprit</li> <li>Patients in cardiogenic shock</li> <li>Patients who cannot give informed consent or have a life expectancy of less than 1 year</li> <li>Absolute contraindications or allergy that cannot be pre- medicated, to iodinated contrast or to any of the study medications, including both aspirin and P2Y<sub>12</sub> inhibitors</li> <li>Enrolment in another study with another investigational device or drug trial that has not reached the primary endpoint</li> <li>PCI in the previous 30 days</li> <li>Presence of a CTO</li> <li>Previous CABG</li> <li>Women of childbearing potential who do not have a negative pregnancy test within 7 days before the procedure and women who are breastfeeding</li> <li>Planned surgery within 6 months after PCI, unless dual antiplatelet therapy is maintained throughout the peri-surgical period</li> </ul>
	<ul> <li>Inclusion criteria for NSTEMI (at least two must be present):</li> <li>History consistent with new, or worsening ischaemia, occurring at rest or with minimal activity</li> <li>Coronary angiography with indication to PCI</li> <li>Troponin T or I or CK-MB above the upper limit of normal</li> <li>Electrocardiographic changes compatible with ischaemia but not diagnostic for STEMI (i.e., ST depression of 1 mm or greater in two contiguous leads, T-wave inversion more than 3 mm, or any dynamic ST shifts)</li> <li>Unstable angina</li> </ul>	
FIRE (2023)	<ul> <li>All criteria must be present:</li> <li>Patients ≥ 75 years</li> <li>MI (STEMI or NSTEMI) with indication to invasive management</li> </ul>	<ul> <li>Planned surgical revascularization</li> <li>Non-cardiovascular co-morbidity reducing life expectancy to &lt; 1 year</li> </ul>

	<ul> <li>Multi-vessel disease defined as at least 1 non-culprit coronary artery lesion at least 2.50 mm in diameter deemed at visual estimation with a % diameter stenosis ranging from 50 to 99% amenable to successful treatment with PCI</li> <li>Successful treatment of culprit lesion</li> </ul>	<ul> <li>Any factor precluding 1-year follow-up</li> <li>Prior CABG Surgery</li> <li>Impossibility to identify a clear culprit lesion</li> <li>Non culprit lesion located in the left main</li> </ul>
COCUA (2023)	<ul> <li>At least 18 years of age</li> <li>STEMI presentation</li> <li>At least 2 significant target lesions in the different target native coronary arteries requiring PCI within 72 hours</li> </ul>	<ul> <li>Adverse reaction to drugs such as heparin, aspirin, clopidogrel, ticlopidine, everolimus and contrast agent</li> <li>Systemic everolimus use within 12 months</li> <li>Pregnancy</li> <li>History of bleeding diathesis or known coagulopathy (including heparin-gastrointestinal or genitourinary bleeding within the prior 3 months, major surgery within 2 months or induce thrombocytopenia)</li> <li>Planned elective surgical procedure that would necessitate thienopyridine interruption during the first 6 months after enrolment</li> <li>Life expectancy less than 1 year owing to a non-cardiac disease</li> <li>Actively participating in another drug or device investigational study which has not completed the primary end point follow-up period</li> <li>Left ventricle ejection fraction &lt;25% or cardiogenic shock</li> </ul>
MULTISTARS AMI (2023)	<ul> <li>Age ≥ 18 years</li> <li>Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset)</li> <li>Suitability for PCI from femoral or radial access</li> <li>Coronary anatomy suitable for complete coronary revascularization with Synergy stent implantation</li> <li>Identifiable culprit lesion/artery</li> <li>At least one non-culprit coronary stenosis ≥ 70% in at least two projections, in a vessel with a lumen diameter ≥ 2.25 - ≤ 5.75 mm, other than the culprit artery</li> <li>TIMI flow 3 or TIMI flow 2 after revascularization of the culprit artery</li> <li>Stable haemodynamic at the end of the culprit vessel revascularization</li> </ul>	<ul> <li>Inability to give informed consent</li> <li>Cardiogenic shock</li> <li>Prolonged resuscitation &gt; 10 minutes</li> <li>General unsuitability for PCI</li> <li>Need for emergency CABG</li> <li>Previous CABG</li> <li>Planned hybrid revascularization</li> <li>Coronary artery dissection</li> <li>STEMI due to stent thrombosis</li> <li>Previous documented allergic reaction to everolimus or to any stent material</li> <li>Severe mechanical complication of acute myocardial infarction</li> <li>Pre-existing severe renal failure (estimated glomerular filtration rate &lt;30 mL/min) or renal replacement therapy</li> <li>CTO of a major coronary artery</li> <li>Left main stem stenosis ≥ 50% or left main stem equivalent (ostial left anterior descending and ostial circumflex stenosis ≥ 70%)</li> <li>In-stent restenosis</li> </ul>

		<ul> <li>Planned coronary, cerebrovascular, or peripheral arterial revascularization</li> <li>Planned cardiac or major surgery</li> <li>Any contraindications for dual antiplatelet therapy with aspirin and a P2Y<sub>12</sub> Inhibitor for at least 90 days, except for patients on oral anticoagulation</li> <li>Known pregnancy at the time of inclusion</li> <li>Participation in another clinical study with an investigational product</li> <li>Life expectancy &lt; 1 year</li> </ul>
FULL REVASC (2024)	<ul> <li>Diagnosis of STEMI undergoing urgent PCI or pharmaco-invasive PCI</li> <li>Patients undergoing urgent PCI for very-high-risk NSTEMI</li> <li>Presenting with multivessel coronary artery disease</li> </ul>	<ul><li>Previous CABG</li><li>Left main coronary artery disease</li><li>Cardiogenic shock</li></ul>

CABG = Coronary Artery Bypass Grafting; CTO = Chronic Total Occlusion; ECG = Electrocardiography; FFR = Fractional Flow Reserve; IRA = Infarct-Related Artery; MI = Myocardial Infarction; MVD = Multivessel Disease; NSTEMI = Non-ST Segment Elevation Myocardial Infarction; PCI = Percutaneous Coronary Intervention; STEMI = ST-Segment Elevation Myocardial Infarction; TIMI = Thrombolysis in Myocardial Infarction;

Supplementary Table 4. Definition of complete revascularisation in intervention and control arms and percentages of crossover.

Trial, Year	Intervention	Control	Crossover from Intervention to Cont <u>rol</u>	Crossover from Control to Intervention
PRAMI (2013)	Immediate PCI of non-infarct arteries with more than 50% stenoses.	No further intervention after PCI of the culprit artery.	No crossover reported.	No crossover reported.
CvLPRIT (2015)	Immediate PCI of non-infarct-related arteries with more than 70% stenoses.	PCI of the infarct-related artery only.	11/150 crossed to IRA- Only revascularization	7/146 crossed to angiography-guided index complete revascularization
DANAMI-3- PRIMULTI (2015)	Revascularization of non-infarct-related arteries with more than 50% stenoses and an FFR value of less than 0.80 two days after the initial PCI.	No further intervention after PCI of the infarct-related artery.	No crossover reported. Median time to revascularization: 2 days	No crossover reported.
SMILE (2016)	One-stage complete revascularization. The presence of significant coronary stenosis was left to the operator's discretion.	Two-stage complete revascularization within three to seven days from the initial PCI. The presence of significant coronary stenosis was left to the operator's discretion.	No crossover reported.	No crossover reported.
COMPARE- ACUTE (2017)	Revascularization of non-infarct-related arteries with more than 50% stenoses and an FFR value of less than 0.80 two days after the initial PCI, generally in the same intervention. If delayed, completion of the procedure within 72 hours was required.	No further intervention after PCI of the infarct-related artery.	No crossover reported. Median time to revascularization: 6 minutes.	No crossover reported.
CROSS-AMI (2019)	Two-stage complete revascularization before discharge if stress echocardiography showed either low workload myocardial ischaemia (<120 bpm or <10 µg/kg per min of dobutamine) or myocardial ischaemia involving >2 coronary segments.	Two-stage complete revascularization before discharge.	No crossover reported. Median time to revascularization: 5 days.	No crossover reported. Median time to revascularization: 5 days.
COMPLETE (2019)	Two-stage complete revascularization of non-culprit lesions with at least 70% stenosis on visual estimation or 50 to 69% accompanied by a FFR measurement of 0.80 or less.	No further intervention after PCI of the culprit lesion.	79/2016 crossed to IRA- Only revascularization. Median time to revascularization: 1 day and 23 days.	95/2025 crossed to angiography-guided staged revascularization.
FLOWER-MI (2021)	Complete revascularization of non-culprit lesions with at least 50% stenosis with a FFR measurement of 0.80 or less. Staged procedures were permitted at operator's discretion.	Complete revascularization of non- culprit lesions with at least 50% stenosis at angiography. Staged procedures were permitted at operator's discretion.	No crossover reported. Median time to revascularization: 2.6 days.	No crossover reported. Median time to revascularization: 2.7 days.
FRAME-AMI (2023)	Complete revascularization of non-culprit lesions with at least 50% stenosis with a FFR measurement	Complete revascularization of non- culprit lesions with at least 50% stenosis at angiography. Staged	No crossover reported. 40% of patients underwent	No crossover reported. 40% of patients underwent

	of 0.80 or less. Staged procedures were permitted at operator's discretion.	procedures were permitted at operator's discretion.	revascularization during a staged procedure.	revascularization during a staged procedure.
BIOVASC (2023)	Immediate complete revascularization of all lesions deemed clinically significant by the operator.	Staged complete revascularization of all lesions deemed clinically significant by the operator.	10/764 crossed to angiography-guided staged complete revascularization.	7/761 crossed to angiography-guided immediate complete revascularization.
FIRE (2023)	Complete revascularization of all functionally significant non-culprit lesion, defined as a lesion with a hyperemic, nonhyperemic, or angiography-based threshold ratio of 0.80, 0.89, and 0.80 or less, respectively. Both physiological assessment and PCI of nonculprit lesions were allowed during either index or staged procedure within the index hospitalization.	No further intervention after PCI of the culprit lesion.	19/720 crossed to culprit- only revascularization.	12/725 crossed to functionally guided index complete revascularization.
COCUA (2023)	Immediate complete revascularization of all lesions deemed clinically significant by the operator.	Staged complete revascularization of all lesions deemed clinically significant by the operator.	No crossover reported. Median time to revascularization: 4 days.	No crossover reported. Median time to revascularization: 0 days.
MULTISTARS AMI (2023)	Immediate complete revascularization of all lesions with at least 70% stenosis at angiography.	Staged complete revascularization of all lesions with at least 70% stenosis at angiography between 19 and 45 days.	12/418 crossed to angiography-guided staged complete revascularization.	No crossover reported. Median time to revascularization: 37 days.
FULL REVASC (2024)	Complete revascularization of non-culprit lesions with a FFR measurement of 0.80 or less. Staged procedures were permitted at operator's discretion.	No further intervention after PCI of the culprit lesion.	No crossover reported. 17% underwent complete revascularization during the index procedure.	3/778 crossed to functionally guided staged complete revascularization.

IRA = Infarct Related Artery; FFR = Fractional Flow Reserve; PCI = Percutaneous Coronary Intervention.

Trial, Year	Myocardial Infarction	Cardiac Death	Death	Definite or Probable Stent Thrombosis	Any Revascularization	Ischaemia-Driven Revascularization	Major Adverse Cardiac Events	Stroke	CIAKI	Major Bleeding
PRAMI (2013)	Χ	Χ			Χ		Χ	Χ	Χ	Χ
CvLPRIT (2015)	Χ	Χ	Χ		Χ	Χ	Χ	X	Χ	Χ
DANAMI-3- PRIMULTI (2015)	X	Χ	X		Χ	X	Χ	X	X	X
SMILE (2016)	Χ	Χ	Χ	Χ	X		Χ	X	Χ	Χ
COMPARE- ACUTE (2017)	Χ	Χ	X	X	X	Χ	Χ	X		Χ
CROSS-AMI (2019)	Χ	Χ	Χ	X	Χ	X	Χ	X	Χ	Χ
COMPLETE (2019)	X	Χ	X	X	X	Χ	Χ	X	Χ	Χ
FLOWER-MI (2021)	Χ		Χ	X	X	X	Χ			
FRAME-AMI (2023)	X	Χ	Χ	Χ	Χ		Χ	X	Χ	
BIOVASC (2023)	Χ	Χ	Χ	X	X	X	Χ	X		Χ
FIRE (2023)	X	Χ	X	X	X	Χ	Χ	X	Χ	Χ
COCUA (2023)	X	Χ	Χ	Χ	X		Χ	X		Χ
MULTISTARS AMI (2023)	X	X	X	X	X	X	X	X	X	X
FULL REVASC (2024)	X	X	X		X		X	X		X

Supplementary Table 5. Available endpoints across trials.

The table shows the availability of the prespecified endpoints (rows) for each trial (columns), indicated by an X if available.

CIAKI = Contrast-Induced Acute Kidney Injury.
## Supplementary Table 6. Myocardial infarction and MACE definitions across trials.

Trial, Year	Myocardial Infarction	Major Adverse Cardiac Events
PRAMI (2013)	Symptoms of cardiac ischaemia and a troponin level above the 99 <sup>th</sup> centile. For patients with a recurrent MI within 14 days after randomization, the definition required new electrocardiographic evidence of ST-segment elevation or left bundle branch block and angiographic evidence of coronary-artery occlusion.	Cardiovascular death, nonfatal MI, or refractory angina.
CvLPRIT (2015)	<ul> <li>Troponin level is not routinely measured post PCI. MI will require a hospital admission, or be diagnosed in hospital, with one or more of the following:</li> <li>Type 1: Spontaneous MI: Recurrent angina symptoms or new ECG changes occurring before PCI or &lt;48 hours from PCI that is compatible with re-MI associated with an elevation of CK-MB, troponin, or total CK beyond ULN and 20% or more above the previous value.</li> <li>Type 4a: CK-MB or total CK &gt;3 times the ULN within 48 hours following PCI. If the pre-PCI CK-MB or total CK level is higher than the ULN, there also needs to be: either the demonstration of a falling CK-MB or total CK level prior to the onset of the suspected event, or a subsequent peak of the cardiac biomarker of at least 20% above the previous value obtained prior to the onset of the suspected event.</li> <li>With either an appropriate clinical presentation or new ischemic ECG changes (ST-segment depression or ST-segment elevation or development of new pathological Q waves/LBBB).</li> <li>Type 4b: MI associated with stent thrombosis as documented by angiography or at autopsy AND fulfilling the criteria of spontaneous MI (Type 1).</li> </ul>	All-cause death, MI, ischaemia-driven revascularization, or heart failure.
DANAMI-3- PRIMULTI (2015)	Typical chest pain accompanied by substantial rise in troponins, development of new Q-waves on the electrocardiograph or both.	All-cause death, MI, or ischaemia- driven revascularization.
SMILE (2016)	MI was defined as symptoms of cardiac ischaemia and a troponin level above the 99 <sup>th</sup> percentile value. For patients with a recurrent MI within 14 days after randomization, the definition required new electrocardiographic evidence of ST-segment elevation, or new onset of left bundle branch block, or ST-segment depression, or transient elevation and/or T-wave changes and a rise of the troponin level above the 99 <sup>th</sup> percentile, with a 20% increase of the troponin value in the second sample and/or with angiographic evidence of ACS.	Cardiac death, MI, stroke, target vessel revascularization, or hospitalization for unstable angina.
COMPARE- ACUTE (2017)	Periprocedural with normal baseline enzymes: CK-MB >3 times ULN within 48 hours from PCI or a rise in CK-MB >5 times ULN within 7 days from CABG. Periprocedural in the setting of evolving MI: if the peak total CK-MB from the index infarction has not been reached, recurrent chest pain lasting >20 minutes and peak CK-MB measured within 24 hours is elevated by at least 50% above the previous level. If the CK-MB have returned to normal within 24 hours post index PCI: either a new elevation of CK-MB >2 times ULN or a rise by >50% above the previous nadir level if the CK-MB level has not returned to <uln.< th=""><th>All-cause death, nonfatal MI, cerebrovascular events, or any revascularization.</th></uln.<>	All-cause death, nonfatal MI, cerebrovascular events, or any revascularization.

	Spontaneous MI: either one between i) typical rise and fall of biochemical markers of myocardial necrosis with at least one among ischemic symptoms, pathologic Q waves or ECG changes or ii) pathologic findings of acute MI.	
CROSS-AMI (2019)	No definition provided.	Cardiovascular death, MI, coronary revascularization, readmission due to cardiac failure.
COMPLETE (2019)	Third universal definition. In patients with already elevated cardiac troponin, new ischemic symptoms for at least 20 minutes and evidence of unequivocally new ischemic electrocardiogram changes were required.	Cardiovascular death, MI, or ischaemia- driven revascularization.
FLOWER-MI (2021)	Fourth universal definition of MI.	All-cause death, nonfatal MI, or unplanned hospitalization leading to urgent revascularization.
FRAME-AMI (2023)	<ul> <li>Any of the following under the evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischaemia. Under these conditions any one of the following criteria meets the diagnosis for MI:</li> <li>1. Detection of a rise and/or fall of cardiac troponin with at least one value above the 99<sup>th</sup> percentile ULN and with at least one of the following: <ul> <li>Symptoms of ischaemia.</li> <li>New or presumed new significant ST-segment—T wave changes or new left bundle branch block.</li> <li>Development of pathological Q waves in the ECG.</li> <li>Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.</li> <li>Identification of an intracoronary thrombus by angiography or autopsy.</li> </ul> </li> <li>For recurrent MI, including MI originated from non-culprit lesions in patients with elevated and are stable or falling cardiac troponin values during the index hospitalization, cardiac troponin must rise by &gt;20% and be at least 5 times the 99<sup>th</sup> percentile URL. Additionally, new ischemic symptoms of at least 20 minutes and new significant ST—T changes or new LBBB are required. These ECG changes must be distinct from the original MI and not due to the usual ECG evolution of this event.</li> <li>2. Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischemic ECG changes or new LBBB, but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be increased.</li> <li>3. PCI- and procedure-related MI</li> <li>PCI-related MI is defined by elevation of cardiac troponin values (&gt;5 × 99<sup>th</sup> percentile URL) in patients with normal baseline values (≤99<sup>th</sup> percentile ULN) or a rise of cardiac troponin values &gt;20% if the baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial ischaemia or (ii) new ischemic ECG changes or (iii) angiographic findings consistent with a procedural complication or (iv) imaging demonstration of new loss of viabl</li></ul>	All-cause death, MI, or repeat revascularization.

	• For procedure-related MI from PCI for non-culprit lesions, angiographic findings consistent with a procedural flow-limiting complication such as coronary dissection, occlusion of a major epicardial artery or a side branch occlusion/thrombus, disruption of collateral flow, or distal embolization need to be confirmed.	
	4. Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocardial ischaemia and with a rise and/or fall of cardiac biomarker values with at least one value above the 99 <sup>th</sup> percentile URL.	
	5. CABG-related MI is arbitrarily defined by elevation of cardiac biomarker values (>10 × 99 <sup>th</sup> percentile URL) in patients with normal baseline cTn values ( $\leq$ 99 <sup>th</sup> percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.	
BIOVASC (2023)	Third universal definition. In patients with already elevated cardiac troponin, new ischemic symptoms for at least 20 minutes and evidence of unequivocally new ischemic electrocardiogram changes were required.	All-cause death, any MI, cerebrovascular events, or unplanned ischaemia-driven revascularization.
FIRE (2023)	Fourth universal definition of MI.	All-cause death, MI, stroke or ischaemia-driven revascularization.
COCUA (2023)	Recurrent symptoms with new ST-segment elevation or re-elevation of cardiac markers at least twice ULN.	All-cause death, recurrent MI, or repeat revascularization.
MULTISTARS AMI (2023)	Third universal definition of MI.	All-cause death, nonfatal MI, stroke, unplanned ischaemia-driven revascularization, or hospitalization for heart failure.
FULL REVASC (2024)	Third universal definition of MI.	All-cause death, MI, or unplanned revascularization.

CK-MB = Creatine Kinase Myocardial Band; ECG = Electrocardiography; LBBB = Left Bundle Branch Block; MI = Myocardial Infarction; PCI = Percutaneous Coronary Intervention; UNL = Upper Limit of the Normal; URL = Upper Reference Limit.

## Supplementary Table 7. Bayesian random-effects network meta-analysis – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.13 [1.13-3.96]	1.24 [0.62-2.48]	1.55 [0.92-2.92]	0.81 [0.30-2.11]
Angio Immediate CR	0.47 [0.25-0.89]		0.58 [0.31-1.11]	0.73 [0.39-1.53]	0.38 [0.13-1.09]
Angio Staged CR	0.81 [0.40-1.61]	1.72 [0.90-3.19]		1.25 [0.59-2.95]	0.65 [0.24-1.74]
Functional Immediate CR	0.64 [0.34-1.09]	1.36 [0.65-2.54]	0.80 [0.34-1.70]		0.52 [0.16-1.48]
Functional Staged CR	1.24 [0.47-3.36]	2.64 [0.91-7.64]	1.54 [0.58-4.21]	1.93 [0.68-6.16]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.24 [0.58-3.05]	1.26 [0.60-3.46]	1.53 [0.80-3.54]	1.40 [0.35-5.51]
Angio Immediate CR	0.80 [0.33-1.72]		1.02 [0.53-2.18]	1.24 [0.46-3.30]	1.12 [0.23-4.85]
Angio Staged CR	0.80 [0.29-1.65]	0.98 [0.46-1.90]		1.22 [0.41-3.30]	1.10 [0.22-4.48]
Functional Immediate CR	0.65 [0.28-1.26]	0.81 [0.30-2.17]	0.82 [0.30-2.46]		0.91 [0.18-4.02]
Functional Staged CR	0.71 [0.18-2.86]	0.89 [0.21-4.35]	0.91 [0.22-4.50]	1.10 [0.25-5.55]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.12 [0.64-1.93]	1.19 [0.68-2.36]	1.27 [0.80-2.22]	0.65 [0.23-1.81]
Angio Immediate CR	0.89 [0.52-1.56]		1.07 [0.66-1.94]	1.13 [0.65-2.17]	0.58 [0.18-1.78]
Angio Staged CR	0.84 [0.42-1.46]	0.93 [0.51-1.51]		1.06 [0.51-2.13]	0.54 [0.16-1.60]
Functional Immediate CR	0.79 [0.45-1.25]	0.88 [0.46-1.53]	0.94 [0.47-1.96]		0.51 [0.15-1.53]
Functional Staged CR	1.54 [0.55-4.42]	1.72 [0.56-5.46]	1.84 [0.63-6.20]	1.95 [0.66-6.53]	
Definite or Probable Stent Thrombos	sis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.80 [0.25-2.55]	0.72 [0.26-2.02]	1.39 [0.52-3.65]	0.18 [0.02-1.49]
Angio Immediate CR	1.24 [0.39-4.05]		0.89 [0.38-2.10]	1.72 [0.53-5.70]	0.23 [0.03-1.71]
Angio Staged CR	1.39 [0.49-3.86]	1.12 [0.48-2.60]		1.94 [0.59-6.31]	0.25 [0.04-1.61]
Functional Immediate CR	0.72 [0.27-1.92]	0.58 [0.18-1.89]	0.52 [0.16-1.70]		0.13 [0.01-1.17]
Functional Staged CR	5.59 [0.67-44.84]	4.43 [0.58-32.79]	3.98 [0.62-24.75]	7.72 [0.85-69.29]	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.97 [1.49-5.62]	2.03 [0.94-4.23]	2.20 [1.16-4.22]	2.75 [0.96-7.76]
Angio Immediate CR	0.34 [0.18-0.67]		0.68 [0.37-1.30]	0.74 [0.37-1.58]	0.93 [0.32-2.88]
Angio Staged CR	0.49 [0.24-1.06]	1.46 [0.77-2.73]		1.09 [0.47-2.65]	1.35 [0.48-4.01]
Functional Immediate CR	0.45 [0.24-0.86]	1.34 [0.63-2.71]	0.92 [0.38-2.14]		1.25 [0.38-4.01]
Functional Staged CR	0.36 [0.13-1.04]	1.08 [0.35-3.16]	0.74 [0.25-2.10]	0.80 [0.25-2.66]	
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR

IRA-Only		3.00 [0.96-8.75]	2.42 [0.77-7.16]	2.07 [0.70-5.99]	3.03 [0.76-11.71]
Angio Immediate CR	0.33 [0.11-1.04]		0.81 [0.28-2.30]	0.69 [0.20-2.49]	1.01 [0.22-4.82]
Angio Staged CR	0.41 [0.14-1.30]	1.24 [0.43-3.55]		0.85 [0.22-3.58]	1.25 [0.32-4.98]
Functional Immediate CR	0.48 [0.17-1.43]	1.45 [0.40-4.97]	1.18 [0.28-4.60]		1.47 [0.27-7.76]
Functional Staged CR	0.33 [0.09-1.31]	0.99 [0.21-4.60]	0.80 [0.20-3.12]	0.68 [0.13-3.65]	
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only	IRA-Only	Angio Immediate CR 1.92 [1.16-3.12]	Angio Staged CR 1.51 [0.87-2.67]	Functional Immediate CR 1.77 [1.11-2.93]	Functional Staged CR 1.62 [0.73-3.55]
IRA-Only Angio Immediate CR	IRA-Only 0.52 [0.32-0.86]	Angio Immediate CR 1.92 [1.16-3.12]	Angio Staged CR 1.51 [0.87-2.67] 0.78 [0.50-1.27]	Functional Immediate CR           1.77 [1.11-2.93]           0.92 [0.55-1.64]	Functional Staged CR 1.62 [0.73-3.55] 0.85 [0.37-1.98]
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.52 [0.32-0.86] 0.66 [0.37-1.14]	Angio Immediate CR 1.92 [1.16-3.12] 1.27 [0.79-2.00]	Angio Staged CR 1.51 [0.87-2.67] 0.78 [0.50-1.27]	Functional Immediate CR           1.77 [1.11-2.93]           0.92 [0.55-1.64]           1.18 [0.62-2.26]	Functional Staged CR 1.62 [0.73-3.55] 0.85 [0.37-1.98] 1.08 [0.48-2.40]
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.52 [0.32-0.86] 0.66 [0.37-1.14] 0.56 [0.34-0.90]	Angio Immediate CR 1.92 [1.16-3.12] 1.27 [0.79-2.00] 1.08 [0.61-1.82]	Angio Staged CR 1.51 [0.87-2.67] 0.78 [0.50-1.27] 0.85 [0.44-1.61]	Functional Immediate CR           1.77 [1.11-2.93]           0.92 [0.55-1.64]           1.18 [0.62-2.26]	Functional Staged CR 1.62 [0.73-3.55] 0.85 [0.37-1.98] 1.08 [0.48-2.40] 0.91 [0.37-2.19]

Values are HRs [95% CrIs].

CrI = Credible Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

Supplementary Table 8. Frequentist and Bayesian random-effects network meta-analysis rank probabilities and SUCRA – 5-node analysis.

Frequentist Random-Effects Model.					
Myocardial Infar	ction				
Ranking	Angio Immediate CR	Angio Staged CR	IRA-Only	Functional Immediate CR	Functional Staged CR
1 <sup>st</sup>	79.0	0.5	0	20.5	0
2 <sup>nd</sup>	20.3	8.8	0	70.4	0.5
3 <sup>rd</sup>	0.7	75.5	6.9	8.8	8.1
4 <sup>th</sup>	0	12.5	62.2	0.3	25.0
5 <sup>th</sup>	0	2.7	30.9	0	66.4
SUCRA	94.5	47.8	19.7	77.0	11.1
Cardiac Death					
Ranking	Angio Immediate CR	Angio Staged CR	IRA-Only	Functional Immediate CR	Functional Staged CR
1 <sup>st</sup>	12.0	11.9	0.1	60.0	16.0
2 <sup>nd</sup>	24.6	29.2	3.4	22.1	20.7
3 <sup>rd</sup>	28.4	27.1	14.6	10.5	19.4
4 <sup>th</sup>	21.3	20.6	36.0	4.9	17.2
5 <sup>th</sup>	13.7	11.2	45.9	2.5	26.7
SUCRA	51.2	50.9	18.9	83.9	45.1
Death					
Ranking	Angio Immediate CR	Angio Staged CR	IRA-Only	Functional Immediate CR	Functional Staged CR
1 <sup>st</sup>	15.1	10.1	0.0	74.2	0.6
2 <sup>nd</sup>	43.4	34.1	2.1	18.1	2.3
3 <sup>rd</sup>	29.5	40.1	19.9	6.3	4.2
4 <sup>th</sup>	9.7	12.5	64.4	1.1	12.3
5 <sup>th</sup>	2.3	3.2	13.6	0.3	80.6
SUCRA	64.5	58.8	26.5	91.6	8.6
<b>Definite or Proba</b>	ble Stent Thrombos	sis			
Ranking	Angio Immediate CR	Angio Staged CR	IRA-Only	Functional Immediate CR	Functional Staged CR
1 <sup>st</sup>	8.7	0.7	18.1	71.7	0.8
2 <sup>nd</sup>	20.7	7.2	52.6	18.7	0.8
3 <sup>rd</sup>	34.0	34.6	22.4	6.7	2.3
4 <sup>th</sup>	32.7	55.0	6.2	2.6	3.5
5 <sup>th</sup>	3.9	2.5	0.7	0.3	92.6
SUCRA	51.5	36.8	70.3	89.2	2.2
Any Revasculariz	ation			-	
Ranking	Angio Immediate CR	Angio Staged CR	IRA-Only	Functional Immediate CR	Functional Staged CR
1 <sup>st</sup>	58.2	4.6	0	21.0	16.2
2 <sup>nd</sup>	28.8	13.2	0	33.2	24.8
3 <sup>rd</sup>	10.3	31.3	0.1	28.2	30.1
4 <sup>th</sup>	2.7	50.5	2.1	17.1	27.6
5 <sup>th</sup>	0	0.4	97.8	0.5	1.3
SUCRA	85.2	44.5	0.8	62.2	57.2
Ischaemia-Driven	Revascularization				
Ranking	Angio Immediate CR	Angio Staged CR	IRA-Only	Functional Immediate CR	Functional Staged CR
1 <sup>st</sup>	34.4	13.4	0	8.7	43.5
2 <sup>nd</sup>	38.7	24.0	0	15.0	22.3
3 <sup>rd</sup>	18.5	36.5	0.1	26.4	18.4
4 <sup>th</sup>	8.3	25.7	7.1	44.8	14.1
5 <sup>th</sup>	0.1	0.4	92.8	5.1	1.6

Major Adverse Cardiac EventsRankingAngio Immediate CRAngio Staged CRIRA-OnlyFunctional Immediate CRFu Staged CR1st43.32.9050.42nd44.413.5033.93rd11.048.80.512.1	unctional taged CR 3.3						
RankingAngio Immediate CRAngio Staged CRIRA-OnlyFunctional Immediate CRFunctional St1st43.32.9050.42nd44.413.5033.93rd11.048.80.512.1	unctional taged CR 3.3						
1 <sup>st</sup> 43.3         2.9         0         50.4           2 <sup>nd</sup> 44.4         13.5         0         33.9           3 <sup>rd</sup> 11.0         48.8         0.5         12.1	3.3						
2 <sup>nd</sup> 44.4         13.5         0         33.9           3 <sup>rd</sup> 11.0         48.8         0.5         12.1							
<b>3<sup>rd</sup></b> 11.0 48.8 0.5 12.1	8.2						
	27.6						
<b>4<sup>th</sup></b> 1.2 33.4 10.7 3.6	51.1						
<b>5<sup>th</sup></b> 0 1.4 88.8 0	9.8						
SUCRA         82.4         44.7         2.8         83.8	36.3						
Bayesian Random-Effects Model							
Myocardial infarction							
RankingAngio Immediate CRAngio Staged CRIRA-OnlyFunctional Immediate CRFu	inctional aged CR						
<b>1</b> <sup>st</sup> 77.8 2.9 0.3 16.4	2.6						
<b>2<sup>nd</sup></b> 18.2 21.5 1.9 53.6	4.8						
<b>3</b> <sup>rd</sup> 3.1 44.9 19.3 22.5	10.1						
<b>4</b> <sup>th</sup> 0.7 23.0 52.6 6.1	17.5						
<b>5</b> <sup>th</sup> 0.1 7.6 25.9 1.4	64.9						
SUCRA 93.2 47.3 24.5 69.3	15.7						
Cardiac Death							
RankingAngioAngioAngioImmediate CRStaged CRIRA-OnlyFunctionalImmediate CRStaged CRImmediate CRStaged CR	anctional taged CR						
<b>1</b> <sup>st</sup> 12.1 13.8 0.9 36.5	36.8						
<b>2<sup>nd</sup></b> 23.7 24.0 6.4 30.6	1 - 0						
	15.3						
<b>3</b> <sup>ra</sup> 2/.1 2/.9 10./ 1/.5	15.3 10.8						
3.a         27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4	15.3 10.8 12.1						
$3^{th}$ $27.1$ $27.9$ $16.7$ $17.5$ $4^{th}$ $21.2$ $22.1$ $33.1$ $11.4$ $5^{th}$ $15.9$ $12.2$ $42.9$ $4.1$	15.3 10.8 12.1 25.0						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0	15.3         10.8         12.1         25.0         56.7						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Eunotional         Eunotional	15.3 10.8 12.1 25.0 56.7						
3 <sup>ch</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Functional Figure CR           Ranking         Angio         Angio         Staged CR         IRA-Only         Functional Immediate CR         Staged CR	15.3 10.8 12.1 25.0 56.7 unctional taged CR						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Functional Immediate CR         Staged CR           1 <sup>st</sup> 14.4         30.8         2.9         45.3	15.3 10.8 12.1 25.0 56.7 unctional taged CR 6.6						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Functional Immediate CR         Staged CR           1 <sup>st</sup> 14.4         30.8         2.9         45.3           2 <sup>nd</sup> 28.4         27.4         14.0         25.4	15.3 10.8 12.1 25.0 56.7 unctional taged CR 6.6 4.8						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Functional 30.8           1 <sup>st</sup> 14.4         30.8         2.9         45.3         51.3         25.4           2 <sup>nd</sup> 28.8         22.6         24.7         18.8         25.4	15.3 10.8 12.1 25.0 56.7 unctional taged CR 6.6 4.8 5.1						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Staged CR           1 <sup>st</sup> 14.4         30.8         2.9         45.3         51.3         25.4           3 <sup>rd</sup> 28.8         22.6         24.7         18.8         4 <sup>th</sup> 21.2         15.0         47.7         8.2	15.3 10.8 12.1 25.0 56.7 unctional taged CR 6.6 4.8 5.1 8.0						
3 <sup>r.t.</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Staged CR           1 <sup>st</sup> 14.4         30.8         2.9         45.3         51.3         51.3         51.3           2 <sup>nd</sup> 28.4         27.4         14.0         25.4         51.3	15.3 10.8 12.1 25.0 56.7 unctional taged CR 6.6 4.8 5.1 8.0 75.4						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Filt           1st         14.4         30.8         2.9         45.3         51.3         21.2         51.3 <t< th=""><th>15.3 10.8 12.1 25.0 56.7 unctional taged CR 6.6 4.8 5.1 8.0 75.4 14.8</th></t<>	15.3 10.8 12.1 25.0 56.7 unctional taged CR 6.6 4.8 5.1 8.0 75.4 14.8						
3 <sup>.4</sup> 27.1       27.9       16.7       17.5         4 <sup>th</sup> 21.2       22.1       33.1       11.4         5 <sup>th</sup> 15.9       12.2       42.9       4.1         SUCRA       48.7       51.3       22.3       71.0         Death       Immediate CR       Staged CR       IRA-Only       Functional Immediate CR       Functional Staged CR         1 <sup>st</sup> 14.4       30.8       2.9       45.3       45.3         2 <sup>nd</sup> 28.4       27.4       14.0       25.4       51.3         3 <sup>rd</sup> 28.8       22.6       24.7       18.8       4 <sup>th</sup> 21.2       15.0       47.7       8.2       5 <sup>th</sup> 5 <sup>th</sup> 7.2       4.2       10.8       2.3       5 <sup>th</sup>	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Functional Staged CR         Functional           1 <sup>st</sup> 14.4         30.8         2.9         45.3         51.4         51.3         51.4         51.3         51.4         51.3         51.3         51.4         51.4         51.4         51.4         51.4         51.4         51.4	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         St           1st         14.4         30.8         2.9         45.3         51.3         25.4         51.3           2 <sup>nd</sup> 28.4         27.4         14.0         25.4         51.3         51	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         14.8         11.9						
3 <sup>-th</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         FV           1 <sup>st</sup> 14.4         30.8         2.9         45.3         51.3         <	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Fi           1 <sup>st</sup> 14.4         30.8         2.9         45.3         51.3         22.4         51.3         22.3         71.0         51.3         22.3         71.0         51.3         51.4         51.3         51.4         51.3         51.4         51.3         51.4         51.4         51.4         51.4         51.4         51.4 <t< th=""><th>15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6</th></t<>	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Fi           anking         Angio         Angio         Staged CR         IRA-Only         Functional Immediate CR         Fi           1st         14.4         30.8         2.9         45.3         55.4         55.4         56.2         57.4         57.4         57.4         57.4         57.6         57.8         57.8           Definite or Probable Stent Thrombosis         Staged CR         IRA-Only         Functional Immediate CR         France           1st         10.6         4.2         10.8         2.3         57.8         57.8           Definite or Probable Stent Thrombosis         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         France           1st         10.6         4.2         18.2         65.1         57.8         57.8           Definite or P	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1						
3 <sup>-1</sup> 27.1       27.9       16.7       17.3         4 <sup>th</sup> 21.2       22.1       33.1       11.4         5 <sup>th</sup> 15.9       12.2       42.9       4.1         SUCRA       48.7       51.3       22.3       71.0         Death       Immediate CR       Staged CR       IRA-Only       Functional Immediate CR       Staged CR         1 <sup>st</sup> 14.4       30.8       2.9       45.3       45.3       54.4         2 <sup>nd</sup> 28.4       27.4       14.0       25.4       54.4       55.4       55.4       56.4       57.8         5 <sup>th</sup> 7.2       4.2       10.8       2.3       55.4       55.4       56.4       57.8       55.4         5 <sup>th</sup> 7.2       4.2       10.8       2.3       55.4       55.4       56.1       57.8         Definite or Probable Stent Thrombosis       Immediate CR       Staged CR       IRA-Only       Functional Immediate CR       Staged CR         1 <sup>st</sup> 10.6       4.2       18.2       65.1       55.4       56.1       56.1         2 <sup>nd</sup> 20.8       11.2       45.5       20.8       56.1       56.1       56.1       56.1	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Fut           1 <sup>st</sup> 14.4         30.8         2.9         45.3         25.4         31.3         31.4           2 <sup>nd</sup> 28.4         27.4         14.0         25.4         31.4         30.8         2.9         45.3         31.4           2 <sup>nd</sup> 28.4         27.4         14.0         25.4         31.4         30.8         31.4         31.4         31.8         31.4           3 <sup>rd</sup> 28.8         22.6         24.7         18.8         31.4         31.8         31.4           3 <sup>th</sup> 7.2         4.2         10.8         2.3         31.4         31.8         31.6           SUCRA         55.4         66.4         37.6         75.8         31.4           1 <sup>st</sup> 10.6         4.2         18.2	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Fill           1st         14.4         30.8         2.9         45.3         45.3         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Fill           1 <sup>st</sup> 14.4         30.8         2.9         45.3         45.3         51.3	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         FV           1st         14.4         30.8         2.9         45.3         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         FV           3 <sup>rd</sup> 28.4         27.4         14.0         25.4         53         54         54         54         54         54         54         54         55.4         55.4         55.4         55.4         55.4         55.4         55.4         55.1         55.8         55.4         55.4         55.4         55.1         55.4         55.1         55.4         55.1         50.8         51.1           Banking         Angio         Staged CR         IRA-Only         Functional Immediate CR         Staged CR         50.1         50.1         50.1	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Fill           1 <sup>st</sup> 14.4         30.8         2.9         45.3         26.4         27.4         14.0         25.4         27.4           3 <sup>rd</sup> 28.4         27.4         14.0         25.4         27.4         14.0         25.4         27.4         14.0         25.4         27.4         14.0         25.4         27.4         14.0         25.4         27.4 <t< th=""><th>15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR</th></t<>	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR						
3 <sup>rd</sup> 27.1         27.9         16.7         17.3           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Fv           2nd         28.4         27.4         14.0         25.4         25.4           3 <sup>rd</sup> 28.8         22.6         24.7         18.8         4           4 <sup>th</sup> 21.2         15.0         47.7         8.2         5           5 <sup>th</sup> 7.2         4.2         10.8         2.3         5           SUCRA         55.4         66.4         37.6         75.8         5           Definite or Probable Stent Thrombosis         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Fv           1 <sup>st</sup> 10.6         4.2         18.2         65.1         5           2 <sup>nd</sup> 20.8         11.2         45.5         20.8         5           3 <sup>rd</sup> 34.3         33.6	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR         40.9         21.5						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         Fu           2 <sup>rd</sup> 28.4         27.4         14.0         25.4         51.3         20.9         45.3           2 <sup>rd</sup> 28.8         22.6         24.7         18.8         24.7         18.8         24.7           3 <sup>rd</sup> 28.8         22.6         24.7         18.8         24.7         35.4         36.4         37.6         75.8           UCRA         55.4         66.4         37.6         75.8         37.6         75.8           Definite or Probable Stent Thrombosis         Kaged CR         IRA-Only         Functional Immediate CR         St           1 <sup>st</sup> 10.6         4.2         18.2         65.1         50.1         50.1           2 <sup>rd</sup> 20.8         11.2         45.5         20.8         50.1         50.1 <t< th=""><th>15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR         4.1         89.7         5.5         unctional         taged CR         4.1         89.7         5.5         unctional         taged CR         40.9         21.5         18.8         16.6</th></t<>	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR         4.1         89.7         5.5         unctional         taged CR         4.1         89.7         5.5         unctional         taged CR         40.9         21.5         18.8         16.6						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Functional Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         St           2 <sup>nd</sup> 28.4         27.4         14.0         25.4         25.4           3 <sup>rd</sup> 28.8         22.6         24.7         18.8         24.1           3 <sup>rd</sup> 28.8         22.6         24.7         18.8         24.1           3 <sup>rd</sup> 28.8         22.6         24.7         18.8         24.1           3 <sup>rd</sup> 28.4         27.4         10.8         2.3         35.4           5 <sup>th</sup> 7.2         4.2         10.8         2.3         35.1           SUCRA         55.4         66.4         37.6         75.8         36.1           Befinite or Probable Stent Thrombosis         Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         St           3 <sup>rd</sup> 30.2 </th <th>15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR         4.0.9         21.5         18.8         16.3         2.4</th>	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR         4.0.9         21.5         18.8         16.3         2.4						
3 <sup>rd</sup> 27.1         27.9         16.7         17.5           4 <sup>th</sup> 21.2         22.1         33.1         11.4           5 <sup>th</sup> 15.9         12.2         42.9         4.1           SUCRA         48.7         51.3         22.3         71.0           Death         Functional Immediate CR         Staged CR         IRA-Only         Functional Immediate CR         St           1 <sup>st</sup> 14.4         30.8         2.9         45.3         20         45.3         20           2 <sup>rod</sup> 28.4         27.4         14.0         25.4         3 <th>15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR         40.9         21.5         18.8         16.3         2.4</th>	15.3         10.8         12.1         25.0         56.7         unctional         taged CR         6.6         4.8         5.1         8.0         75.4         14.8         unctional         taged CR         1.9         1.7         2.6         4.1         89.7         5.5         unctional         taged CR         40.9         21.5         18.8         16.3         2.4						

Ranking	Angio Immediate CR	Angio Staged CR	IRA-Only	Functional Immediate CR	Functional Staged CR
1 <sup>st</sup>	35.5	11.6	0.1	41.5	41.5
2 <sup>nd</sup>	32.6	28.3	0.8	21.0	21.0
3 <sup>rd</sup>	22.3	34.2	2.7	19.0	19.0
4 <sup>th</sup>	8.2	22.3	11.5	14.7	14.7
5 <sup>th</sup>	1.5	3.7	84.8	3.8	3.8
SUCRA	73.1	55.4	5.0	46.0	70.4
Major Adverse C	ardiac Events				
Ranking	Angio Immediate CR	Angio Staged CR	IRA-Only	Functional Immediate CR	Functional Staged CR
1 <sup>st</sup>	42.3	5.4	0	29.4	25.8
2 <sup>nd</sup>	35.6	16.4	0.3	31.5	16.2
3 <sup>rd</sup>	17.4	34.8	2.2	24.2	21.3
4 <sup>th</sup>	4.4	38.4	12.9	17.0	27.4
5 <sup>th</sup>	0.3	5.0	84.6	0.8	9.3
SUCRA	78.8	44.7	4.6	66.5	55.5

Values are percentages.

CR = Complete Revascularization; IRA = Infarct Related Artery; SUCRA= Surface Under the Cumulative Ranking Curve.

		Frequentist		Bayesian	
	W (%)	HR [95 CI]	Pinconsistency	HR [95 CrI]	Pinconsistency
Myocardial Infarction					
Angio Immediate CR					
vs			0.641		0.507
IRA–only					
Direct	35	0.37 [0.17-0.78]		0.37 [0.13-1.00]	
Indirect	65	0.46 [0.26-0.80]		0.55 [0.24-1.33]	
Network		0.42 0.27-0.66		0.47 [0.25-0.89]	
Angio Staged CR					
vs			0.575		0.610
IRA-Only					
Direct	56	0.68 [0.38-1.22]		0.68 [0.21-2.50]	
Indirect	44	0.87 [0.45-1.68]		0.95 [0.35-2.33]	
Network		0.76 [0.49-1.18]		0.81 [0.40-1.61]	
Functional Immediate CR					
vs			0.071		0.061
IRA-Only					
Direct	74	0.67 [0.41-1.12]		0.82 [0.47-1.38]	
Indirect	26	0.27 [0.12-0.63]		0.27 [0.10-0.74]	
Network		0.53 [0.34-0.82]		0.64 [0.34-1.09]	
Functional Staged CR					
vs			0.430		0.443
IRA-Only					
Direct	83	1.03 [0.62-1.74]		0.93 [0.26-3.45]	
Indirect	17	1.83 [0.58-5.79]		1.96 [0.40-10.03]	
Network		1.14 [0.71-1.83]		1.24 [0.47-3.36]	
Angio Immediate CR					
VS			0.207		0.270
Angio Staged CR					
Direct	66	0.45 [0.26-0.79]		0.47 [0.23-1.01]	
Indirect	34	0.83 [0.39-1.78]		0.93 [0.30-3.03]	
Network		0.56 [0.36-0.87]		0.58 [0.31-1.11]	
Angio Immediate CR					
VS			0.071		0.057
Functional Immediate CR					
Direct	56	1.19 [0.62-2.29]		1.21 [0.57-2.70]	

Supplementary Table 9. Node-splitting analysis for the frequentist and Bayesian frameworks – 5-node analysis.

Indirect	44	0.48 [0.23-1.00]		0.40 [0.18-1.00]	
Network		0.80 [0.49-1.30]		0.73 [0.39-1.53]	
Angio Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.37 [0.20-0.69]		0.38 [0.13-1.09]	
Network		0.37 [0.20-0.69]		0.38 [0.13-1.09]	
Angio Staged CR					
vs			-		-
Functional Immediate CR					
Direct	0	-		-	
Indirect	100	1.43 [0.82-2.50]		1.25 [0.59-2.95]	
Network		1.43 [0.82-2.50]		1.25 [0.59-2.95]	
Angio Staged CR					
vs			0.379		0.469
Functional Staged CR					
Direct	31	0.45 [0.16-1.29]		0.45 [0.11-1.85]	
Indirect	69	0.79 [0.39-1.60]		0.93 [0.21-4.35]	
Network		0.67 [0.37-1.20]		0.65 [0.24-1.74]	
Functional Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.47 [0.25-0.88]		0.52 [0.16-1.48]	
Network		0.47 [0.25-0.88]		0.52 [0.16-1.48]	
Cardiac Death					
Angio Immediate CR					
vs			0.028		0.040
IRA-only					
Direct	40	0.31 [0.10-0.92]		0.31 [0.100.97]	
Indirect	60	1.32 [0.66-2.67]		1.37 [0.59-3.85]	
Network		0.77 [0.39-1.54]		0.80 [0.33-1.72]	
Angio Staged CR					
VS			0.502		0.584
IRA-Only					
Direct	58	0.93 [0.39-2.23]		0.93 [0.21-4.17]	
Indirect	42	0.57 [0.19-1.74]		0.60 [0.15-2.08]	
Network		0.77 [0.40-1.50]		0.80 [0.29-1.65]	
<b>Functional Immediate CR</b>			0.021		0.025

vs					
IRA-Only					
Direct	82	0.78 [0.37-1.66]		0.80 [0.44-1.60]	
Indirect	18	0.11 [0.02-0.49]		0.11 [0.02-0.56]	
Network		0.55 [0.28-1.09]		0.65 [0.28-1.26]	
Functional Staged CR					
vs			0.624		0.512
IRA-Only					
Direct	92	0.76 [0.35-1.62]		0.56 [0.11-2.99]	
Indirect	8	1.53 [0.10-22.79]		1.61 [0.09-26.65]	
Network		0.80 [0.40-1.61]		0.71 [0.18-2.86]	
Angio Immediate CR					
vs			0.782		0.816
Angio Staged CR					
Direct	77	1.07 [0.55-2.07]		1.08 [0.47-2.70]	
Indirect	23	0.83 [0.16-4.30]		0.89 [0.16-5.26]	
Network		1.01 [0.56-1.80]		1.02 [0.53-2.18]	
Angio Immediate CR					
vs			0.027		0.025
Functional Immediate CR					
Direct	35	5.26 [1.24-22.36]		5.26 [1.19-25.00]	
Indirect	65	0.78 [0.32-1.89]		0.73 [0.22-1.78]	
Network		1.41 [0.60-3.34]		1.24 [0.46-3.30]	
Angio Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.96 [0.37-2.48]		1.12 [0.23-4.85]	
Network		0.96 [0.37-2.48]		1.12 [0.23-4.85]	
Angio Staged CR					
vs			-		-
Functional Immediate CR					
Direct	0	-		-	
Indirect	100	1.41 [0.58-3.42]		1.22 [0.41-3.30]	
Network		1.41 [0.58-3.42]		1.22 [0.41-3.30]	
Angio Staged CR					
vs			0.595		0.510
Functional Staged CR					
Direct	15	0.51 [0.04-6.15]		0.50 [0.04-7.14]	
Indirect	85	1.06 [0.37-3.10]		1.47 [0.21-9.09]	

Network		0.96 [0.37-2.48]		1.10 [0.22-4.48]	
Functional Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.68 [0.25-1.85]		0.91 [0.18-4.02]	
Network		0.68 [0.25-1.85]		0.91 [0.18-4.02]	
Death					
Angio Immediate CR					
vs			0.379		0.233
IRA-only					
Direct	35	0.62 [0.35-1.12]		0.62 [0.26-1.45]	
Indirect	65	1.02 [0.58-1.77]		1.15 [0.58-2.56]	
Network		0.83 [0.58-1.17]		0.89 [0.52-1.56]	
Angio Staged CR					
vs			0.502		0.749
IRA-Only					
Direct	70	0.91 [0.62-1.33]		0.91 [0.31-2.70]	
Indirect	30	0.69 [0.35-1.39]		0.75 [0.28-1.75]	
Network		0.85 [0.62-1.18]		0.84 [0.42-1.46]	
Functional Immediate CR		* *			
vs			0.379		0.248
IRA-Only					
Direct	78	0.73 [0.51-1.05]		0.89 [0.48-1.62]	
Indirect	22	0.47 [0.19-1.17]		0.48 [0.15-1.32]	
Network		0.68 [0.49-0.94]		0.79 [0.45-1.25]	
Functional Staged CR					
vs			0.545		0.674
IRA-Only					
Direct	97	1.20 [0.83-1.74]		1.40 [0.41-4.67]	
Indirect	3	2.46 [0.25-24.51]		2.46 [0.21-28.61]	
Network		1.22 [0.85-1.76]		1.54 [0.55-4.42]	
Angio Immediate CR					
vs			0.640		0.871
Angio Staged CR					
Direct	65	1.02 [0.66-1.55]		1.12 [0.60-2.33]	
Indirect	35	0.87 [0.53-1.42]		1.01 [0.31-3.57]	
Network		0.97 [0.69-1.36]		1.07 [0.66-1.94]	
Angio Immediate CR			0.404		0.262
vs			0.404		0.202

Functional Immediate CR					
Direct	50	1.43 [0.83-2.48]		1.56 [0.70-3.85]	
Indirect	50	1.03 [0.59-1.81]		0.84 [0.34-2.08]	
Network		1.22 [0.83-1.79]		1.13 [0.65-2.17]	
Angio Immediate CR				<u> </u>	
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.68 [0.41-1.12]		0.58 [0.18-1.78]	
Network		0.68 [0.41-1.12]		0.58 [0.18-1.78]	
Angio Staged CR					
vs			-		-
<b>Functional Immediate CR</b>					
Direct	0	-		-	
Indirect	100	1.26 [0.83-1.91]		1.06 [0.51-2.13]	
Network		1.26 [0.83-1.91]		1.06 [0.51-2.13]	
Angio Staged CR					
vs			0.506		0.689
Functional Staged CR					
Direct	5	0.34 [0.04-3.11]		0.35 [0.03-3.70]	
Indirect	95	0.73 [0.46-1.16]		0.61 [0.15-2.27]	
Network		0.70 [0.43-1.13]		0.54 [0.16-1.6]	
Functional Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.56 [0.34-0.91]		0.51 [0.15-1.53]	
Network		0.56 [0.34-0.91]		0.51 [0.15-1.53]	
Definite or Probable Stent Three	ombosis				
Angio Immediate CR					
vs			-		-
IRA-only					
Direct	0	-		-	
Indirect	100	1.24 [0.56-2.74]		1.24 [0.39-4.05]	
Network		1.24 [0.56-2.74]		1.24 [0.39-4.05]	
Angio Staged CR					
vs			0.931		0.941
IRA-Only					
Direct	89	1.38 [0.76-2.50]		1.37 [0.34-5.56]	
Indirect	11	1.49 [0.28-7.82]		1.56 [0.15-16.66]	

Network		1.39 [0.80-2.43]		1.39 [0.49-3.86]	
Functional Immediate CR					
vs			0.931		0.947
IRA-Only					
Direct	78	0.73 [0.32-1.67]		0.74 [0.23-2.36]	
Indirect	22	0.68 [0.14-3.21]		0.79 [0.07-8.56]	
Network		0.72 [0.35-1.49]		0.72 [0.27-1.92]	
Functional Staged CR		* *		ь	
vs			-		-
IRA-Only					
Direct	0	-		-	
Indirect	100	5.57 [1.05-29.66]		5.59 [0.67-44.84]	
Network		5.57 [1.05-29.66]		5.59 [0.67-44.84]	
Angio Immediate CR				<u> </u>	
vs			0.937		0.943
Angio Staged CR					
Direct	83	0.88 [0.42-1.81]		0.89 [0.34-2.38]	
Indirect	17	0.95 [0.14-6.47]		1.00 [0.08-11.11]	
Network		0.89 [0.46-1.72]		0.89 [0.38-2.10]	
Angio Immediate CR				E d	
vs			0.931		0.951
Functional Immediate CR					
Direct	50	1.79 [0.52-6.17]		1.82 [0.33-10.00]	
Indirect	50	1.65 [0.47-5.75]		1.35 [0.18-11.11]	
Network		1.72 [0.71-4.14]		1.72 [0.53-5.70]	
Angio Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	_		_	
Indirect	100	0.22 [0.04-1.23]		0.23 [0.03-1.71]	
Network		0.22 [0.04-1.23]		0.23 [0.03-1.71]	
Angio Staged CR		L J		L d	
vs			-		-
Functional Immediate CR					
Direct	0	-		_	
Indirect	100	1.93 [0.84-4.43]		1.94 [0.59-6.31]	
Network		1.93 [0.84-4.43]		1.94 [0.59-6.31]	
Angio Staged CR					
vs			-		-
Functional Staged CR					

Direct	100	0.25 [0.05-1.21]		0.25 [0.04-1.61]	
Indirect	0	-		-	
Network		0.25 [0.05-1.21]		0.25 [0.04-1.61]	
Functional Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.13 [0.02-0.77]		0.13 [0.01-1.17]	
Network		0.13 [0.02-0.77]		0.13 [0.01-1.17]	
Any Revascularization					
Angio Immediate CR					
vs			0.264		0.328
IRA-only					
Direct	46	0.47 [0.20-1.09]		0.47 [0.18-1.27]	
Indirect	54	0.25 [0.12-0.52]		0.26 [0.11-0.64]	
Network		0.33 [0.19-0.59]		0.34 [0.18-0.67]	
Angio Staged CR					
vs			0.008		0.007
IRA-Only					
Direct	34	0.18 [0.06-0.53]		0.18 [0.09-0.37]	
Indirect	66	0.88 [0.55-1.41]		0.86 [0.49-1.49]	
Network		0.51 [0.27-0.95]		0.49 [0.24-1.06]	
Functional Immediate CR					
vs			0.315		0.246
IRA-Only					
Direct	65	0.53 [0.25-1.14]		0.55 [0.27-1.15]	
Indirect	35	0.27 [0.09-0.80]		0.25 [0.08-0.87]	
Network		0.42 [0.22-0.78]		0.45 [0.24-0.86]	
Functional Staged CR					
vs			0.982		0.702
IRA-Only					
Direct	77	0.44 [0.20-0.95]		0.31 [0.07-1.31]	
Indirect	23	0.45 [0.10-2.00]		0.46 [0.08-2.62]	
Network		0.44 [0.22-0.87]		0.36 [0.13-1.04]	
Angio Immediate CR					
vs			0.011		0.002
Angio Staged CR					
Direct	76	0.47 [0.26-0.87]		0.45 [0.31-0.67]	
Indirect	24	1.93 [0.79-4.73]		2.38 [1.20-4.76]	
Network		0.66 [0.39-1.12]		0.68 [0.37-1.30]	

Angio Immediate CR					
vs			0.302		0.327
<b>Functional Immediate CR</b>					
Direct	60	1.06 [0.46-2.42]		1.05 [0.41-2.78]	
Indirect	40	0.53 [0.19-1.46]		0.48 [0.17-1.43]	
Network		0.80 [0.42-1.52]		0.74 [0.37-1.58]	
Angio Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.76 [0.34-1.70]		0.93 [0.32-2.88]	
Network		0.76 [0.34-1.70]		0.93 [0.32-2.88]	
Angio Staged CR					
vs			-		-
Functional Immediate CR					
Direct	0	-		-	
Indirect	100	1.21 [0.57-2.59]		1.09 [0.47-2.65]	
Network		1.21 [0.57-2.59]		1.09 [0.47-2.65]	
Angio Staged CR		<b>L</b>			
vs			0.981		0.700
Functional Staged CR					
Direct	42	1.14 [0.34-3.83]		1.15 [0.26-5.00]	
Indirect	58	0.76 [0.34-1.70]		1.70 [0.32-9.09]	
Network		1.15 [0.52-2.52]		1.35 [0.48-4.01]	
Functional Immediate CR					
VS			-		-
Functional Staged CR					
Direct	0	_		-	
Indirect	100	0.95 [0.39-2.29]		1.25 [0.38-4.01]	
Network		0.95 [0.39-2.29]		1.25 [0.38-4.01]	
Ischaemia-Driven Revasculari	zation				
Angio Immediate CR					
vs			0.088		0.148
IRA-only					
Direct	37	0.76 [0.21-2.80]		0.76 [0.16-3.70]	
Indirect	63	0.20 [0.09-0.44]		0.20 0.06-0.72	
Network		0.33 [0.15-0.74]		0.33 [0.11-1.04]	
Angio Staged CR				L 3	
vs			0.029		0.049
IRA-Only					

	4.4	0 10 [0 05 0 50]		0 10 [0 0( 0 55]	
	44	0.18 [0.05-0.59]	-	0.18 [0.06-0.55]	
Indirect	56	0.80 [0.44-1.47]		0.79 [0.30-2.17]	
Network		0.41 [0.19-0.91]		0.41 [0.14-1.30]	
Functional Immediate CR			0.600		0.602
VS			0.688		0.693
IRA-Only		0.5450.00.1.053		0.5450.14.0.111	
Direct	77	0.54 [0.23-1.27]		0.54 [0.14-2.11]	
Indirect	33	0.35 [0.05-2.44]		0.34 [0.03-3.90]	
Network		0.49 [0.23-1.03]		0.48 [0.17-1.43]	
Functional Staged CR					
VS			0.870		0.892
IRA-Only					
Direct	62	0.31 [0.09-1.08]		0.31 [0.04-2.16]	
Indirect	38	0.37 [0.06-2.14]		0.37 [0.03-4.47]	
Network		0.33 [0.12-0.88]		0.33 [0.09-1.31]	
Angio Immediate CR					
vs			0.002		0.022
Angio Staged CR					
Direct	73	0.51 [0.22-1.20]		0.55 [0.12-0.99]	
Indirect	27	2.97 [1.51-5.82]		2.94 [0.95-8.33]	
Network		0.81 [0.39-1.67]		0.81 [0.28-2.30]	
Angio Immediate CR					
vs			0.638		0.695
Functional Immediate CR					
Direct	49	0.87 [0.24-3.17]		0.87 [0.12-5.88]	
Indirect	51	0.55 [0.14-2.16]		0.56 [0.08-4.17]	
Network		0.69 [0.28-1.69]		0.69 [0.20-2.49]	
Angio Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	1.01 [0.33-3.08]		1.01 [0.22-4.82]	
Network		1.01 [0.33-3.08]		1.01 [0.22-4.82]	
Angio Staged CR				ь х.	
vs			-		-
<b>Functional Immediate CR</b>					
Direct	0	-		_	
Indirect	100	0.85 [0.32-2.29]		0.85 [0.22-3.58]	
Network		0.85 [0.32-2.29]		0.85 [0.22-3.58]	
Angio Staged CR			0.870	• •	0.891

vs					
Functional Staged CR		1 1 ( [0 01 4 07]		1 16 50 16 0 201	
Direct	57	1.16 [0.31-4.35]		1.15 [0.16-8.33]	
Indirect	43	1.39 [0.25-7.59]		1.39 [0.13-16.67]	
Network		1.25 [0.46-3.39]		1.25 [0.32-4.98]	
Functional Immediate CR					
vs			-		-
Functional Staged CR	-				
Direct	0	-		-	
Indirect	100	1.47 [0.44-4.85]		1.47 [0.27-7.76]	
Network		1.47 [0.44-4.85]		1.47 [0.27-7.76]	
Major Adverse Cardiac Event	S				
Angio Immediate CR			0.677		0.590
vs					
IRA-only					
Direct	45	0.45 [0.26-0.80]		0.51 [0.21-0.98]	
Indirect	55	0.54 [0.31-0.94]		0.59 [0.30-1.22]	
Network		0.49 [0.34-0.72]		0.52 [0.32-0.86]	
Angio Staged CR			0.342		0.444
vs					
IRA-Only					
Direct	37	0.51 [0.26-1.01]		0.51 [0.19-1.39]	
Indirect	63	0.77 [0.46-1.30]		0.78 [0.37-1.56]	
Network		0.66 [0.44-1.00]		0.66 [0.37-1.14]	
Functional Immediate CR					
vs			0.171		0.101
IRA-Only					
Direct	67	0.59 [0.35-0.97]		0.69 [0.41-1.13]	
Indirect	33	0.32 [0.16-0.64]		0.31 [0.13-0.73]	
Network		0.48 [0.32-0.73]		0.56 [0.34-0.90]	
Functional Staged CR					
vs			0.903		0.750
IRA-Only					
Direct	79	0.74 [0.44-1.24]		0.56 [0.19-1.63]	
Indirect	21	0.69 [0.24-1.97]		0.72 [0.19-2.70]	
Network		0.73 [0.46-1.15]		0.62 [0.28-1.36]	
Angio Immediate CR				k d	
vs			0.432		0.326
Angio Staged CR					
Direct	77	0.69 [0.46-1.03]		0.69 [0.42-1.21]	
		<b>b b b b b b b b b b</b>		<u> </u>	

Indirect	23	0.97 [0.45-2.09]		1.16 [0.43-3.03]	
Network		0.75 [0.53-1.06]		0.78 [0.50-1.27]	
Angio Immediate CR					
vs			0.119		0.103
<b>Functional Immediate CR</b>					
Direct	58	1.33 [0.75-2.35]		1.32 [0.69-2.63]	
Indirect	42	0.71 [0.41-1.21]		0.60 [0.30-1.28]	
Network		1.03 [0.67-1.59]		0.92 [0.55-1.64]	
Angio Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.68 [0.39-1.18]		0.85 [0.37-1.98]	
Network		0.68 [0.39-1.18]		0.85 [0.37-1.98]	
Angio Staged CR					
vs			-		-
Functional Immediate CR					
Direct	0	-		-	
Indirect	100	1.38 [0.83-2.29]		1.18 [0.62-2.26]	
Network		1.38 [0.83-2.29]		1.18 [0.62-2.26]	
Angio Staged CR					
vs			0.904		0.751
Functional Staged CR					
Direct	37	0.95 [0.39-2.31]		0.95 [0.30-3.03]	
Indirect	63	0.66 [0.36-1.20]		1.22 [0.35-4.35]	
Network		0.91 [0.53-1.56]		1.08 [0.48-2.40]	
Functional Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.66 [0.36-1.20]		0.91 [0.37-2.19]	
Network		0.66 [0.36-1.20]		0.91 [0.37-2.19]	

Abbreviations: CI = Confidence Interval; CrI = Credible Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery; W = Weight.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.70 [1.12-2.74]	1.04 [0.59-1.80]
Immediate CR	0.59 [0.37-0.89]		0.61 [0.34-1.02]
Staged CR	0.96 [0.56-1.70]	1.64 [0.98-2.91]	
Cardiac Death	· · · · · ·	· · · · · · · · · · · · · · · · · · ·	
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.39 [0.96-2.15]	1.28 [0.84-2.28]
Immediate CR	0.72 [0.47-1.05]		0.92 [0.60-1.54]
Staged CR	0.78 [0.44-1.19]	1.08 [0.65-1.68]	
Death	· · · · · · · · · · · · · · · · · · ·	· · · · · ·	
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.16 [0.80-1.66]	1.10 [0.72-1.81]
Immediate CR	0.86 [0.60-1.24]		0.95 [0.63-1.53]
Staged CR	0.91 [0.55-1.38]	1.05 [0.65-1.58]	
<b>Definite or Probable Stent</b>	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.12 [0.52-2.47]	0.85 [0.40-1.92]
Immediate CR	0.89 [0.40-1.94]		0.76 [0.37-1.60]
Staged CR	1.18 [0.52-2.51]	1.32 [0.62-2.69]	
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.62 [1.45-4.75]	1.97 [0.94-4.13]
Immediate CR	0.38 [0.21-0.69]		0.76 [0.39-1.49]
Staged CR	0.51 [0.24-1.06]	1.32 [0.67-2.59]	
Ischaemia-Driven Revascu	larization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.66 [0.80-8.54]	2.40 [0.73-7.62]
Immediate CR	0.38 [0.11-1.25]		0.90 [0.28-2.95]
Staged CR	0.42 [0.13-1.36]	1.11 [0.34-3.60]	
Major Adverse Cardiac Ev	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.85 [1.29-2.69]	1.49 [0.96-2.35]
Immediate CR	0.54 [0.37-0.77]		0.80 [0.54-1.21]
Staged CR	0.67 [0.43-1.04]	1.24 [0.82-1.86]	

Supplementary Table 10. Bayesian random-effects network meta-analysis – 3-node analysis.

Values are HRs [95% CrIs].

CrI = Credible Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

Supplementary Table 11. Frequentist and Bayesian rank probabilities and SUCRA – 3-node analysis.

	Frequentist Random-Effects Model						
Myocardial	Infarction						
Ranking	IRA-Only	Immediate CR	Staged CR				
1 <sup>st</sup>	0	100	0				
2 <sup>nd</sup>	29.6	0.1	70.4				
3 <sup>rd</sup>	70.4	0.0	29.6				
SUCRA	14.8	100	35.3				
Cardiac Dea	ath						
Ranking	IRA-Only	Immediate CR	Staged CR				
1 <sup>st</sup>	0.2	87.5	12.3				
2 <sup>nd</sup>	7.2	11.6	81.2				
3rd	92.6	0.9	6.5				
SUCRA	4 8	93.0	52.3				
Dooth		,,,,,	52.5				
Death	IDA Only	Immediate CD	Staged CD				
	25.0	95.0	5.4				
	33.9	4.1	00.0				
J <sup>1</sup>	63.1	0.3	30.0				
SUCRA	20.0	97.3	32.8				
Definite or 1	Probable Stent Throm	bosis					
Ranking	IRA-Only	Immediate CR	Staged CR				
1 <sup>st</sup>	36.7	57.5	5.8				
2 <sup>nd</sup>	44.8	31.5	23.7				
3 <sup>rd</sup>	18.5	11.0	70.5				
SUCRA	57.6	73.0	19.4				
Any Revasc	ularization						
Ranking	IRA-Only	Immediate CR	Staged CR				
1 <sup>st</sup>	0	89.8	10.2				
2 <sup>nd</sup>	0.6	10.2	89.1				
3 <sup>rd</sup>	99.4	0	0.7				
SUCRA	0	94.8	55.0				
Ischaemia-I	Driven Revascularizat	ion					
Ranking	IRA-Only	Immediate CR	Staged CR				
1 <sup>st</sup>	0	59.6	40.4				
2 <sup>nd</sup>	1.3	40.0	58.7				
3 <sup>rd</sup>	98.7	0.4	0.9				
SUCRA	0.8	79.7	69.6				
Maior Adve	erse Cardiac Events						
Ranking	IRA-Only	Immediate CR	Staged CR				
1 <sup>st</sup>	0	96.7	33				
2 <sup>nd</sup>	0	33	96.7				
3 <sup>rd</sup>	100	0	0				
SUCRA	12.2	98.3	51.7				
beenar	Dovocion Do	ndom Efforts Mode	J				
Bayesian Kandom-Effects Model							
Myocardial	Interction	I I' ( OD					
Kanking	IKA-Only		Staged CK				
	0.8	90.3	2.9				
	43.5	5.5	55.0				
3 <sup>ru</sup>	55.7	0.2	44.1				
SUCRA	22.6	98.1	29.4				
Cardiac Dea	ath						
Ranking	IRA-Only	Immediate CR	Staged CR				
1 <sup>st</sup>	1.4	62.7	35.9				
2 <sup>nd</sup>	12.6	34.4	53.0				

3 <sup>rd</sup>	86.0	2.9	11.1
SUCRA	7.7	79.9	62.4
Death			
Ranking	IRA-Only	Immediate CR	Staged CR
1 <sup>st</sup>	9.4	53.9	36.7
2 <sup>nd</sup>	28.4	34.9	36.7
3 <sup>rd</sup>	62.2	11.2	26.6
SUCRA	23.6	71.4	55.1
Definite or l	Probable Stent Throm	ibosis	
Ranking	IRA-Only	Immediate CR	Staged CR
1 <sup>st</sup>	32.9	54.2	12.8
2 <sup>nd</sup>	40.3	30.7	29.0
3 <sup>rd</sup>	26.8	15.1	58.2
SUCRA	53.1	69.6	27.3
Any Revasc	ularization		
Ranking	IRA-Only	Immediate CR	Staged CR
1 <sup>st</sup>	0.2	81.3	18.5
2 <sup>nd</sup>	3.3	18.5	78.3
3 <sup>rd</sup>	96.6	0.2	3.2
SUCRA	1.8	90.6	57.6
Ischaemia-I	Driven Revascularizat	ion	
Ranking	IRA-Only	Immediate CR	Staged CR
1 <sup>st</sup>	0.9	56.7	42.4
2 <sup>nd</sup>	5.3	41.2	53.5
3 <sup>rd</sup>	93.8	2.1	4.2
SUCRA	3.6	77.3	69.1
Major Adve	erse Cardiac Events		
Ranking	IRA-Only	Immediate CR	Staged CR
1 <sup>st</sup>	0.1	86.9	13.0
2 <sup>nd</sup>	3.5	13.0	83.5
3 <sup>rd</sup>	96.4	0.1	3.5
SUCRA	1.8	93.4	54.8

Values are percentages.

CR = Complete Revascularization; IRA = Infarct Related Artery; SUCRA= Surface Under the Cumulative Ranking Curve.

Supplementary Table 12. Frequentist and Bayesian network node-splitting analysis – 3-node analysis.

	Frequentist			Bayesian	
	W (%)	HR [95 CI]	Pinconsistency	HR [95 CrI]	Pinconsistency
Myocardial Infarction	on				
Index CR					
vs IRA-only			0.255		0.170
Direct	72	0.57 [0.39-0.83]		0.69 [0.42-0.99]	
Indirect	28	0.38 [0.21-0.68]		0.34 [0.15-0.89]	
Network		0.51 [0.37-0.70]		0.59 [0.37-0.89]	
Staged CR					
vs			0.155		0.168
IRA-only					
Direct	79	0.85 [0.61-1.19]		0.74 [0.41-1.45]	
Indirect	21	1.35 [0.79-2.32]	-	1.52 [0.64-3.01]	
Network		0.93 [0.69-1.25]		0.96 [0.56-1.70]	
Index CR			0.259		0.172
VS Staged CD			0.258		0.173
Direct	40	0.45 [0.27.0.75]		0.46 [0.25 0.88]	
Indirect	49 51	$\frac{0.43 [0.27 - 0.73]}{0.67 [0.41 - 1.09]}$		0.40 [0.23-0.88]	
Network	51	0.55 [0.38-0.79]		0.61 [0.34-1.02]	
Cardiac Death		0.55 [0.56 0.77]		0.01 [0.54 1.02]	
Index CR					
vs			0.275		0.579
IRA-only					
Direct	72	0.61 [0.43-0.88]		0.68 [0.39-1.07]	
Indirect	28	0.90 [0.50-1.61]		0.88 [0.33-2.24]	
Network		0.68 [0.50-0.93]		0.72 [0.47-1.05]	
Staged CR					
vs			0.277		0.590
IRA-only					
Direct	84	0.88 [0.67-1.16]		0.85 [0.38-1.62]	
Indirect	16	0.60 [0.31-1.14]		0.65 [0.27-1.40]	
Network		0.83 [0.65-1.06]		0.78 [0.44-1.19]	
Index CR					
VS			0.275		0.575
Staged CR	4.4	1.02 [0.(1.1.71]		1.05.50.56.2.001	
Direct	44 56			1.05 [0.36-2.08]	
Network		0.70 [0.44-1.10]	-	0.00 [0.34-2.00]	
Death		0.82 [0.39-1.10]		0.92 [0.00-1.34]	
Index CR					
VS			0.148		0 464
IRA-only			0.110		0.101
Direct	75	0.70 [0.54-0.91]		0.81 [0.50-1.25]	
Indirect	25	1.17 [0.61-2.21]		1.12 [0.49-3.22]	
Network		0.77 [0.61-0.96]		0.86 [0.60-1.24]	
Staged CR					
vs			0.170		0.466
IRA-only					
Direct	84	1.03 [0.84-1.26]		1.02 [0.53-2.17]	
Indirect	16	0.66 [0.36-1.20]		0.74 [0.32-1.43]	
Network		0.97 [0.80-1.17]		0.91 [0.55-1.38]	
Index CR			0.155		0.462
VS			0.155		0.402

Staged CR					
Direct	41	0.99 [0.66-1.47]		1.10 [0.63-2.08]	
Indirect	59	0.68 [0.49-0.94]		0.79 [0.31-1.70]	
Network		0.79 [0.61-1.02]		0.95 [0.63-1.53]	
<b>Definite or Probable</b>	Stent Thro	ombosis			
Index CR					
vs			0.431		0.537
IRA-only					
Direct	50	0.73 [0.32-1.67]		0.73 [0.27-2.03]	
Indirect	50	1.21 [0.47-3.09]		1.21 [0.31-4.70]	
Network		0.91 [0.49-1.69]		0.89 [0.40-1.94]	
Staged CR					
vs			0.431		0.528
IRA-only					
Direct	80	1.38 [0.76-2.50]		1.38 [0.48-4.03]	
Indirect	20	0.84 [0.28-2.51]		0.83 [0.22-3.12]	
Network		1.23 [0.73-2.08]		1.18 [0.52-2.51]	
Index CR					
vs			0.513		0.525
Staged CR					
Direct	70	0.88 [0.42-1.81]		0.89 [0.38-2.08]	
Indirect	30	0.53 [0.15-1.96]		0.53 [0.13-2.27]	
Network		0.74 [0.41-1.34]		0.76 [0.37-1.60]	
Any Revascularization	on		1		1
Index CR					
vs			0.014		0.001
IRA-only					
Direct	70	0.51 [0.28-0.91]		0.53 [0.39-0.70]	
Indirect	30	0.15 [0.07-0.32]		0.10 [0.06-0.19]	
Network		0.35 [0.22-0.58]		0.38 [0.21-0.69]	
Staged CR					
vs			0.001		0.001
IRA-only					
Direct	64	0.33 [0.17-0.63]		0.22 [0.14-0.36]	
Indirect	36	1.11 [0.77-1.61]		1.18 [0.70-1.85]	
Network		0.50 [0.30-0.84]		0.51 [0.24-1.06]	
Index CR					
vs			0.020		0.002
Staged CR					
Direct	66	0.48 [0.25-0.90]		0.45 [0.31-0.68]	
Indirect	34	1.54 [0.72-3.27]		2.38 [1.33-4.00]	
Network		0.71 [0.42-1.19]		0.76 [0.39-1.49]	
Ischaemia-Driven Re	evasculariz	ation			
Index CR					
vs			0.002		0.018
IRA-only					
Direct	74	0.60 [0.28-1.30]		0.59 [0.34-1.03]	
Indirect	26	0.12 [0.07-0.22]		0.12 [0.05-0.31]	
Network		0.39 [0.20-0.77]		0.38 [0.11-1.25]	
Staged CR					
vs			0.004		0.016
IRA-only					
Direct	62	0.23 [0.09-0.60]		0.22 [0.12-0.45]	
Indirect	38	1.03 [0.69-1.54]		1.07 [0.49-2.70]	
Network		0.43 [0.20-0.90]		0.42 [0.13-1.36]	
Index CR				· · · · ·	
vs			0.003		0.016
Staged CR					
Direct	63	0.51 [0.20-1.29]		0.54 [0.27-0.97]	
Indirect	37	2.62 [1.54-4.46]		2.63 [1.08-6.25]	

Network		0.92 [0.44-1.93]		0.90 [0.28-2.95]				
Major Adverse Cardiac Events								
Index CR								
vs			0.554		0.205			
IRA-only								
Direct	69	0.53 [0.38-0.73]		0.61 [0.40-0.86]				
Indirect	31	0.44 [0.26-0.74]		0.36 [0.18-0.78]				
Network		0.50 [0.38-0.65]		0.54 [0.37-0.77]				
Staged CR								
vs			0.485		0.209			
IRA-only								
Direct	66	0.65 [0.46-0.91]		0.53 [0.30-0.96]				
Indirect	34	0.79 [0.50-1.24]		0.89 [0.46-1.51]				
Network		0.69 [0.52-0.91]		0.67 [0.43-1.04]				
Index CR								
vs			0.537		0.211			
Staged CR								
Direct	65	0.68 [0.48-0.96]		0.68 [0.45-1.11]				
Indirect	35	0.82 [0.50-1.33]		1.15 [0.55-2.22]				
Network		0.72 [0.55-0.96]		0.80 [0.54-1.21]				

CI = Confidence Interval; CrI = Credible Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery; W = Weight.

<b>Supplementary</b>	Table 13. F	requentist rand	lom-effects network	meta-analysis for	· periprocedura	l outcomes – 5-r	10de analysis.
					· · · · · · · · · · · · · · · · · · ·		

Stroke					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.84 [0.43-1.63]	0.71 [0.45-1.12]	0.68 [0.31-1.50]	0.62 [0.10-3.69]
Angio Immediate CR	1.19 [0.61-2.31]		0.84 [0.48-1.49]	0.81 [0.33-2.02]	0.73 [0.11-4.80]
Angio Staged CR	1.41 [0.89-2.22]	1.18 [0.67-2.09]		0.96 [0.41-2.27]	0.87 [0.14-5.30]
Functional Immediate CR	1.47 [0.67-3.22]	1.23 [0.50-3.06]	1.04 [0.44-2.46]		0.90 [0.13-6.34]
Functional Staged CR	1.62 [0.27-9.68]	1.36 [0.21-8.90]	1.15 [0.19-7.00]	1.11 [0.16-7.74]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					
Contrast-Induced Acute Kidney Inju	ry				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.75 [0.37-1.53]	0.73 [0.44-1.21]	0.86 [0.66-1.14]	1.02 [0.44-2.38]
Angio Immediate CR	1.33 [0.65-2.72]		0.97 [0.51-1.85]	1.15 [0.54-2.45]	1.36 [0.49-3.83]
Angio Staged CR	1.37 [0.83-2.28]	1.03 [0.54-1.97]		1.19 [0.67-2.10]	1.41 [0.60-3.32]
Functional Immediate CR	1.16 [0.88-1.52]	0.87 [0.41-1.85]	0.84 [0.48-1.49]		1.19 [0.49-2.88]
Functional Staged CR	0.98 [0.42-2.28]	0.73 [0.26-2.06]	0.71 [0.30-1.68]	0.84 [0.35-2.05]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					
Major Bleeding					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.02 [0.61-1.70]	0.78 [0.54-1.13]	1.08 [0.69-1.70]	3.57 [0.75-17.11]
Angio Immediate CR	0.98 [0.59-1.64]		0.77 [0.49-1.21]	1.06 [0.54-2.11]	3.51 [0.70-17.72]
Angio Staged CR	1.28 [0.89-1.84]	1.30 [0.83-2.05]		1.38 [0.77-2.48]	4.57 [0.95-21.88]
Functional Immediate CR	0.92 [0.59-1.45]	0.94 [0.47-1.86]	0.72 [0.40-1.29]		3.30 [0.65-16.84]
Functional Staged CR	0.28 [0.06-1.34]	0.28 [0.06-1.44]	0.22 [0.05-1.05]	0.30 [0.06-1.55]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					

Values are OR [95% CI].

CI = Confidence Interval; CR = Complete Revascularization; OR = Odds Ratio; IRA = Infarct Related Artery.

Supplementary Table 14. Bayesian random-effects network meta-analysis for periprocedural outcomes – 5-node analysis.

Stroke					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.85 [0.44-1.64]	0.72 [0.46-1.13]	0.68 [0.31-1.50]	0.94 [0.53-1.65]
Angio Immediate CR	1.18 [0.61-2.29]		0.85 [0.48-1.49]	0.81 [0.32-2.01]	1.11 [0.47-2.63]
Angio Staged CR	1.40 [0.89-2.20]	1.18 [0.67-2.08]		0.95 [0.40-2.26]	1.31 [0.64-2.68]
Functional Immediate CR	1.46 [0.67-3.21]	1.24 [0.50-3.08]	1.05 [0.44-2.48]		1.37 [0.52-3.61]
Functional Staged CR	1.07 [0.60-1.89]	0.90 [0.38-2.15]	0.77 [0.37-1.57]	0.73 [0.28-1.92]	
Contrast-Induced Acute Kidney Inju	iry				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.01 [0.39-3.14]	0.87 [0.40-2.30]	0.84 [0.32-2.10]	0.95 [0.31-3.10]
Angio Immediate CR	0.99 [0.32-2.57]		0.87 [0.32-2.25]	0.84 [0.20-2.63]	0.94 [0.22-3.67]
Angio Staged CR	1.15 [0.43-2.49]	1.15 [0.44-3.15]		0.97 [0.25-2.91]	1.09 [0.33-3.37]
Functional Immediate CR	1.19 [0.48-3.15]	1.20 [0.38-5.03]	1.03 [0.34-4.08]		1.14 [0.28-5.20]
Functional Staged CR	1.05 [0.32-3.19]	1.07 [0.27-4.62]	0.92 [0.30-3.03]	0.88 [0.19-3.53]	
Major Bleeding					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.00 [0.60-1.66]	0.76 [0.53-1.09]	1.08 [0.69-1.70]	1.08 [0.59-1.99]
Angio Immediate CR	1.01 [0.60-1.68]		0.76 [0.48-1.20]	1.09 [0.55-2.16]	1.09 [0.50-2.39]
Angio Staged CR	1.32 [0.92-1.90]	1.31 [0.83-2.07]		1.43 [0.80-2.55]	1.43 [0.71-2.87]
Functional Immediate CR	0.92 [0.59-1.45]	0.92 [0.46-1.82]	0.70 [0.39-1.25]		1.00 [0.47-2.14]
Functional Staged CR	0.92 [0.50-1.70]	0.92 [0.42-2.02]	0.70 [0.35-1.40]	1.00 [0.47-2.14]	

Values are OR [95% CrI].

CrI = Credible Interval; CR = Complete Revascularization; OR = Odds Ratio; IRA = Infarct Related Artery.

		Frequentist		Bayesian	
	W (%)	OR [95 CI]	Pinconsistency	OR [95 CrI]	Pinconsistency
Stroke					
Angio Immediate CR					
vs			0.708		0.349
IRA-only					
Direct	16	1.58 [0.30-8.26]		2.44 [0.32-33.33]	
Indirect	84	1.12 [0.54-2.30]		0.80 [0.11-2.86]	
Network		1.19 [0.61-2.31]		1.18 [0.61-2.29]	
Angio Staged CR					
vs			0.554		0.824
IRA-Only					
Direct	87	1.32 [0.81-2.15]		1.32 [0.24-7.69]	
Indirect	13	1.98 [0.57-6.86]		1.06 [0.17-5.88]	
Network		1.41 [0.89-2.22]		1.40 [0.89-2.20]	
Functional Immediate CR					
vs			0.927		0.691
IRA-Only					
Direct	77	1.43 [0.59-3.50]		1.00 [0.14-3.70]	
Indirect	23	1.57 [0.30-8.30]		1.66 [0.12-23.75]	
Network		1.47 [0.67-3.22]		1.46 [0.67-3.21]	
Functional Staged CR					
vs			0.374		-
IRA-Only					
Direct	97	1.12 [0.63-2.00]		1.29 [0.50-5.26]	
Indirect	3	0.27 [0.01-5.88]		-	
Network		1.62 [0.27-9.68]		1.07 [0.60-1.89]	
Angio Immediate CR					
vs			0.819		0.666
Angio Staged CR					
Direct	81	0.82 [0.44-1.54]		0.78 [0.24-2.34]	
Indirect	19	0.97 [0.27-3.54]		1.39 [0.19-20.00]	
Network		0.84 [0.48-1.49]		0.85 [0.48-1.49]	
Angio Immediate CR					
vs			0.927		0.685
Functional Immediate CR					
Direct	37	0.76 [0.17-3.44]		0.75 [0.08-6.67]	

Supplementary Table 15. Node-splitting analysis for periprocedural outcomes – 5-node analysis.

Indirect	63	0.83 [0.27-2.62]		1.19 [0.21-14.29]	
Network		0.81 [0.33-2.02]		0.81 [0.32-2.01]	
Angio Immediate CR					
VS			-		-
Functional Staged CR					
Direct	0	_			
Indirect	100	0.73 [0.11-4.80]		1.11 [0.47-2.63]	
Network		0.73 [0.11-4.80]		1.11 [0.47-2.63]	
Angio Staged CR					
VS			-		-
Functional Immediate CR					
Direct	0	-		-	
Indirect	100	0.96 [0.41-2.27]		0.95 [0.40-2.26]	
Network		0.96 [0.41-2.27]		0.95 [0.40-2.26]	
Angio Staged CR					
VS			0.374		0.106
Functional Staged CR					
Direct	6	5.00 [0.24-105.01]		5.00 [0.24-105.01]	
Indirect	94	1.21[0.58-2.53]		1.10 [0.21-4.76]	
Network		0.87 [0.14-5.30]		1.31 [0.64-2.68]	
Functional Immediate CR					
VS			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	0.90 [0.13-6.34]		1.37 [0.52-3.61]	
Network		0.90 [0.13-6.34]		1.37 [0.52-3.61]	
Contrast-Induced Acute Kidne	ey Injury		-		
Angio Immediate CR					
VS			0.291		0.419
IRA-only					
Direct	25	0.61 [0.14-2.70]		0.57 [0.10-2.78]	
Indirect	75	1.54 [0.65-3.67]		1.33 [0.33-3.70]	
Network		1.33 [0.65-2.72]		0.99 [0.32-2.57]	
Angio Staged CR					
VS			0.191		0.211
IRA-Only					
Direct	78	1.59 [0.89-2.84]		1.61 [0.54-4.76]	
Indirect	22	0.70 [0.23-2.09]		0.57 [0.19-2.13]	
Network		1.37 [0.83-2.28]		1.15 [0.43-2.49]	
Functional Immediate CR			0.532		0.627

vs					
IRA-Only					
Direct	99	1.15 [0.87-1.51]		1.15 [0.39-3.40]	
Indirect	1	2.58 [0.21-32.49]		2.38 [0.13-75.62]	
Network		1.16 [0.88-1.52]		1.19 [0.48-3.15]	
Functional Staged CR					
vs			0.806		0.616
IRA-Only					
Direct	59	0.85 [0.28-2.56]		0.83 [0.19-3.74]	
Indirect	41	1.08 [0.24-4.80]		1.47 [0.22-8.93]	
Network		0.98 [0.42-2.28]		1.05 [0.32-3.19]	
Angio Immediate CR					
vs			0.177		0.282
Angio Staged CR					
Direct	77	1.17 [0.55-2.49]		1.19 [0.37-4.00]	
Indirect	23	0.40 [0.10-1.58]		0.41 [0.07-2.22]	
Network		0.97 [0.51-1.85]		0.87 [0.32-2.25]	
Angio Immediate CR					
vs			0.532		0.633
<b>Functional Immediate CR</b>					
Direct	11	0.51 [0.05-5.65]		0.44 [0.01-6.67]	
Indirect	89	1.15 [0.50-2.65]		0.93 [0.18-3.70]	
Network		1.15 [0.54-2.45]		0.84 [0.20-2.63]	
Angio Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	1.36 [0.49-3.83]		0.94 [0.22-3.67]	
Network		1.36 [0.49-3.83]		0.94 [0.22-3.67]	
Angio Staged CR					
vs			-		-
Functional Immediate CR					
Direct	0	-		-	
Indirect	100	1.19 [0.67-2.10]		0.97 [0.25-2.91]	
Network		1.19 [0.67-2.10]		0.97 [0.25-2.91]	
Angio Staged CR					
vs			0.806		0.630
Functional Staged CR					
Direct	51	1.19 [0.36-3.99]		0.85 [0.17-4.17]	
Indirect	49	1.51 [0.37-6.17]		1.45 [0.23-8.33]	

Network		1.41 [0.60-3.32]		1.09 [0.33-3.37]	
Functional Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	1.19 [0.49-2.88]		1.14 [0.28-5.20]	
Network		1.19 [0.49-2.88]		1.14 [0.28-5.20]	
Major Bleeding	<b>_</b>		<b>_</b>		
Angio Immediate CR					
vs			0.561		0.766
IRA-only					
Direct	38	0.83 [0.36-1.90]		0.82 [0.42-4.17]	
Indirect	62	1.20 [0.48-3.02]		1.05 [0.22-3.57]	
Network		0.98 [0.59-1.64]		1.01 [0.60-1.68]	
Angio Staged CR		<u> </u>			
vs			0.911		0.269
IRA-Only					
Direct	84	1.33 [0.90-1.98]		1.33 [0.42-4.17]	
Indirect	16	1.25 [0.46-3.43]		0.60 [0.16-1.85]	
Network		1.28 [0.89-1.84]		1.32 [0.92-1.90]	
Functional Immediate CR		* *		<b>L L</b>	
vs			-		-
IRA-Only					
Direct	100	0.92 [0.59-1.45]		0.92 [0.59-1.45]	
Indirect	0	_		-	
Network		0.92 [0.59-1.45]		0.92 [0.59-1.45]	
Functional Staged CR					
vs			0.332		0.753
IRA-Only					
Direct	93	1.00 [0.53-1.89]		0.87 [0.27-2.16]	
Indirect	7	0.32 [0.03-2.97]		5.98 [0.51-186.42]	
Network		0.28 [0.06-1.34]		0.92 [0.50-1.70]	
Angio Immediate CR					
vs			0.566		0.138
Angio Staged CR					
Direct	75	0.82 [0.49-1.39]		0.99 [0.46-2.38]	
Indirect	25	0.60 [0.24-1.51]		0.77 [0.18-4.76]	
Network		0.77 [0.49-1.21]		0.76 [0.48-1.20]	
Angio Immediate CR		· · ·		• •	
vs			-		-

Functional Immediate CR					
Direct	0	-		-	
Indirect	100	1.06 [0.54-2.11]		1.09 [0.55-2.16]	
Network		1.06 [0.54-2.11]		1.09 [0.55-2.16]	
Angio Immediate CR					
Vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	3.51 [0.70-17.72]		1.09 [0.50-2.39]	
Network		3.51 [0.70-17.72]		1.09 [0.50-2.39]	
Angio Staged CR					
vs			-		-
Functional Immediate CR					
Direct	0	-		-	
Indirect	100	1.38 [0.77-2.48]		1.43 [0.80-2.55]	
Network		1.38 [0.77-2.48]		1.43 [0.80-2.55]	
Angio Staged CR					
vs			0.332		0.138
Functional Staged CR					
Direct	10	4.03 [0.44-36.45]		0.19 [0.01-1.89]	
Indirect	90	1.28 [0.61-2.66]		1.33 [0.39-5.26]	
Network		4.57 [0.95-21.88]		1.43 [0.71-2.87]	
Functional Immediate CR					
vs			-		-
Functional Staged CR					
Direct	0	-		-	
Indirect	100	3.30 [0.65-16.84]		1.00 [0.47-2.14]	
Network		3.30 [0.65-16.84]		1.00 [0.47-2.14]	

CI = Confidence Interval; CrI = Credible Interval; CR = Complete Revascularization; IRA = Infarct Related Artery; OR = Odds Ratio; W = Weight.

Supplementary Table 16. Frequentist random-effects network meta-analysis for periprocedural outcomes – 3-node analysis.

Stroke							
	IRA-Only	Index CR	Staged CR				
IRA-Only		0.83 [0.49-1.42]	0.77 [0.55-1.10]				
Immediate CR	1.20 [0.70-2.05]		0.93 [0.56-1.55]				
Staged CR	1.29 [0.91-1.83]	1.07 [0.64-1.79]					
Heterogeneity:	$1^{2}=0\%; \tau^{2}=0$						
Contrast-Induced Acute Kidney Injury							
	IRA-Only	Index CR	Staged CR				
IRA-Only		0.85 [0.66-1.11]	0.80 [0.52-1.23]				
Immediate CR	1.17 [0.90-1.52]		0.93 [0.59-1.48]				
Staged CR	1.26 [0.82-1.93]	1.07 [0.68-1.70]					
Heterogeneity:	$1^{2}=0\%; \tau^{2}=0$						
<b>Major Bleeding</b>							
	IRA-Only	Index CR	Staged CR				
IRA-Only		1.07 [0.77-1.50]	0.83 [0.62-1.12]				
Immediate CR	0.93 [0.67-1.30]		0.77 [0.54-1.12]				
Staged CR	1.20 [0.89-1.62]	1.29 [0.89-1.87]					
Heterogeneity:	$[^2=0\%; \tau^2=0$						

Values are OR [95% CI].

CI = Confidence Interval; CR = Complete Revascularization; IRA = Infarct Related Artery; OR = Odds Ratio.

Supplementary Table 17. Bayesian random-effects network metaanalysis for periprocedural outcomes – 3-node analysis.

Stroke							
	IRA-Only	Index CR	Staged CR				
IRA-Only		0.85 [0.43-1.72]	0.75 [0.38-1.27]				
Immediate CR	1.18 [0.58-2.35]		0.87 [0.42-1.64]				
Staged CR	1.34 [0.79-2.64]	1.15 [0.61-2.39]					
Contrast-Induced Acute Kidney Injury							
	IRA-Only	Index CR	Staged CR				
IRA-Only		0.89 [0.51-1.89]	0.85 [0.45-1.80]				
Immediate CR	1.12 [0.53-1.98]		0.94 [0.43-2.03]				
Staged CR	1.18 [0.56-2.24]	1.06 [0.49-2.32]					
<b>Major Bleeding</b>							
	IRA-Only	Index CR	Staged CR				
IRA-Only		1.06 [0.68-1.77]	0.92 [0.61-1.68]				
Immediate CR	0.94 [0.56-1.48]		0.87 [0.55-1.54]				
Staged CR	1.08 [0.60-1.63]	1.14 [0.65-1.81]					

Values are OR [95% CrI].

CrI = Credible Interval; CR = Complete Revascularization; IRA = Infarct Related Artery; OR = Odds Ratio.

Supplementary Table 18. Node-splitting analysis for periprocedural outcomes – 3-node analysis.

	Frequentist			Bayesian		
	W (%)	OR [95 CI]	Pinconsistency	OR [95 CrI]	Pinconsistency	
Stroke						
Index CR						
vs IRA-only			0.499		0.729	
Direct	46	1.47 [0.67-3.22]		1.31 [0.46-3.38]		
Indirect	54	1.01 [0.49-2.10]		1.03 [0.34-3.48]		
Network		1.20 [0.70-2.05]		1.18 [0.58-2.35]		
Staged CR						
vs			0.499		0.732	
IRA-only						
Direct	88	1.23 [0.85-1.79]		1.30 [0.66-3.13]		
Indirect	12	1.79 [0.65-4.89]		1.64 [0.43-5.98]		
Network		1.29 [0.91-1.83]		1.34 [0.79-2.64]		
Index CR						
vs			0.499		0.751	
Staged CR						
Direct	66	0.82 [0.44-1.54]		0.81 [0.32-1.89]		
Indirect	34	1.19 [0.50-2.83]		1.00 [0.25-3.13]		
Network		0.93 [0.56-1.55]		0.87 [0.42-1.64]		
Contrast-Induced Ac	ute Kidney	' Injury			T	
Index CR			0.441		0.525	
VS IRA_only			0.441		0.535	
Direct	92	1 14 [0 87-1 49]		1 03 [0 39-7 21]		
Indirect	8	1 63 [0 65-4 06]		1.61 [0.17-3.24]		
Network	Ű	1.17 [0.91-1.52]		1.12 [0.53-1.98]		
Staged CR						
VS			0.441		0.534	
IRA-only						
Direct	71	1.39 [0.83-2.32]		1.34 [0.52-3.06]		
Indirect	29	0.97 [0.44-2.17]		0.85 [0.17-3.24]		
Network		1.26 [0.82-1.93]		1.18 [0.56-2.24]		
Index CR						
VS			0.441		0.532	
Staged CR						
Direct	37	1.17 [0.55-2.49]		1.20 [0.36-4.00]		
Indirect	63	0.82 [0.46-1.46]		0.76 [0.22-2.75]		
Network		0.93 [0.59-1.48]		0.94 [0.43-2.03]		
Major Bleeding					1	
Index CR			0.026		0.541	
VS ID A culu			0.936		0.541	
IKA-only Divest	74	0.00.00.00.00.00		1 02 [0 20 2 04]		
Direct	74	0.90 [0.01-1.34]		1.03 [0.39-2.04]		
Natwork	20					
		0.93 [0.07-1.30]		0.94 [0.30-1.48]		
staget CK			0.715		0.534	
IRA-only			0.715		0.554	
Direct	74	1.23 [0.88-1 72]		1.32 [0.53-3.04]		
Indirect	26	1.10 [0.57-2.11]		0.85 [0.18-3.19]		
Network		1.20 [0.89-1.62]		1.08 [0.60-1.63]		
Index CR		. [	0.715		0.526	
vs			0.715		0.536	

Staged CR			
Direct	53	0.82 [0.49-1.39]	1.19 [0.37-4.00]
Indirect	47	0.73 [0.43-1.23]	0.77 [0.22-2.38]
Network		0.77 [0.54-1.12]	0.87 [0.55-1.54]

CI = Confidence Interval; CrI = Credible Interval; CR = Complete Revascularization; IRA = Infarct Related Artery; OR = Odds Ratio; W = Weight.
Supplementary	Table 10	Influonco	onolycic for	myooordial	inform	5 node analysis
Supplementary	Table 19.	muence	allaly 515 101	myocarulai	marcuon –	5-mode analysis.

	Angio Immediate CR vs Angio Staged CR	Angio Immediate CR vs IRA-Only	Angio Immediate CR vs Functional Immediate CR	Angio Immediate CR vs Functional Staged CR	Angio Staged CR vs IRA- Only	Angio Staged CR vs Functional Immediate CR	Angio Staged CR vs Functional Staged CR	Functional Immediate CR vs IRA-Only	Functional Staged CR vs IRA-Only	Functional Immediate CR vs Functional Staged CR	Residual I <sup>2</sup>
PRAMI	6.31	19.31	7.34	9.31	5.37	0.15	2.01	3.49	0.18	0.96	44
DANAMI-3-PRIMULTI	0.31	0.31	0.10	16.55	1.31	0.54	15.86	0.05	29.09	17.79	44
CvLPRIT	5.14	16.16	6.00	7.64	4.37	0.12	1.63	2.83	0.15	0.78	45
COMPARE-ACUTE	2.16	7.28	12.77	3.26	1.83	17.37	0.67	34.24	0.06	18.60	38
COMPLETE	22.51	22.86	8.93	5.45	55.54	33.72	31.12	4.28	3.89	0	41
FIRE	2.68	8.93	15.45	4.04	2.27	20.78	0.83	39.39	0.08	22.19	44
CROSS-AMI	3.58	3.65	1.24	18.85	13.77	6.10	30.63	0.57	16.86	13.17	42
FLOWER-MI	4.42	14.12	33.20	6.59	3.75	16.74	1.39	12.26	0.13	7.45	43
FRAME-AMI	2.68	8.91	22.81	4.03	2.27	10.68	0.83	7.67	0.08	4.57	0
BIOVASC	30.21	10.86	3.87	8.01	9.14	11.24	3.51	1.80	0.32	1.82	39
MULTISTARS-AMI	21.67	7.22	2.51	5.27	6.04	7.48	2.27	1.16	0.21	1.17	39
SMILE	8.80	2.64	0.89	1.90	2.19	2.74	0.80	0.41	0.07	0.41	44
COCUA	4.89	1.42	0.48	1.02	1.18	1.48	0.43	0.22	0.04	0.22	44
FULL REVASC	0.88	0.90	0.30	36.25	3.67	1.53	35.07	0.14	54.05	38.28	45

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

	Angio Immediate CR vs Angio Staged CR	Angio Immediate CR vs IRA-Only	Angio Immediate CR vs Functional Immediate CR	Angio Immediate CR vs Functional Staged CR	Angio Staged CR vs IRA- Only	Angio Staged CR vs Functional Immediate CR	Angio Staged CR vs Functional Staged CR	Functional Immediate CR vs IRA-Only	Functional Staged CR vs IRA-Only	Functional Immediate CR vs Functional Staged CR	Residual I <sup>2</sup>
PRAMI	6.40	24.38	11.33	12.50	11.38	2.97	5.01	1.46	0.08	0.40	36
DANAMI-3-PRIMULTI	0.04	0.10	0.04	17.26	0.25	0.10	17.38	0	29.13	17.85	46
CvLPRIT	3.78	15.64	6.84	7.59	6.87	1.73	2.94	0.85	0.04	0.23	39
<b>COMPARE-ACUTE</b>	0.32	1.50	11.39	0.67	0.60	12.88	0.25	24.82	0	13.21	41
COMPLETE	18.06	35.63	17.98	17.08	58.16	36.70	36.34	2.48	0.84	0.18	47
FIRE	1.31	5.89	34.62	2.70	2.43	37.86	1.01	57.64	0.02	38.54	47
CROSS-AMI	1.10	2.71	1.09	10.24	6.53	2.83	14.55	0.13	8.01	5.50	16
FRAME-AMI	4.39	17.79	35.33	8.75	7.93	24.88	3.42	17.54	0.05	10.01	45
BIOVASC	16.73	4.09	1.66	2.36	3.09	2.75	1.29	0.20	0.02	0.16	45
MULTISTARS-AMI	25.31	6.70	2.77	3.91	5.10	4.54	2.16	0.33	0.03	0.28	48
SMILE	13.78	3.28	1.32	1.89	2.47	2.20	1.03	0.16	0.02	0.13	36
COCUA	0.16	0.41	0.16	46.21	1.02	0.43	46.41	0.02	62.85	47.21	46
FULL REVASC	6.40	24.38	11.33	12.50	11.38	2.97	5.01	1.46	0.08	0.40	39

### Supplementary Table 20. Influence analysis for cardiac death – 5-node analysis.

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

Supplementary	Table 21. 1	Influence analy	sis for all-caus	e death – 5-node analys	is.
Supplementary	1 4010 211 1	minucine analy	bib ioi un caub	c ucum s nouc analys	10.

	Angio Immediate CR vs Angio Staged CR	Angio Immediate CR vs IRA-Only	Angio Immediate CR vs Functional Immediate CR	Angio Immediate CR vs Functional Staged CR	Angio Staged CR vs IRA- Only	Angio Staged CR vs Functional Immediate CR	Angio Staged CR vs Functional Staged CR	Functional Immediate CR vs IRA-Only	Functional Staged CR vs IRA-Only	Functional Immediate CR vs Functional Staged CR	Residual I <sup>2</sup>
PRAMI	7.04	19.11	8.25	9.92	5.12	0.28	2.22	2.56	0	1.05	40
DANAMI-3-PRIMULTI	0	0	0	11.44	0.01	0.01	12.09	0	19.83	12.18	40
CvLPRIT	5.68	15.83	6.68	8.06	4.12	0.22	1.77	2.05	0	0.84	34
<b>COMPARE-ACUTE</b>	0.67	2.07	5.19	0.98	0.48	7.49	0.20	15.99	0	7.66	39
COMPLETE	32.72	35.04	17.04	18.77	70.26	49.55	49.81	5.65	0.14	1.78	39
FIRE	5.39	15.09	31.53	7.65	3.90	40.48	1.68	61.54	0	41.07	40
CROSS-AMI	0.43	0.47	0.18	2.78	2.04	0.86	4.73	0.05	2.69	1.93	38
FLOWER-MI	6.52	17.88	36.39	9.22	4.74	19.07	2.05	14.13	0	6.93	39
FRAME-AMI	1.91	5.74	13.78	2.76	1.37	6.18	0.58	4.40	0	2.04	15
BIOVASC	15.26	5.46	2.15	2.79	3.58	4.22	1.53	0.64	0	0.32	33
MULTISTARS-AMI	15.73	5.64	2.23	2.89	3.70	4.36	1.59	0.66	0	0.33	40
SMILE	27.32	10.75	4.38	5.65	7.18	8.42	3.15	1.32	0	0.66	40
COCUA	6.73	2.26	0.87	1.14	1.46	1.74	0.62	0.26	0	0.13	39
FULL REVASC	0.04	0.05	0.02	64.25	0.20	0.08	65.67	0.01	77.48	65.87	34

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

#### Supplementary Table 22. Influence analysis for definite or probable stent thrombosis – 5-node analysis.

	Angio Immediate CR vs Angio Staged CR	Angio Immediate CR vs IRA-Only	Angio Immediate CR vs Functional Immediate CR	Angio Immediate CR vs Functional Staged CR	Angio Staged CR vs IRA- Only	Angio Staged CR vs Functional Immediate CR	Angio Staged CR vs Functional Staged CR	Functional Immediate CR vs IRA-Only	Functional Staged CR vs IRA-Only	Functional Immediate CR vs Functional Staged CR	Residual I <sup>2</sup>
COMPARE-ACUTE	3.78	7.05	15.83	0.59	2.39	27.70	0	40.54	0.27	7.66	0
COMPLETE	17.10	71.52	49.67	3.00	88.62	66.77	0	21.85	46.49	30.32	0
FIRE	3.36	6.29	14.26	0.52	2.12	25.30	0	37.61	0.24	6.83	0
CROSS-AMI	0	0	0	100	0	0	100	0	100	100	0
FLOWER-MI	17.10	28.48	50.32	3.00	11.38	33.22	0	21.85	1.41	9.72	0
BIOVASC	37.13	23.43	10.73	8.14	1.54	5.72	0	3.29	0.17	1.30	0
MULTISTARS-AMI	31.54	19.27	8.58	6.47	1.21	4.52	0	2.59	0.14	1.01	0
SMILE	6.64	3.56	1.43	1.06	0.19	0.73	0	0.41	0.02	0.16	0
COCUA	7.58	4.08	1.64	1.22	0.22	0.83	0	0.47	0.02	0.18	0

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

#### Angio Angio Angio Staged Angio Staged Functional Angio Angio Angio Staged Functional Functional Immediate CR Immediate CR Immediate CR CR vs CR vs **Immediate CR** Staged CR vs Immediate CR CR vs IRA-Immediate CR Residual I<sup>2</sup> vs Angio Staged vs Functional vs Functional Functional Functional vs Functional vs IRA-Only Only vs IRA-Only IRA-Only Immediate CR **Immediate CR** CR Staged CR Staged CR Staged CR PRAMI 3.43 9.11 0.75 0.52 78 21.17 6.08 8.16 3.18 4.21 0.80 76 **DANAMI-3-PRIMULTI** 0.76 1.07 22.90 2.82 19.91 35.79 22.56 0.26 1.08 0.18 10.42 **CvLPRIT** 3.96 23.76 6.98 0.87 3.67 0.93 77 9.34 4.85 0.60 **COMPARE-ACUTE** 1.00 7.11 2.47 14.99 0.93 31.88 0.15 77 14.35 2.78 16.47 COMPLETE 37.28 71 13.62 18.16 5.08 3.14 18.27 16.31 3.50 3.00 0 FIRE 8.13 16.22 2.84 3.20 16.93 1.07 35.10 0.17 18.56 1.16 69 **CROSS-AMI** 4.93 6.80 1.73 27.28 16.35 6.85 37.36 21.01 78 1.18 18.00 **FLOWER-MI** 1.48 32.00 3.61 20.14 14.41 64 10.18 4.06 1.37 0.22 9.28 FRAME-AMI 25.93 3.05 78 1.11 7.78 2.7115.80 1.02 11.14 0.16 7.07 BIOVASC 22.43 3.69 0.91 3.39 7.12 2.45 0.40 1.05 74 7.76 0.62 **MULTISTARS-AMI** 23.32 3.87 3.56 7.46 2.58 0.65 78 0.96 8.13 0.42 1.10 SMILE 20.69 3.34 0.83 3.07 6.47 7.06 2.22 0.36 0.95 78 0.56 COCUA 78 10.07 1.46 0.36 1.34 2.88 3.16 0.96 0.24 0.15 0.41 77 FULL REVASC 1.04 28.83 25.32 28.43 1.45 0.35 3.80 1.46 0.24 43.19

#### Supplementary Table 23. Influence analysis for MACE – 5-node analysis.

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

#### Supplementary Table 24. Influence analysis for any revascularisation – 5-node analysis.

	Angio Immediate CR vs Angio Staged CR	Angio Immediate CR vs IRA-Only	Angio Immediate CR vs Functional Immediate CR	Angio Immediate CR vs Functional Staged CR	Angio Staged CR vs IRA- Only	Angio Staged CR vs Functional Immediate CR	Angio Staged CR vs Functional Staged CR	Functional Immediate CR vs IRA-Only	Functional Staged CR vs IRA-Only	Functional Immediate CR vs Functional Staged CR	Residual I <sup>2</sup>
PRAMI	3.73	23.53	6.53	9.01	10.15	0.71	3.48	5.22	0.80	0.92	82
DANAMI-3-PRIMULTI	1.05	1.38	0.32	21.79	3.67	1.41	18.20	0.25	34.88	21.46	81
CvLPRIT	3.48	22.27	6.11	8.44	9.52	0.66	3.25	4.88	0.74	0.86	78
COMPARE-ACUTE	1.13	8.33	15.25	2.84	3.23	15.73	1.05	33.68	0.24	17.64	82
COMPLETE	12.40	15.67	4.05	2.04	33.61	16.00	13.92	3.22	3.47	0.03	43
FIRE	1.04	7.68	14.15	2.61	2.96	14.60	0.97	31.75	0.22	16.40	81
CROSS-AMI	6.13	7.90	1.91	30.71	18.94	8.08	42.25	1.51	23.31	20.46	82
FLOWER-MI	1.50	10.76	34.68	3.73	4.24	21.76	1.39	15.83	0.31	10.74	82
FRAME-AMI	0.95	7.10	25.18	2.40	2.73	14.98	0.89	10.65	0.20	7.09	80
BIOVASC	24.14	3.85	0.90	4.10	8.17	9.00	2.76	0.71	0.63	1.42	79
MULTISTARS-AMI	21.52	3.34	0.78	3.56	7.12	7.86	2.39	0.61	0.54	1.23	81
SMILE	22.02	3.43	0.80	3.66	7.32	8.07	2.46	0.63	0.56	1.26	82
COCUA	8.67	1.18	0.27	1.26	2.59	2.87	0.84	0.21	0.19	0.43	81
FULL REVASC	1.41	1.84	0.42	27.20	4.85	1.88	22.99	0.33	41.80	26.82	77

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

#### Supplementary Table 25. Influence analysis for ischaemia-driven revascularisation – 5-node analysis.

	Angio Immediate CR vs Angio Staged CR	Angio Immediate CR vs IRA-Only	Angio Immediate CR vs Functional Immediate CR	Angio Immediate CR vs Functional Staged CR	Angio Staged CR vs IRA- Only	Angio Staged CR vs Functional Immediate CR	Angio Staged CR vs Functional Staged CR	Functional Immediate CR vs IRA-Only	Functional Staged CR vs IRA-Only	Functional Immediate CR vs Functional Staged CR	Residual I <sup>2</sup>
DANAMI-3-PRIMULTI	4.69	7.31	2.85	45.67	19.01	9.28	42.74	0.81	61.77	49.33	84
CvLPRIT	11.03	37.03	17.95	13.54	16.50	2.74	3.35	5.75	2.79	0.03	87
COMPARE-ACUTE	1.35	6.10	16.11	1.70	2.14	19.14	0.38	38.51	0.32	17.08	74
COMPLETE	14.30	21.11	9.05	0.47	44.34	25.76	12.27	2.70	10.38	2.94	87
FIRE	1.37	6.18	16.30	1.72	2.17	19.35	0.39	38.83	0.32	17.27	48
CROSS-AMI	4.69	7.31	2.85	44.19	19.01	9.28	57.22	0.81	38.19	33.06	86
FLOWER-MI	6.96	26.18	48.81	8.63	10.64	32.29	2.05	22.62	1.70	16.83	88
BIOVASC	39.66	12.17	4.90	13.12	12.11	13.18	2.36	1.42	1.96	3.56	88
MULTISTARS-AMI	33.70	9.68	3.83	10.46	9.63	10.51	1.84	1.10	1.52	2.77	86

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

	Angio Immediate CR vs Angio Staged CR	Angio Immediate CR vs IRA-Only	Angio Immediate CR vs Functional Immediate CR	Angio Immediate CR vs Functional Staged CR	Angio Staged CR vs IRA- Only	Angio Staged CR vs Functional Immediate CR	Angio Staged CR vs Functional Staged CR	Functional Immediate CR vs IRA-Only	Functional Staged CR vs IRA-Only	Functional Immediate CR vs Functional Staged CR	Residual I <sup>2</sup>
BIOVASC	47.20	32.72	12.32	22.32	2.59	4.83	0.98	2.27	0	1.58	0
COCUA	4.13	2.29	0.67	1.37	0.13	0.24	0.05	0.11	0	0.08	0
<b>COMPARE-ACUTE</b>	0.20	0.37	3.74	0.21	0.11	5.37	0.04	7.24	0	4.87	0
COMPLETE	16.20	65.35	35.27	50.15	86.69	53.38	70.82	8.27	0.50	3.93	0
CROSS-AMI	0.06	0.63	0.18	3.28	2.14	0.38	5.55	0.03	3.41	1.52	0
CvLPRIT	6.45	11.25	3.53	6.73	3.54	0.09	1.35	0.60	0	0.36	0
DANAMI-3-PRIMULTI	0	0	0	2.90	0.01	0	4.13	0	6.70	2.39	0
FIRE	5.84	10.24	54.26	6.10	3.20	63.40	1.22	70.46	0	61.01	0
FRAME-AMI	8.31	14.29	36.58	8.67	4.60	26.82	1.77	22.30	0	16.13	0
MULTISTARS-AMI	0.02	0.20	0.06	78.73	0.68	0.12	84.23	0.01	89.90	75.19	0
PRAMI	24.02	14.67	4.73	9.22	0.93	1.76	0.35	0.82	0	0.56	0
SMILE	2.63	4.73	1.42	2.75	1.42	0.03	0.53	0.24	0	0.14	0
FULL REVASC	5.54	3.09	0.91	1.85	0.17	0.33	0.06	0.15	0	0.10	0

### Supplementary Table 26. Influence analysis for stroke – 5-node analysis.

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

#### Supplementary Table 27. Influence analysis for contrast-induced acute kidney injury – 5-node analysis.

	Angio Immediate CR vs Angio Staged CR	Angio Immediate CR vs IRA-Only	Angio Immediate CR vs Functional Immediate CR	Angio Immediate CR vs Functional Staged CR	Angio Staged CR vs IRA- Only	Angio Staged CR vs Functional Immediate CR	Angio Staged CR vs Functional Staged CR	Functional Immediate CR vs IRA-Only	Functional Staged CR vs IRA-Only	Functional Immediate CR vs Functional Staged CR	Residual I <sup>2</sup>
COMPLETE	12.78	47.61	44.44	6.43	78.24	73.57	27.44	0.11	21.27	19.03	0
CROSS-AMI	0.44	2.66	2.35	38.36	9.77	7.74	50.73	0	40.95	38.75	0
CvLPRIT	8.59	14.47	12.97	5.80	4.10	3.03	0.45	0.02	0.32	0.24	0
DANAMI-3-PRIMULTI	0.44	2.66	2.35	41.87	9.77	7.74	49.27	0	59.04	56.62	0
FIRE	5.57	9.61	89.22	3.72	2.62	94.70	0.28	98.83	0.20	88.62	0
FRAME-AMI	5.57	9.61	10.78	3.72	2.62	3.75	0.28	1.17	0.20	0.58	0
MULTISTARS-AMI	76.97	64.98	62.02	52.64	11.99	10.96	1.41	0.23	1.01	1.22	0
PRAMI	6.38	10.93	9.75	4.27	3.01	2.22	0.33	0.02	0.23	0.18	0
COMPLETE	12.78	47.61	44.44	6.43	78.24	73.57	27.44	0.11	21.27	19.03	0

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

	Angio Immediate CR vs Angio Staged CR	Angio Immediate CR vs IRA-Only	Angio Immediate CR vs Functional Immediate CR	Angio Immediate CR vs Functional Staged CR	Angio Staged CR vs IRA- Only	Angio Staged CR vs Functional Immediate CR	Angio Staged CR vs Functional Staged CR	Functional Immediate CR vs IRA-Only	Functional Staged CR vs IRA-Only	Functional Immediate CR vs Functional Staged CR	Residual I <sup>2</sup>
BIOVASC	23.45	13.84	8.29	6.58	1.57	0.62	0.37	0	0	0	0
COCUA	6.97	3.78	2.16	1.69	0.39	0.15	0.09	0	0	0	0
COMPARE-ACUTE	0	0	5.37	0	0	7.31	0	11.48	0	4.40	0
COMPLETE	21.10	56.93	42.65	30.88	83.75	66.90	54.51	0	1.06	0.68	0
CROSS-AMI	0.13	0.66	0.37	6.92	2.51	1.00	9.96	0	7.45	4.94	0
CvLPRIT	9.59	16.82	10.21	7.50	4.93	1.99	1.19	0	0.01	0.01	0
DANAMI-3-PRIMULTI	0	0	0	4.59	0.02	0.01	5.73	0	7.70	5.11	0
FIRE	0	0	77.13	0	0	82.42	0	88.52	0	73.23	0
MULTISTARS-AMI	0.06	0.30	0.17	76.33	1.15	0.45	80.29	0	84.84	78.31	0
PRAMI	41.44	27.07	17.28	13.99	3.54	1.42	0.85	0	0.01	0	0
SMILE	12.56	21.50	13.35	9.89	6.56	2.68	1.61	0	0.01	0.01	0
FULL REVASC	3.56	1.90	1.08	0.84	0.19	0.08	0.04	0	0	0	0

## Supplementary Table 28. Influence analysis for major bleeding – 5-node analysis.

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

Supplementary Table 29. Influence analysis for myocardial infarction – 3-node analysis.

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	Residual I <sup>2</sup>
PRAMI	11.17	1.27	4.81	0
DANAMI-3-PRIMULTI	1.53	13.20	4.10	0
CvLPRIT	9.18	1.02	3.90	0
COMPARE-ACUTE	23.70	3.08	11.10	0
COMPLETE	5.72	37.26	14.30	0
FIRE	28.28	3.88	13.68	0
BIOVASC	10.98	7.94	23.48	0
MULTISTARS-AMI	7.10	5.07	15.98	0
SMILE	2.51	1.77	6.03	0
COCUA	1.34	0.94	3.27	0
FULL REVASC	3.91	28.44	10.04	0

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

Sui	pplementary	v Table 30.	Influence	analysis for	r cardiac (	death – :	3-node analy	sis.
~ ~								0-0-

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	Residual I <sup>2</sup>
PRAMI	7.20	0.56	3.71	20
DANAMI-3-PRIMULTI	0.39	5.21	1.32	31
CvLPRIT	3.93	0.29	1.99	22
<b>COMPARE-ACUTE</b>	7.53	0.58	3.89	25
COMPLETE	6.69	49.85	19.52	0
FIRE	53.63	7.70	36.49	25
BIOVASC	6.60	3.35	12.45	19
MULTISTARS-AMI	4.31	2.17	8.32	35
SMILE	8.91	4.58	16.45	31
COCUA	3.25	1.62	6.34	0
FULL REVASC	2.88	29.10	9.10	31

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

Sup	plementary	Table 31.	Influence ana	alvsis for a	all-cause deat	h – 3-node analysis.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~				.,		

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	Residual I <sup>2</sup>
PRAMI	9.02	0.61	4.63	41
DANAMI-3-PRIMULTI	0.38	5.78	1.62	40
CvLPRIT	7.31	0.49	3.72	33
<b>COMPARE-ACUTE</b>	8.64	0.58	4.42	40
COMPLETE	4.87	45.12	18.03	35
FIRE	49.81	5.81	32.70	40
BIOVASC	4.77	2.67	9.29	26
MULTISTARS-AMI	4.94	2.76	9.60	39
SMILE	9.72	5.56	18.02	13
COCUA	1.94	1.07	3.89	0
FULL REVASC	3.04	33.53	11.89	40

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

Supplementary Table 32. Influence analysis for definite or probable stent thrombosis – 3-node analysis.

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	Residual I <sup>2</sup>
COMPARE-ACUTE	29.35	8.52	14.09	0
COMPLETE	43.41	77.39	33.98	0
FIRE	27.23	7.74	12.88	0
BIOVASC	14.22	5.94	29.57	0
MULTISTARS-AMI	11.70	4.80	25.12	0
SMILE	2.16	0.83	5.29	0
COCUA	2.47	0.96	6.04	0

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

CR = Complete Revascularization; IRA = Infarct Related Artery.

.

Supplementary Table 33. Influence analysis for any revascularisation – 3-node analysis.

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	Residual I <sup>2</sup>
PRAMI	16.61	4.57	4.12	84
DANAMI-3-PRIMULTI	5.45	19.31	6.61	83
CvLPRIT	15.79	4.32	3.89	68
<b>COMPARE-ACUTE</b>	19.54	5.52	4.98	84
COMPLETE	6.17	21.45	7.47	46
FIRE	18.52	5.19	4.68	84
BIOVASC	5.30	7.13	20.60	82
MULTISTARS-AMI	4.69	6.31	18.57	84
SMILE	4.80	6.47	18.96	85
COCUA	1.81	2.47	7.89	85
FULL REVASC	6.62	22.75	8.01	83

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

Supplementary Table 34. Influence analysis for ischaemia-driven revascularisation – 3-node analysis.

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	Residual I <sup>2</sup>
DANAMI-3-PRIMULTI	8.22	29.96	12.93	89
CvLPRIT	22.74	5.81	5.60	89
<b>COMPARE-ACUTE</b>	25.60	6.72	6.48	16
COMPLETE	9.15	32.49	14.31	92
FIRE	25.78	6.78	6.54	16
BIOVASC	9.35	15.08	33.85	92
MULTISTARS-AMI	7.77	12.68	29.50	92

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

### Supplementary Table 35. Influence analysis for MACE – 3-node analysis.

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	Residual I <sup>2</sup>
PRAMI	13.53	3.44	3.63	73
DANAMI-3-PRIMULTI	4.70	17.82	5.78	65
CvLPRIT	15.74	4.08	4.30	65
<b>COMPARE-ACUTE</b>	18.70	4.98	5.25	65
COMPLETE	7.01	24.88	8.56	69
FIRE	21.46	5.85	6.17	65
BIOVASC	5.50	6.39	19.46	72
MULTISTARS-AMI	5.86	6.81	20.54	66
SMILE	4.84	5.63	17.43	71
COCUA	1.84	2.15	7.21	67
FULL REVASC	6.44	23.23	7.88	65

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

Supplementary Table 36. Influence analysis for stroke – 3-n
-------------------------------------------------------------

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	Residual I <sup>2</sup>
BIOVASC	27.28	4.26	38.29	0
COCUA	2.06	0.25	3.35	0
COMPARE-ACUTE	3.35	0.54	2.05	0
COMPLETE	14.34	51.45	7.06	0
CvLPRIT	7.37	1.24	4.59	0
DANAMI-3-PRIMULTI	0.41	2.53	0.19	0
FIRE	32.61	7.10	22.64	0
MULTISTARS-AMI	7.52	33.98	3.56	0
PRAMI	12.76	1.71	19.48	0
SMILE	3.10	0.50	1.90	0
FULL REVASC	2.77	0.34	4.49	0

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

Supplementary Table 37. Influence analysis for contrast-induced acute kidney injury – 3-node analysis.

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	<b>Residual I</b> <sup>2</sup>
COMPLETE	4.31	55.74	46.59	0
CvLPRIT	1.73	0.06	0.26	0
DANAMI-3-PRIMULTI	0.64	15.34	11.15	0
FIRE	88.88	22.25	54.48	0
MULTISTARS-AMI	8.08	28.93	37.01	0
PRAMI	1.31	0.05	0.20	0
FIRE	32.61	7.10	22.64	0
MULTISTARS-AMI	7.52	33.98	3.56	0
PRAMI	12.76	1.71	19.48	0

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

Sun	nlementarv	Table 38.	Influence a	analysis for n	naior bleedi	ng – 3-node ar	alvsis.
Jup	picification	Table 50.	innuciee e	inary 515 101 11	lajoi biccun	ng J-nouc ai	141 y 515.

	Immediate CR vs IRA-Only	Staged CR vs IRA-Only	Immediate CR vs Staged CR	Residual I <sup>2</sup>
BIOVASC	7.00	4.63	15.47	0
COCUA	1.95	1.26	4.60	0
<b>COMPARE-ACUTE</b>	6.28	0.71	2.69	0
COMPLETE	12.38	56.91	25.94	0
CvLPRIT	7.16	0.82	3.08	0
DANAMI-3-PRIMULTI	0.20	1.86	0.50	0
FIRE	48.46	9.14	27.90	0
MULTISTARS-AMI	2.68	20.44	6.38	0
PRAMI	13.41	9.07	27.33	0
SMILE	9.15	1.07	3.98	0
FULL REVASC	0.98	0.63	2.35	0

The table reports the influence of each trial on each comparison evaluated by leave-one-out analysis. Values are percentages.

### Supplementary Table 39. Frequentist random-effects network meta-analysis after excluding the COMPLETE trial – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.21 [1.27-3.83]	1.16 [0.58-2.33]	1.87 [1.15-3.06]	0.85 [0.50-1.45]
Angio Immediate CR	0.45 [0.26-0.78]		0.52 [0.30-0.91]	0.85 [0.49-1.47]	0.38 [0.19-0.77]
Angio Staged CR	0.86 [0.43-1.74]	1.91 [1.10-3.29]		1.62 [0.78-3.36]	0.73 [0.34-1.56]
Functional Immediate CR	0.53 [0.33-0.87]	1.18 [0.68-2.05]	0.62 [0.30-1.29]		0.45 [0.23-0.91]
Functional Staged CR	1.18 [0.69-2.02]	2.60 [1.30-5.22]	1.37 [0.64-2.90]	2.21 [1.10-4.44]	
Heterogeneity: I <sup>2</sup> =41%; $\tau^2$ =0.108					
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.56 [0.62-3.93]	1.75 [0.57-5.31]	1.95 [0.88-4.32]	1.29 [0.55-2.99]
Angio Immediate CR	0.64 [0.25-1.61]		1.12 [0.55-2.26]	1.25 [0.44-3.53]	0.82 [0.25-2.68]
Angio Staged CR	0.57 [0.19-1.74]	0.89 [0.44-1.81]		1.12 [0.33-3.79]	0.74 [0.20-2.70]
Functional Immediate CR	0.51 [0.23-1.14]	0.80 [0.28-2.26]	0.90 [0.26-3.03]		0.66 [0.21-2.06]
Functional Staged CR	0.78 [0.33-1.80]	1.21 [0.37-3.95]	1.36 [0.37-4.97]	1.52 [0.48-4.74]	
Heterogeneity: $I^2=47\%$ ; $\tau^2=0.258$					
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.30 [0.78-2.19]	1.44 [0.72-2.88]	1.56 [0.99-2.47]	0.80 [0.48-1.34]
Angio Immediate CR	0.77 [0.46-1.28]		1.11 [0.68-1.80]	1.20 [0.71-2.01]	0.61 [0.30-1.25]
Angio Staged CR	0.69 [0.35-1.39]	0.90 [0.56-1.47]		1.08 [0.54-2.18]	0.55 [0.24-1.27]
Functional Immediate CR	0.64 [0.40-1.01]	0.83 [0.50-1.40]	0.92 [0.46-1.86]		0.51 [0.26-1.01]
Functional Staged CR	1.25 [0.75-2.10]	1.64 [0.80-3.34]	1.81 [0.78-4.17]	1.96 [0.99-3.88]	
Heterogeneity: I <sup>2</sup> =39%; $\tau^2$ =0.079					
Definite or Probable Stent Thrombos	sis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.76 [0.17-3.38]	0.67 [0.13-3.51]	1.36 [0.60-3.11]	0.17 [0.02-1.65]
Angio Immediate CR	1.31 [0.30-5.79]		0.88 [0.42-1.81]	1.79 [0.52-6.17]	0.22 [0.04-1.24]
Angio Staged CR	1.49 [0.28-7.82]	1.14 [0.55-2.36]		2.04 [0.48-8.57]	0.25 [0.05-1.21]
Functional Immediate CR	0.73 [0.32-1.67]	0.56 [0.16-1.93]	0.49 [0.12-2.07]		0.12 [0.01-1.04]
Functional Staged CR	5.97 [0.61-58.73]	4.56 [0.8-25.89]	4.00 [0.83-19.35]	8.15 [0.96-68.79]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.31 [1.57-3.38]	1.14 [0.71-1.83]	2.04 [1.43-2.92]	1.92 [1.31-2.81]
Angio Immediate CR	0.43 [0.30-0.64]		0.49 [0.35-0.70]	0.88 [0.60-1.31]	0.83 [0.51-1.36]
Angio Staged CR	0.88 [0.55-1.41]	2.03 [1.44-2.86]		1.79 [1.09-2.95]	1.69 [1.00-2.85]

Functional Immediate CR	0.49 [0.34-0.70]	1.13 [0.76-1.67]	0.56 [0.34-0.92]		0.94 [0.57-1.56]			
Functional Staged CR	0.52 [0.36-0.76]	1.20 [0.74-1.96]	0.59[0.35-1.00]	1.06 [0.64-1.76]				
Heterogeneity: $I^2=43\%$ ; $\tau^2=0.050$								
Ischaemia-Driven Revascularization								
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR			
IRA-Only		2.07 [1.22-3.53]	1.25 [0.68-2.29]	1.84 [1.22-2.79]	2.30 [1.27-4.17]			
Angio Immediate CR	0.48 [0.28-0.82]		0.60 [0.41-0.90]	0.89 [0.51-1.55]	1.11 [0.58-2.14]			
Angio Staged CR	0.80 [0.44-1.47]	1.66 [1.11-2.47]		1.47 [0.77-2.80]	1.84 [0.97-3.50]			
Functional Immediate CR	0.54 [0.36-0.82]	1.13 [0.64-1.97]	0.68 [0.36-1.29]		1.25 [0.63-2.49]			
Functional Staged CR	0.43 [0.24-0.79]	0.90 [0.47-1.73]	0.54 [0.29-1.03]	0.80 [0.40-1.59]				
Heterogeneity: $I^2=48\%$ ; $\tau^2=0.054$								
Major Adverse Cardiac Events								
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR			
IRA-Only		1.86 [1.22-2.82]	1.30 [0.77-2.18]	2.00 [1.32-3.04]	1.32 [0.83-2.09]			
Angio Immediate CR	0.54 [0.35-0.82]		0.70 [0.48-1.02]	1.08 [0.69-1.68]	0.71 [0.41-1.24]			
Angio Staged CR	0.77 [0.46-1.30]	1.43 [0.98-2.09]		1.55 [0.88-2.70]	1.02 [0.57-1.84]			
Functional Immediate CR	0.50 [0.33-0.76]	0.93 [0.60-1.44]	0.65 [0.37-1.13]		0.66 [0.36-1.19]			
Functional Staged CR	0.76 [0.48-1.20]	1.40 [0.80-2.45]	0.98 [0.54-1.77]	1.52 [0.84-2.74]				
Heterogeneity: $I^2=71\%$ ; $\tau^2=0.109$								

Values are HRs [95% CIs]

CI = Confidence Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

Supplementary Table 40. Bayesian random-effects network meta-analysis after excluding the COMPLETE trial – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.96 [0.96-4.07]	1.05 [0.41-2.82]	1.53 [0.87-3.02]	0.75 [0.26-2.22]
Angio Immediate CR	0.51 [0.25-1.04]		0.53 [0.27-1.13]	0.78 [0.39-1.72]	0.38 [0.12-1.16]
Angio Staged CR	0.95 [0.35-2.42]	1.87 [0.88-3.77]		1.46 [0.55-3.91]	0.71 [0.23-2.09]
Functional Immediate CR	0.65 [0.33-1.15]	1.28 [0.58-2.56]	0.68 [0.26-1.81]		0.49 [0.14-1.51]
Functional Staged CR	1.34 [0.45-3.92]	2.61 [0.86-8.14]	1.40 [0.48-4.40]	2.04 [0.66-7.05]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.50 [0.53-4.53]	1.69 [0.49-6.90]	1.60 [0.75-4.15]	1.49 [0.32-6.70]
Angio Immediate CR	0.67 [0.22-1.87]		1.13 [0.50-2.74]	1.08 [0.34-3.61]	0.99 [0.18-5.07]
Angio Staged CR	0.59 [0.14-2.04]	0.89 [0.37-2.00]		0.96 [0.23-3.93]	0.88 [0.14-4.63]
Functional Immediate CR	0.63 [0.24-1.33]	0.92 [0.28-2.96]	1.04 [0.25-4.42]		0.92 [0.15-4.66]
Functional Staged CR	0.67 [0.15-3.11]	1.01 [0.20-5.57]	1.14 [0.22-6.98]	1.08 [0.21-6.59]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.12 [0.64-1.92]	1.19 [0.68-2.39]	1.27 [0.79-2.23]	0.66 [0.23-1.86]
Angio Immediate CR	0.90 [0.52-1.56]		1.07 [0.66-1.96]	1.14 [0.65-2.19]	0.59 [0.19-1.83]
Angio Staged CR	0.84 [0.42-1.48]	0.93 [0.51-1.51]		1.06 [0.51-2.16]	0.55 [0.16-1.64]
Functional Immediate CR	0.79 [0.45-1.26]	0.88 [0.46-1.54]	0.94 [0.46-1.98]		0.52 [0.15-1.57]
Functional Staged CR	1.52 [0.54-4.41]	1.70 [0.55-5.37]	1.83 [0.61-6.09]	1.94 [0.64-6.47]	
Definite or Probable Stent Thrombos	sis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.76 [0.10-6.13]	0.67 [0.07-6.92]	1.36 [0.42-4.36]	0.17 [0.01-3.43]
Angio Immediate CR	1.32 [0.16-10.41]		0.88 [0.33-2.34]	1.79 [0.32-9.95]	0.22 [0.02-2.00]
Angio Staged CR	1.49 [0.14-14.57]	1.13 [0.43-3.02]		2.03 [0.28-14.29]	0.25 [0.03-1.79]
Functional Immediate CR	0.74 [0.23-2.39]	0.56 [0.10-3.13]	0.49 [0.07-3.61]		0.12 [0.01-2.02]
Functional Staged CR	6.00 [0.29-124.82]	4.57 [0.5-40.52]	4.00 [0.56-29.11]	8.15 [0.50-131.79]	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.30 [1.46-3.51]	1.16 [0.67-2.07]	1.92 [1.35-2.86]	2.22 [1.13-4.18]
Angio Immediate CR	0.43 [0.28-0.69]		0.50 [0.34-0.78]	0.84 [0.55-1.36]	0.96 [0.48-1.90]
Angio Staged CR	0.86 [0.48-1.50]	1.98 [1.28-2.92]		1.66 [0.93-3.00]	1.91 [0.93-3.66]
Functional Immediate CR	0.52 [0.35-0.74]	1.20 [0.73-1.82]	0.60 [0.33-1.07]		1.15 [0.54-2.27]
Functional Staged CR	0.45 [0.24-0.88]	1.04 [0.53-2.07]	0.52 [0.27-1.07]	0.87 [0.44-1.85]	
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR

IRA-Only		2.06 [0.94-4.47]	1.25 [0.50-3.17]	1.83 [0.93-3.52]	2.30 [0.89-5.51]
Angio Immediate CR	0.48 [0.22-1.07]		0.61 [0.31-1.21]	0.89 [0.39-2.05]	1.11 [0.41-2.88]
Angio Staged CR	0.80 [0.31-2.02]	1.65 [0.82-3.27]		1.47 [0.54-3.96]	1.84 [0.71-4.45]
Functional Immediate CR	0.55 [0.28-1.07]	1.13 [0.49-2.55]	0.68 [0.25-1.86]		1.25 [0.42-3.49]
Functional Staged CR	0.44 [0.18-1.12]	0.90 [0.35-2.43]	0.54 [0.22-1.41]	0.80 [0.29-2.40]	
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only	IRA-Only	Angio Immediate CR 1.76 [1.01-3.1]	Angio Staged CR 1.29 [0.65-2.69]	Functional Immediate CR 1.72 [1.06-2.93]	Functional Staged CR 1.52 [0.66-3.54]
IRA-Only Angio Immediate CR	IRA-Only 0.57 [0.32-0.99]	Angio Immediate CR 1.76 [1.01-3.1]	Angio Staged CR 1.29 [0.65-2.69] 0.73 [0.45-1.26]	Functional Immediate CR 1.72 [1.06-2.93] 0.97 [0.55-1.77]	Functional Staged CR 1.52 [0.66-3.54] 0.86 [0.36-2.05]
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.57 [0.32-0.99] 0.77 [0.37-1.53]	Angio Immediate CR 1.76 [1.01-3.1] 1.37 [0.79-2.21]	Angio Staged CR 1.29 [0.65-2.69] 0.73 [0.45-1.26]	Functional Immediate CR   1.72 [1.06-2.93]   0.97 [0.55-1.77]   1.33 [0.63-2.79]	Functional Staged CR 1.52 [0.66-3.54] 0.86 [0.36-2.05] 1.18 [0.49-2.69]
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.57 [0.32-0.99] 0.77 [0.37-1.53] 0.58 [0.34-0.95]	Angio Immediate CR 1.76 [1.01-3.1] 1.37 [0.79-2.21] 1.03 [0.57-1.81]	Angio Staged CR 1.29 [0.65-2.69] 0.73 [0.45-1.26] 0.75 [0.36-1.59]	Functional Immediate CR   1.72 [1.06-2.93]   0.97 [0.55-1.77]   1.33 [0.63-2.79]	Functional Staged CR 1.52 [0.66-3.54] 0.86 [0.36-2.05] 1.18 [0.49-2.69] 0.88 [0.34-2.21]

Values are HRs [95% CIs]

CrI = Credible Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

# Supplementary Table 41. Frequentist random-effects network meta-analysis after excluding the COMPLETE trial – 3-node analysis.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.80 [1.38-2.34]	0.89 [0.67-1.17]
Immediate CR	0.56 [0.43-0.72]		0.49 [0.36-0.68]
Staged CR	1.13 [0.85-1.49]	2.02 [1.48-2.77]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=$	=0		
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.52 [1.11-2.09]	1.35 [0.95-1.92]
Immediate CR	0.66 [0.48-0.90]		0.89 [0.61-1.30]
Staged CR	0.74 [0.52-1.05]	1.12 [0.77-1.64]	
Heterogeneity: I <sup>2</sup> =5%; $\tau^2$ <	60.001		
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.25 [0.95-1.66]	1.01 [0.74-1.38]
Immediate CR	0.80 [0.60-1.06]		0.81 [0.58-1.12]
Staged CR	0.99 [0.72-1.36]	1.24 [0.89-1.72]	
Heterogeneity: $I^2=37\%$ ; $\tau^2$	=0.023		
Definite or Probable Stent	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.36 [0.60-3.11]	1.20 [0.40-3.59]
Immediate CR	0.73 [0.32-1.67]		0.88 [0.42-1.81]
Staged CR	0.84 [0.28-2.51]	1.14 [0.55-2.36]	
Heterogeneity: $I^2=0\%$ ; $\tau^2<0.0$	001		
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.49 [1.70-3.65]	1.51 [0.97-2.33]
Immediate CR	0.40 [0.27-0.59]		0.60 [0.40-0.90]
Staged CR	0.66 [0.43-1.03]	1.65 [1.11-2.47]	
Heterogeneity: $I^2=67\%$ ; $\tau^2$	=0.135		
Ischaemia-Driven Revascu	larization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.14 [1.25-3.65]	1.54 [0.78-3.05]
Immediate CR	0.47 [0.27-0.80]		0.72 [0.40-1.31]
Staged CR	0.65 [0.33-1.29]	1.39 [0.77-2.53]	
Heterogeneity: I <sup>2</sup> =75%; $\tau^2$	=0.203		
Major Adverse Cardiac Ev	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.91 [1.48-2.46]	1.30 [0.97-1.73]
Immediate CR	0.52 [0.41-0.68]		0.68 [0.52-0.89]
Staged CR	0.77 [0.58-1.03]	1.47 [1.13-1.92]	
Heterogeneity: $I^2=63\%$ ; $\tau^2=0$	).055		

Values are HR [95% CI].

CI = Confidence Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

# Supplementary Table 42. Bayesian random-effects network meta-analysis after excluding the COMPLETE trial – 3-node analysis.

Myocardial Infarction			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.65 [1.09-2.78]	0.84 [0.45-1.75]
Immediate CR	0.61 [0.36-0.92]		0.50 [0.28-0.92]
Staged CR	1.20 [0.57-2.25]	1.98 [1.09-3.55]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=$	0		
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.49 [0.97-2.47]	1.60 [0.83-3.36]
Immediate CR	0.67 [0.40-1.03]		1.07 [0.60-1.94]
Staged CR	0.63 [0.30-1.21]	0.93 [0.52-1.66]	
Heterogeneity: I <sup>2</sup> =5%; $\tau^{2}$ <	0.001		
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.16 [0.75-1.82]	1.12 [0.62-2.23]
Immediate CR	0.86 [0.55-1.33]		0.96 [0.58-1.74]
Staged CR	0.89 [0.45-1.62]	1.04 [0.57-1.72]	
Heterogeneity: $I^2=37\%$ ; $\tau^2$	=0.023		
<b>Definite or Probable Stent</b>	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.36 [0.49-3.70]	1.19 [0.31-4.60]
Immediate CR	0.74 [0.27-2.05]		0.88 [0.37-2.15]
Staged CR	0.84 [0.22-3.20]	1.14 [0.47-2.70]	
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.24 [1.42-3.64]	1.34 [0.71-2.67]
Immediate CR	0.45 [0.27-0.71]		0.60 [0.35-1.05]
Staged CR	0.75 [0.37-1.41]	1.67 [0.95-2.86]	
Ischaemia-Driven Revascu	larization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.14 [1.03-4.4]	1.53 [0.61-3.94]
Immediate CR	0.47 [0.23-0.97]		0.71 [0.32-1.65]
Staged CR	0.65 [0.25-1.64]	1.40 [0.61-3.16]	
Major Adverse Cardiac Ev	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.77 [1.21-2.65]	1.33 [0.80-2.35]
Immediate CR	0.56 [0.38-0.83]		0.75 [0.49-1.20]
Staged CR	0.75 [0.43-1.25]	1.33 [0.84-2.03]	

Values are HR [95% CrI].

CrI = Credible Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

Supplementary Table 43. Frequentist random-effects network meta-analysis after excluding trials with NSTEMI – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.79 [1.72-4.52]	1.45 [0.71-2.94]	1.48 [0.94-2.31]	0.89 [0.48-1.64]
Angio Immediate CR	0.36 [0.22-0.58]		0.52 [0.27-0.98]	0.53 [0.32-0.88]	0.32 [0.16-0.64]
Angio Staged CR	0.69 [0.34-1.41]	1.93 [1.02-3.66]		1.02 [0.48-2.19]	0.61 [0.30-1.25]
Functional Immediate CR	0.68 [0.43-1.06]	1.89 [1.14-3.13]	0.98 [0.46-2.10]		0.60 [0.29-1.24]
Functional Staged CR	1.13 [0.61-2.08]	3.15 [1.57-6.33]	1.63 [0.8-3.32]	1.67 [0.81-3.45]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		3.13 [1.31-7.47]	4.11 [1.30-12.92]	0.80 [0.26-2.45]	1.84 [0.67-5.07]
Angio Immediate CR	0.32 [0.13-0.76]		1.31 [0.56-3.05]	0.26 [0.06-1.05]	0.59 [0.17-2.04]
Angio Staged CR	0.24 [0.08-0.77]	0.76 [0.33-1.77]		0.19 [0.04-0.97]	0.45 [0.11-1.76]
Functional Immediate CR	1.25 [0.41-3.82]	3.91 [0.95-16.12]	5.13 [1.04-25.43]		2.30 [0.51-10.38]
Functional Staged CR	0.54 [0.20-1.50]	1.70 [0.49-5.91]	2.23 [0.57-8.79]	0.44 [0.10-1.97]	
Heterogeneity: I <sup>2</sup> =0%; $\tau^2$ <0.001					
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.46 [0.91-2.34]	2.24 [1.01-4.94]	1.38 [0.79-2.39]	0.72 [0.34-1.51]
Angio Immediate CR	0.68 [0.43-1.10]		1.53 [0.79-2.98]	0.94 [0.57-1.55]	0.49 [0.21-1.15]
Angio Staged CR	0.45 [0.20-0.99]	0.65 [0.34-1.27]		0.62 [0.27-1.40]	0.32 [0.12-0.89]
Functional Immediate CR	0.73 [0.42-1.26]	1.06 [0.65-1.74]	1.62 [0.71-3.69]		0.52 [0.21-1.29]
Functional Staged CR	1.39 [0.66-2.92]	2.03 [0.87-4.76]	3.11 [1.12-8.61]	1.92 [0.77-4.75]	
Heterogeneity: I <sup>2</sup> =0%; $\tau^2$ <0.001					
Definite or Probable Stent Thrombos	sis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.22 [0.23-6.57]	1.22 [0.17-8.95]	2.17 [0.69-6.81]	0.31 [0.02-3.87]
Angio Immediate CR	0.82 [0.15-4.43]		1.01 [0.35-2.90]	1.79 [0.52-6.17]	0.25 [0.04-1.68]
Angio Staged CR	0.82 [0.11-5.98]	0.99 [0.35-2.87]		1.78 [0.35-9.07]	0.25 [0.05-1.21]
Functional Immediate CR	0.46 [0.15-1.44]	0.56 [0.16-1.93]	0.56 [0.11-2.87]		0.14 [0.01-1.36]
Functional Staged CR	3.27 [0.26-41.41]	3.98 [0.60-26.58]	4.00 [0.83-19.35]	7.11 [0.74-68.64]	
Heterogeneity: I <sup>2</sup> =0%; $\tau^2$ =0					
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.59 [1.52-4.40]	1.56 [0.72-3.37]	2.11 [1.14-3.9]	2.46 [1.18-5.14]
Angio Immediate CR	0.39 [0.23-0.66]		0.60 [0.30-1.19]	0.81 [0.44-1.52]	0.95 [0.43-2.11]
Angio Staged CR	0.64 [0.30-1.39]	1.66 [0.84-3.29]		1.35 [0.56-3.26]	1.58 [0.73-3.43]

Functional Immediate CR	0.47 [0.26-0.88]	1.23 [0.66-2.29]	0.74 [0.31-1.78]		1.17 [0.47-2.90]
Functional Staged CR	0.41 [0.19-0.85]	1.05 [0.47-2.33]	0.63 [0.29-1.37]	0.86 [0.34-2.13]	
Heterogeneity: $I^2=53\%$ ; $\tau^2=0.123$					
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.14 [0.93-4.91]	1.29 [0.44-3.73]	2.02 [0.86-4.78]	2.26 [0.89-5.75]
Angio Immediate CR	0.47 [0.20-1.07]		0.60 [0.24-1.54]	0.95 [0.39-2.31]	1.06 [0.36-3.06]
Angio Staged CR	0.78 [0.27-2.25]	1.66 [0.65-4.25]		1.57 [0.47-5.21]	1.75 [0.66-4.67]
Functional Immediate CR	0.49 [0.21-1.17]	1.06 [0.43-2.58]	0.64 [0.19-2.11]		1.12 [0.34-3.67]
Functional Staged CR	0.44 [0.17-1.13]	0.95 [0.33-2.74]	0.57 [0.21-1.52]	0.90 [0.27-2.94]	
Heterogeneity: $I^2=71\%$ ; $\tau^2=0.231$					
<b>Major Adverse Cardiac Events</b>					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.33 [1.58-3.44]	1.65 [0.96-2.83]	2.07 [1.31-3.29]	1.70 [1.00-2.87]
Angio Immediate CR	0.43 [0.29-0.63]		0.71 [0.45-1.11]	0.89 [0.55-1.43]	0.73 [0.41-1.29]
Angio Staged CR	0.61 [0.35-1.04]	1.42 [0.90-2.23]		1.26 [0.67-2.36]	1.03 [0.57-1.84]
Functional Immediate CR	0.48 [0.30-0.77]	1.13 [0.70-1.81]	0.80 [0.42-1.49]		0.82 [0.42-1.60]
Functional Staged CR	0.59 [0.35-1.00]	1.38 [0.77-2.45]	0.97 [0.54-1.74]	1.22 [0.63-2.38]	
Heterogeneity: $I^2=53\%$ ; $\tau^2=0.060$					

Values are HRs [95% CIs].

CI = Confidence Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

Supplementary Table 44. Bayesian random-effects network meta-analysis after excluding trials with NSTEMI – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.79 [1.36-5.65]	1.48 [0.56-4.35]	1.49 [0.67-3.42]	0.88 [0.34-2.23]
Angio Immediate CR	0.36 [0.18-0.73]		0.53 [0.23-1.38]	0.53 [0.23-1.25]	0.32 [0.11-0.88]
Angio Staged CR	0.67 [0.23-1.79]	1.87 [0.72-4.4]		1.00 [0.30-3.06]	0.59 [0.21-1.54]
Functional Immediate CR	0.67 [0.29-1.49]	1.87 [0.80-4.31]	1.00 [0.33-3.34]		0.59 [0.18-1.89]
Functional Staged CR	1.13 [0.45-2.91]	3.16 [1.13-8.78]	1.69 [0.65-4.80]	1.69 [0.53-5.49]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		3.13 [0.97-10.11]	4.21 [0.91-19.77]	0.80 [0.16-4.08]	1.86 [0.44-8.14]
Angio Immediate CR	0.32 [0.10-1.03]		1.34 [0.42-4.31]	0.26 [0.03-1.94]	0.60 [0.11-3.23]
Angio Staged CR	0.24 [0.05-1.09]	0.74 [0.23-2.36]		0.19 [0.02-1.82]	0.44 [0.08-2.59]
Functional Immediate CR	1.25 [0.24-6.37]	3.92 [0.52-29.85]	5.26 [0.55-50.69]		2.34 [0.27-21.51]
Functional Staged CR	0.54 [0.12-2.25]	1.67 [0.31-8.88]	2.25 [0.39-13.19]	0.43 [0.05-3.72]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.46 [0.69-3.09]	2.36 [0.79-7.68]	1.36 [0.52-3.39]	0.73 [0.25-2.28]
Angio Immediate CR	0.68 [0.32-1.44]		1.61 [0.67-4.21]	0.93 [0.36-2.26]	0.49 [0.14-1.78]
Angio Staged CR	0.42 [0.13-1.27]	0.62 [0.24-1.50]		0.58 [0.15-1.93]	0.31 [0.08-1.22]
Functional Immediate CR	0.73 [0.30-1.92]	1.08 [0.44-2.75]	1.73 [0.52-6.54]		0.53 [0.13-2.31]
Functional Staged CR	1.38 [0.44-4.06]	2.02 [0.56-6.94]	3.23 [0.82-13.24]	1.88 [0.43-7.46]	
Definite or Probable Stent Thrombos	is				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.22 [0.07-19.28]	1.32 [0.05-32.18]	2.16 [0.32-14.98]	0.33 [0.01-15.81]
Angio Immediate CR	0.82 [0.05-13.42]		1.08 [0.23-5.64]	1.79 [0.24-13.19]	0.27 [0.02-4.34]
Angio Staged CR	0.76 [0.03-18.25]	0.93 [0.18-4.38]		1.67 [0.12-19.96]	0.25 [0.03-2.28]
Functional Immediate CR	0.46 [0.07-3.17]	0.56 [0.08-4.13]	0.60 [0.05-8.08]		0.15 [0.01-4.66]
Functional Staged CR	3.03 [0.06-139.64]	3.68 [0.23-53.21]	3.98 [0.44-35.66]	6.58 [0.21-173.62]	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.60 [1.18-5.41]	1.56 [0.55-4.64]	2.12 [0.81-5.32]	2.48 [0.85-6.95]
Angio Immediate CR	0.38 [0.18-0.85]		0.60 [0.25-1.58]	0.81 [0.32-2.12]	0.95 [0.31-2.93]
Angio Staged CR	0.64 [0.22-1.83]	1.66 [0.63-3.99]		1.37 [0.36-4.58]	1.58 [0.52-4.46]
Functional Immediate CR	0.47 [0.19-1.24]	1.23 [0.47-3.11]	0.73 [0.22-2.75]		1.17 [0.31-4.47]
Functional Staged CR	0.40 [0.14-1.18]	1.05 [0.34-3.21]	0.63 [0.22-1.92]	0.85 [0.22-3.25]	
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR

IRA-Only		2.15 [0.7-6.55]	1.28 [0.31-5.46]	2.03 [0.61-6.53]	2.29 [0.63-8.17]
Angio Immediate CR	0.47 [0.15-1.44]		0.59 [0.17-2.21]	0.95 [0.28-3.18]	1.06 [0.25-4.42]
Angio Staged CR	0.78 [0.18-3.22]	1.68 [0.45-5.86]		1.60 [0.30-8.04]	1.77 [0.47-6.34]
Functional Immediate CR	0.49 [0.15-1.63]	1.06 [0.31-3.52]	0.63 [0.12-3.36]		1.12 [0.21-5.73]
Functional Staged CR	0.44 [0.12-1.59]	0.94 [0.23-4.01]	0.56 [0.16-2.13]	0.89 [0.17-4.66]	
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only	IRA-Only	Angio Immediate CR 1.93 [1.16-3.13]	Angio Staged CR 1.52 [0.87-2.68]	Functional Immediate CR 1.77 [1.12-2.94]	Functional Staged CR 1.62 [0.73-3.57]
IRA-Only Angio Immediate CR	IRA-Only 0.52 [0.32-0.87]	Angio Immediate CR 1.93 [1.16-3.13]	Angio Staged CR 1.52 [0.87-2.68] 0.79 [0.50-1.27]	Functional Immediate CR   1.77 [1.12-2.94]   0.92 [0.54-1.63]	Functional Staged CR 1.62 [0.73-3.57] 0.84 [0.36-1.98]
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.52 [0.32-0.87] 0.66 [0.37-1.15]	Angio Immediate CR 1.93 [1.16-3.13] 1.27 [0.79-2.00]	Angio Staged CR 1.52 [0.87-2.68] 0.79 [0.50-1.27]	Functional Immediate CR   1.77 [1.12-2.94]   0.92 [0.54-1.63]   1.17 [0.62-2.28]	Functional Staged CR 1.62 [0.73-3.57] 0.84 [0.36-1.98] 1.07 [0.47-2.39]
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.52 [0.32-0.87] 0.66 [0.37-1.15] 0.56 [0.34-0.90]	Angio Immediate CR 1.93 [1.16-3.13] 1.27 [0.79-2.00] 1.09 [0.61-1.84]	Angio Staged CR 1.52 [0.87-2.68] 0.79 [0.50-1.27] 0.85 [0.44-1.62]	Functional Immediate CR   1.77 [1.12-2.94]   0.92 [0.54-1.63]   1.17 [0.62-2.28]	Functional Staged CR 1.62 [0.73-3.57] 0.84 [0.36-1.98] 1.07 [0.47-2.39] 0.92 [0.36-2.20]

Values are HRs [95% CrIs].

CrI = Credible Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

Supplementary Table 45. Frequentist random-effects network meta-analysis for periprocedural outcomes after excluding trials with NSTEMI – 5node analysis.

Stroke					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.93 [0.37-2.31]	0.72 [0.45-1.15]	4.53 [0.24-84.50]	0.62 [0.10-3.71]
Angio Immediate CR	1.08 [0.43-2.70]		0.78 [0.32-1.87]	4.90 [0.23-105.07]	0.67 [0.09-4.88]
Angio Staged CR	1.39 [0.87-2.22]	1.29 [0.53-3.10]		6.31 [0.33-121.96]	0.86 [0.14-5.26]
Functional Immediate CR	0.22 [0.01-4.11]	0.20 [0.01-4.38]	0.16 [0.01-3.07]		0.14 [0.00-4.22]
Functional Staged CR	1.61 [0.27-9.65]	1.49 [0.20-10.87]	1.16 [0.19-7.07]	7.31 [0.24-225.45]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					
Contrast-Induced Acute Kidney Inju	ıry				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.69 [0.33-1.47]	0.71 [0.43-1.18]	-	1.01 [0.43-2.36]
Angio Immediate CR	1.44 [0.68-3.04]		1.02 [0.53-1.98]	-	1.46 [0.51-4.16]
Angio Staged CR	1.41 [0.85-2.35]	0.98 [0.51-1.90]		-	1.43 [0.60-3.38]
Functional Immediate CR	-	-	-		-
Functional Staged CR	0.99 [0.42-2.31]	0.69 [0.24-1.96]	0.70 [0.30-1.66]	-	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					
Major Bleeding					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.18 [0.68-2.04]	0.74 [0.51-1.07]	1.34 [0.35-5.08]	3.48 [0.73-16.64]
Angio Immediate CR	0.85 [0.49-1.46]		0.63 [0.37-1.06]	1.13 [0.27-4.80]	2.95 [0.57-15.11]
Angio Staged CR	1.35 [0.94-1.95]	1.59 [0.94-2.69]		1.81 [0.45-7.22]	4.70 [0.98-22.50]
Functional Immediate CR	0.75 [0.20-2.84]	0.88 [0.21-3.73]	0.55 [0.14-2.21]		2.60 [0.33-20.33]
Functional Staged CR	0.29 [0.06-1.38]	0.34 [0.07-1.74]	0.21 [0.04-1.02]	0.38 [0.05-3.01]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					

Values are OR [95% CI]

CI = Confidence Interval; CR = Complete Revascularization; IRA = Infarct Related Artery; OR = Odds Ratio.

Supplementary Table 46. Bayesian random-effects network meta-analysis for periprocedural outcomes after excluding trials with NSTEMI – 5-node analysis.

Stroke						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		0.73 [0.13-3.03]	0.72 [0.18-2.80]	-	0.10 [0.00-0.98]	
Angio Immediate CR	1.37 [0.33-7.67]		0.98 [0.26-4.79]	-	0.14 [0.00-2.05]	
Angio Staged CR	1.38 [0.36-5.70]	1.02 [0.21-3.85]		-	0.14 [0.00-1.54]	
Functional Immediate CR	-	-	-		-	
Functional Staged CR	9.77 [1.02-361.55]	7.12 [0.49-298.03]	6.94 [0.65-272.03]	-		
Contrast-Induced Acute Kidney Injury						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		0.95 [0.34-3.26]	0.84 [0.37-2.31]	-	0.93 [0.30-3.10]	
Angio Immediate CR	1.05 [0.37-2.95]		0.90 [0.31-2.38]	-	0.99 [0.21-4.01]	
Angio Staged CR	1.18 [0.43-2.69]	1.12 [0.42-3.23]		-	1.10 [0.33-3.48]	
Functional Immediate CR	-	-	-		-	
Functional Staged CR	1.07 [0.32-3.33]	1.01 [0.25-4.68]	0.91 [0.29-2.99]	-		
Major Bleeding						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		1.22 [0.47-3.50]	0.99 [0.45-3.52]	1.47 [0.25-10.96]	1.03 [0.20-6.16]	
Angio Immediate CR	0.82 [0.29-2.11]		0.82 [0.35-2.58]	1.19 [0.15-10.60]	0.84 [0.14-5.53]	
Angio Staged CR	1.01 [0.28-2.25]	1.22 [0.39-2.87]		1.43 [0.16-11.73]	1.00 [0.17-5.31]	
Functional Immediate CR	0.69 [0.09-4.05]	0.84 [0.09-6.77]	0.70 [0.09-6.40]		0.70 [0.06-9.05]	
Functional Staged CR	0.97 [0.16-5.03]	1.20 [0.18-7.21]	1.00 [0.19-5.76]	1.43 [0.11-18.14]		

Values are OR [95% CrI]

CrI = Credible Interval; CR = Complete Revascularization; IRA = Infarct Related Artery; OR = Odds Ratio.

Supplementary Table 47. Frequentist random-effects network meta-analysis after excluding trials with NSTEMI – 3-node analysis.

<b>Myocardial Infarction</b>						
	IRA-Only	Immediate CR	Staged CR			
IRA-Only		1.96 [1.24-3.09]	0.95 [0.51-1.79]			
Immediate CR	0.51 [0.32-0.81]		0.49 [0.26-0.92]			
Staged CR	1.05 [0.56-1.97]	2.05 [1.09-3.87]				
Heterogeneity: I <sup>2</sup> =8%; τ <sup>2</sup> =0.051						
Cardiac Death						
	IRA-Only	Immediate CR	Staged CR			
IRA-Only		1.74 [0.85-3.58]	2.12 [0.86-5.23]			
Immediate CR	0.57 [0.28-1.18]		1.22 [0.53-2.80]			
Staged CR	0.47 [0.19-1.16] 0.82 [0.36-1.88]					
Heterogeneity: $I^2=22\%$ ; $\tau^2=0$	0.107					
Death						
	IRA-Only	Immediate CR	Staged CR			
IRA-Only		1.19 [0.71-2.00]	1.28 [0.63-2.59]			
Immediate CR	0.84 [0.50-1.42]		1.08 [0.55-2.11]			
Staged CR	0.78 [0.39-1.58]	0.93 [0.47-1.81]				
Heterogeneity: $I^2=42\%$ ; $\tau^2=0.094$						
<b>Definite or Probable Stent</b>	Thrombosis					
	IRA-Only	Immediate CR	Staged CR			
IRA-Only		2.17 [0.69-6.81]	2.18 [0.46-10.37]			
Immediate CR	0.46 [0.15-1.44]		1.01 [0.35-2.90]			
Staged CR	0.46 [0.10-2.17]	0.99 [0.35-2.87]				
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$						
Any Revascularization						
	IRA-Only	Immediate CR	Staged CR			
IRA-Only		2.58 [1.46-4.55]	1.90 [0.88-4.12]			
Immediate CR	0.39 [0.22-0.68]		0.74 [0.35-1.55]			
Staged CR	0.52 [0.24-1.14]	1.35 [0.65-2.83]				
Heterogeneity: $I^2 = 70\%$ ; $\tau^2 = 0.224$						
Ischaemia-Driven Revascu	larization					
	IRA-Only	Immediate CR	Staged CR			
IRA-Only		2.58 [1.46-4.55]	1.90 [0.88-4.12]			
Immediate CR	0.39 [0.22-0.68]		0.74 [0.35-1.55]			
Staged CR	0.52 [0.24-1.14]	1.35 [0.65-2.83]				
Heterogeneity: $I^2=84\%$ ; $\tau^2=0$	).428					
Major Adverse Cardiac Events						
	IRA-Only	Immediate CR	Staged CR			
IRA-Only		2.26 [1.63-3.13]	1.63 [1.06-2.50]			
Immediate CR	0.44 [0.32-0.61]		0.72 [0.48-1.08]			
Staged CR	0.61 [0.40-0.94]	1.39 [0.93-2.07]				
Heterogeneity: I <sup>2</sup> =55%; $\tau^2$ =0	0.056					

Values are HR [95% CI]. Values are OR [95% CI]

CI = Confidence Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

Supplementary Table 48. Bayesian random-effects network meta-analysis after excluding trials with NSTEMI – 3-node analysis.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.97 [1.05-4.01]	0.97 [0.42-2.48]
Immediate CR	0.51 [0.25-0.96]		0.49 [0.21-1.19]
Staged CR	1.03 [0.40-2.38]	2.03 [0.84-4.76]	
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.76 [0.71-4.54]	2.15 [0.68-7.33]
Immediate CR	0.57 [0.22-1.40]		1.22 [0.42-3.56]
Staged CR	0.47 [0.14-1.48]	0.82 [0.28-2.36]	
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.18 [0.54-2.46]	1.30 [0.50-3.83]
Immediate CR	0.85 [0.41-1.87]		1.10 [0.47-3.06]
Staged CR	0.77 [0.26-2.01]	0.91 [0.33-2.13]	
Definite or Probable Stent	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.16 [0.50-9.20]	2.26 [0.33-16.06]
Immediate CR	0.46 [0.11-1.99]		1.05 [0.30-3.81]
Staged CR	0.44 [0.06-3.03]	0.95 [0.26-3.33]	
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.58 [1.19-5.52]	1.90 [0.69-5.29]
Immediate CR	0.39 [0.18-0.84]		0.74 [0.29-1.90]
Staged CR	0.53 [0.19-1.45]	1.36 [0.53-3.48]	
Ischaemia-Driven Revascu	ilarization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.34 [0.82-6.51]	1.80 [0.50-6.24]
Immediate CR	0.43 [0.15-1.22]		0.77 [0.21-2.71]
Staged CR	0.56 [0.16-2.02]	1.31 [0.37-4.72]	
Major Adverse Cardiac E	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.25 [1.31-3.72]	1.63 [0.90-3.50]
Immediate CR	0.44 [0.27-0.76]		0.73 [0.43-1.51]
Staged CR	0.61 [0.29-1.11]	1.38 [0.66-2.34]	

Values are HR [95% CrI].

CrI = Credible Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.

Supplementary Table 49. Frequentist random-effects network meta-analysis after excluding the CROSS-AMI trial – 5-node analysis.

Myocardial infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.25 [1.39-3.66]	1.20 [0.72-2.00]	1.88 [1.18-2.99]	0.97 [0.55-1.69]
Angio Immediate CR	0.44 [0.27-0.72]		0.53 [0.33-0.86]	0.83 [0.50-1.40]	0.43 [0.21-0.90]
Angio Staged CR	0.83 [0.50-1.38]	1.87 [1.16-3.03]		1.56 [0.85-2.87]	0.81 [0.38-1.71]
Functional Immediate CR	0.53 [0.33-0.85]	1.20 [0.72-2.02]	0.64 [0.35-1.18]		0.52 [0.25-1.07]
Functional Staged CR	1.03 [0.59-1.80]	2.33 [1.11-4.87]	1.24 [0.58-2.64]	1.94 [0.94-4.00]	
Heterogeneity: $I^2=42\%$ ; $\tau^2=0.094$					
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.26 [0.61-2.58]	1.25 [0.61-2.56]	1.82 [0.90-3.72]	1.33 [0.60-2.94]
Angio Immediate CR	0.80 [0.39-1.63]		0.99 [0.54-1.81]	1.45 [0.60-3.54]	1.06 [0.36-3.08]
Angio Staged CR	0.80 [0.39-1.64]	1.01 [0.55-1.84]		1.46 [0.57-3.72]	1.06 [0.37-3.10]
Functional Immediate CR	0.55 [0.27-1.12]	0.69 [0.28-1.68]	0.68 [0.27-1.74]		0.73 [0.25-2.11]
Functional Staged CR	0.75 [0.34-1.67]	0.95 [0.32-2.76]	0.94 [0.32-2.74]	1.37 [0.47-3.99]	
Heterogeneity: $I^2=47\%$ ; $\tau^2=0.188$					
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.26 [0.61-2.58]	1.25 [0.61-2.56]	1.82 [0.90-3.72]	1.33 [0.60-2.94]
Angio Immediate CR	0.80 [0.39-1.63]		0.99 [0.54-1.81]	1.45 [0.60-3.54]	1.06 [0.36-3.08]
Angio Staged CR	0.80 [0.39-1.64]	1.01 [0.55-1.84]		1.46 [0.57-3.72]	1.06 [0.37-3.10]
Functional Immediate CR	0.55 [0.27-1.12]	0.69 [0.28-1.68]	0.68 [0.27-1.74]		0.73 [0.25-2.11]
Functional Staged CR	0.75 [0.34-1.67]	0.95 [0.32-2.76]	0.94 [0.32-2.74]	1.37 [0.47-3.99]	
Heterogeneity: I <sup>2</sup> =38%; τ <sup>2</sup> =0.012					
Definite or probable Stent thrombosi	s				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.81 [0.37-1.79]	0.72 [0.41-1.26]	1.39 [0.67-2.87]	-
Angio Immediate CR	1.24 [0.56-2.74]		0.89 [0.46-1.72]	1.72 [0.71-4.14]	-
Angio Staged CR	1.39 [0.80-2.43]	1.13 [0.58-2.18]		1.93 [0.84-4.43]	-
Functional Immediate CR	0.72 [0.35-1.49]	0.58 [0.24-1.40]	0.52 [0.23-1.19]		-
Functional Staged CR	-	-	-	-	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.97 [1.59-5.53]	1.96 [0.94-4.07]	2.40 [1.24-4.64]	2.28 [1.01-5.14]
Angio Immediate CR	0.34 [0.18-0.63]		0.66 [0.37-1.18]	0.81 [0.41-1.59]	0.77 [0.28-2.14]
Angio Staged CR	0.51 [0.25-1.06]	1.51 [0.85-2.70]		1.22 [0.53-2.82]	1.16 [0.39-3.47]

Functional Immediate CR	0.42 [0.22-0.81]	1.24 [0.63-2.44]	0.82 [0.36-1.88]		0.95 [0.33-2.71]	
Functional Staged CR	0.44 [0.19-0.99]	1.30 [0.47-3.63]	0.86 [0.29-2.57]	1.05 [0.37-3.00]		
Heterogeneity: I <sup>2</sup> =82%; τ <sup>2</sup> =0.299						
Ischaemia-Driven Revascularization						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		2.91 [1.17-7.26]	2.32 [0.87-6.20]	2.04 [0.88-4.76]	3.23 [0.81-12.89]	
Angio Immediate CR	0.34 [0.14-0.86]		0.80 [0.35-1.83]	0.70 [0.25-1.94]	1.11 [0.21-5.83]	
Angio Staged CR	0.43 [0.16-1.15]	1.25 [0.55-2.88]		0.88 [0.28-2.79]	1.39 [0.25-7.59]	
Functional Immediate CR	0.49 [0.21-1.14]	1.42 [0.52-3.92]	1.14 [0.36-3.60]		1.58 [0.31-7.99]	
Functional Staged CR	0.31 [0.08-1.24]	0.90 [0.17-4.75]	0.72 [0.13-3.94]	0.63 [0.13-3.21]		
Heterogeneity: $I^2=87\%$ ; $\tau^2=0.424$						
Major Adverse Cardiac Events						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		2.03 [1.34-3.08]	1.53 [0.95-2.48]	2.10 [1.35-3.26]	1.36 [0.79-2.34]	
Angio Immediate CR	0.49 [0.32-0.75]		0.75 [0.52-1.11]	1.03 [0.65-1.64]	0.67 [0.34-1.33]	
Angio Staged CR	0.65 [0.40-1.06]	1.33 [0.90-1.94]		1.37 [0.78-2.39]	0.89 [0.43-1.83]	
Functional Immediate CR	0.48 [0.31-0.74]	0.97 [0.61-1.54]	0.73 [0.42-1.28]		0.65 [0.32-1.31]	
Functional Staged CR	0.74 [0.43-1.27]	1.50 [0.75-2.98]	1.13 [0.55-2.34]	1.55 [0.77-3.12]		
Heterogeneity: $I^2=78\%$ ; $\tau^2=0.130$						

Values are HRs [95% CIs].

CI = Confidence Interval; CR = Complete Revascularization; HR = Hazard Ratio; IRA = Infarct Related Artery.
Supplementary Table 50. Bayesian random-effects network meta-analysis after excluding the CROSS-AMI trial – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.03 [1.02-3.87]	1.14 [0.51-2.43]	1.55 [0.88-2.93]	1.07 [0.30-3.86]
Angio Immediate CR	0.49 [0.26-0.98]		0.56 [0.29-1.09]	0.77 [0.40-1.64]	0.52 [0.12-2.30]
Angio Staged CR	0.88 [0.41-1.96]	1.79 [0.92-3.46]		1.36 [0.61-3.44]	0.93 [0.21-4.30]
Functional Immediate CR	0.65 [0.34-1.13]	1.30 [0.61-2.53]	0.73 [0.29-1.64]		0.69 [0.16-2.73]
Functional Staged CR	0.93 [0.26-3.37]	1.91[0.44-8.00]	1.07 [0.23-4.79]	1.46 [0.37-6.30]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.21 [0.53-3.07]	1.20 [0.51-3.49]	1.53 [0.77-3.58]	1.78 [0.34-9.43]
Angio Immediate CR	0.83 [0.33-1.88]		1.00 [0.49-2.18]	1.28 [0.46-3.64]	1.47 [0.22-9.26]
Angio Staged CR	0.83 [0.29-1.95]	1.00 [0.46-2.03]		1.27 [0.40-3.84]	1.47 [0.20-9.27]
Functional Immediate CR	0.65 [0.28-1.30]	0.78 [0.28-2.18]	0.79 [0.26-2.48]		1.15 [0.18-6.66]
Functional Staged CR	0.56 [0.11-2.92]	0.68 [0.11-4.59]	0.68 [0.11-5.02]	0.87 [0.15-5.47]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.10 [0.61-1.92]	1.17 [0.63-2.38]	1.26 [0.78-2.27]	0.71 [0.21-2.42]
Angio Immediate CR	0.91 [0.52-1.63]		1.06 [0.64-1.98]	1.15 [0.65-2.27]	0.65 [0.17-2.52]
Angio Staged CR	0.86 [0.42-1.58]	0.94 [0.51-1.55]		1.08 [0.51-2.30]	0.61 [0.15-2.34]
Functional Immediate CR	0.79 [0.44-1.28]	0.87 [0.44-1.54]	0.93 [0.44-1.95]		0.56 [0.14-2.04]
Functional Staged CR	1.40 [0.41-4.66]	1.55 [0.40-5.81]	1.65 [0.43-6.76]	1.78 [0.49-7.05]	
Definite or Probable Stent Thrombos	lis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.80 [0.28-2.24]	0.72 [0.30-1.70]	1.37 [0.57-3.30]	
Angio Immediate CR	1.25 [0.45-3.55]		0.90 [0.41-1.94]	1.72 [0.58-5.02]	
Angio Staged CR	1.40 [0.59-3.37]	1.12 [0.51-2.43]		1.92 [0.66-5.56]	
Functional Immediate CR	0.73 [0.30-1.76]	0.58 [0.19-1.72]	0.52 [0.18-1.51]		
Functional Staged CR	_	-	-	-	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.97 [1.5-5.63]	2.03 [0.94-4.26]	2.21 [1.18-4.17]	2.76 [0.96-7.66]
Angio Immediate CR	0.34 [0.18-0.67]		0.68 [0.37-1.29]	0.75 [0.37-1.59]	0.93 [0.31-2.85]
Angio Staged CR	0.49 [0.23-1.06]	1.46 [0.78-2.71]		1.09 [0.47-2.66]	1.36 [0.48-3.88]
Functional Immediate CR	0.45 [0.24-0.85]	1.34 [0.63-2.70]	0.92 [0.38-2.15]		1.25 [0.38-3.96]
Functional Staged CR	0.36 [0.13-1.04]	1.08 [0.35-3.21]	0.74 [0.26-2.09]	0.80 [0.25-2.64]	
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR

IRA-Only		2.91 [0.78-10.15]	2.32 [0.55-9.05]	2.04 [0.6-6.68]	3.23 [0.45-22.91]	
Angio Immediate CR	0.34 [0.10-1.29]		0.80 [0.24-2.73]	0.70 [0.17-2.99]	1.11 [0.11-12.07]	
Angio Staged CR	0.43 [0.11-1.81]	1.26 [0.37-4.10]		0.88 [0.17-4.60]	1.39 [0.13-15.71]	
Functional Immediate CR	0.49 [0.15-1.66]	1.43 [0.33-5.90]	1.14 [0.22-5.85]		1.59 [0.16-15.73]	
Functional Staged CR	0.31 [0.04-2.21]	0.90 [0.08-9.21]	0.72 [0.06-7.79]	0.63 [0.06-6.15]		
Major Adverse Cardiac Events						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only	IRA-Only	Angio Immediate CR 1.89 [1.09-3.22]	Angio Staged CR 1.46 [0.77-2.83]	Functional Immediate CR 1.77 [1.07-3.00]	Functional Staged CR 1.79 [0.61-5.28]	
IRA-Only Angio Immediate CR	IRA-Only 0.53 [0.31-0.92]	Angio Immediate CR 1.89 [1.09-3.22]	Angio Staged CR 1.46 [0.77-2.83] 0.77 [0.47-1.31]	Functional Immediate CR   1.77 [1.07-3.00]   0.94 [0.53-1.74]	Functional Staged CR 1.79 [0.61-5.28] 0.95 [0.29-3.18]	
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.53 [0.31-0.92] 0.68 [0.35-1.30]	Angio Immediate CR 1.89 [1.09-3.22] 1.29 [0.76-2.12]	Angio Staged CR 1.46 [0.77-2.83] 0.77 [0.47-1.31]	Functional Immediate CR   1.77 [1.07-3.00]   0.94 [0.53-1.74]   1.21 [0.59-2.53]	Functional Staged CR 1.79 [0.61-5.28] 0.95 [0.29-3.18] 1.22 [0.35-4.25]	
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.53 [0.31-0.92] 0.68 [0.35-1.30] 0.57 [0.33-0.94]	Angio Immediate CR 1.89 [1.09-3.22] 1.29 [0.76-2.12] 1.07 [0.57-1.88]	Angio Staged CR 1.46 [0.77-2.83] 0.77 [0.47-1.31] 0.83 [0.40-1.68]	Functional Immediate CR   1.77 [1.07-3.00]   0.94 [0.53-1.74]   1.21 [0.59-2.53]	Functional Staged CR 1.79 [0.61-5.28] 0.95 [0.29-3.18] 1.22 [0.35-4.25] 1.01 [0.30-3.28]	

Supplementary Table 51. Frequentist random-effects network meta-analysis after excluding trials at high risk for bias – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.26 [1.39-3.67]	1.37 [0.85-2.20]	1.87 [1.18-2.95]	0.88 [0.54-1.45]
Angio Immediate CR	0.44 [0.27-0.72]		0.61 [0.35-1.04]	0.83 [0.50-1.38]	0.39 [0.20-0.76]
Angio Staged CR	0.73 [0.45-1.18]	1.65 [0.96-2.84]		1.37 [0.74-2.51]	0.65 [0.35-1.20]
Functional Immediate CR	0.54 [0.34-0.84]	1.21 [0.72-2.02]	0.73 [0.40-1.34]		0.47 [0.24-0.92]
Functional Staged CR	1.13 [0.69-1.86]	2.56 [1.31-4.99]	1.55 [0.84-2.87]	2.12 [1.09-4.11]	
Heterogeneity: $I^2=45\%$ ; $\tau^2=0.086$					
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.41 [0.66-3.00]	1.24 [0.59-2.62]	1.88 [0.90-3.94]	1.24 [0.56-2.73]
Angio Immediate CR	0.71 [0.33-1.52]		0.88 [0.42-1.85]	1.34 [0.53-3.39]	0.88 [0.30-2.57]
Angio Staged CR	0.81 [0.38-1.70]	1.13 [0.54-2.38]		1.52 [0.57-4.06]	1.00 [0.36-2.81]
Functional Immediate CR	0.53 [0.25-1.11]	0.75 [0.30-1.89]	0.66 [0.25-1.77]		0.66 [0.23-1.93]
Functional Staged CR	0.81 [0.37-1.77]	1.13 [0.39-3.30]	1.00 [0.36-2.81]	1.52 [0.52-4.44]	
Heterogeneity: $I^2=48\%$ ; $\tau^2=0.212$					
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.32 [0.95-1.83]	1.10 [0.85-1.41]	1.49 [1.14-1.94]	0.83 [0.62-1.12]
Angio Immediate CR	0.76 [0.55-1.05]		0.83 [0.59-1.17]	1.13 [0.79-1.61]	0.63 [0.41-0.98]
Angio Staged CR	0.91 [0.71-1.17]	1.20 [0.85-1.70]		1.36 [0.96-1.92]	0.76 [0.52-1.12]
Functional Immediate CR	0.67 [0.52-0.88]	0.89 [0.62-1.26]	0.74 [0.52-1.04]		0.56 [0.38-0.83]
Functional Staged CR	1.20 [0.89-1.61]	1.58 [1.02-2.46]	1.32 [0.90-1.94]	1.79 [1.20-2.66]	
Heterogeneity: I <sup>2</sup> =23%; $\tau^2 < 0.001$					
Definite or Probable Stent Thrombos	is				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.87 [0.35-2.16]	0.71 [0.40-1.25]	1.42 [0.68-2.97]	0.18 [0.03-0.95]
Angio Immediate CR	1.16 [0.46-2.89]		0.82 [0.35-1.92]	1.64 [0.64-4.17]	0.21 [0.03-1.23]
Angio Staged CR	1.41 [0.80-2.47]	1.22 [0.52-2.85]		2.00 [0.85-4.69]	0.25 [0.05-1.21]
Functional Immediate CR	0.71 [0.34-1.48]	0.61 [0.24-1.56]	0.50 [0.21-1.18]		0.13 [0.02-0.75]
Functional Staged CR	5.63 [1.06-30.03]	4.87 [0.81-29.20]	4.00 [0.83-19.35]	7.98 [1.33-47.97]	
Heterogeneity: I <sup>2</sup> =0%; $\tau^2$ =0					
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.85 [1.55-5.24]	2.11 [1.06-4.22]	2.35 [1.23-4.52]	2.31 [1.14-4.70]
Angio Immediate CR	0.35 [0.19-0.64]		0.74 [0.38-1.44]	0.82 [0.42-1.61]	0.81 [0.34-1.93]
Angio Staged CR	0.47 [0.24-0.94]	1.35 [0.69-2.63]		1.11 [0.48-2.59]	1.10 [0.47-2.53]

Functional Immediate CR	0.43 [0.22-0.82]	1.21 [0.62-2.37]	0.90 [0.39-2.09]		0.98 [0.39-2.50]			
Functional Staged CR	0.43 [0.21-0.88]	1.23 [0.52-2.93]	0.91 [0.40-2.11]	1.02 [0.40-2.59]				
Heterogeneity: $I^2=83\%$ ; $\tau^2=0.293$								
Ischaemia-Driven Revascularization								
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR			
IRA-Only		2.56 [1.15-5.68]	2.86 [1.29-6.34]	1.96 [0.95-4.04]	3.27 [1.27-8.42]			
Angio Immediate CR	0.39 [0.18-0.87]		1.12 [0.48-2.62]	0.77 [0.32-1.85]	1.28 [0.41-3.95]			
Angio Staged CR	0.35 [0.16-0.77]	0.89 [0.38-2.09]		0.68 [0.25-1.85]	1.14 [0.43-3.00]			
Functional Immediate CR	0.51 [0.25-1.05]	1.30 [0.54-3.14]	1.46 [0.54-3.95]		1.67 [0.52-5.30]			
Functional Staged CR	0.31 [0.12-0.79]	0.78 [0.25-2.42]	0.88 [0.33-2.30]	0.60 [0.19-1.91]				
Heterogeneity: $I^2=85\%$ ; $\tau^2=0.294$								
Major Adverse Cardiac Events								
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR			
IRA-Only		2.01 [1.37-2.97]	1.53 [0.99-2.35]	2.07 [1.38-3.12]	1.38 [0.88-2.16]			
Angio Immediate CR	0.50 [0.34-0.73]		0.76 [0.50-1.16]	1.03 [0.67-1.58]	0.68 [0.39-1.19]			
Angio Staged CR	0.66 [0.43-1.01]	1.32 [0.86-2.02]		1.36 [0.80-2.32]	0.90 [0.52-1.55]			
Functional Immediate CR	0.48 [0.32-0.73]	0.97 [0.63-1.50]	0.74 [0.43-1.26]		0.66 [0.37-1.20]			
Functional Staged CR	0.73 [0.46-1.14]	1.46 [0.84-2.56]	1.11 [0.64-1.91]	1.51 [0.83-2.73]				
Heterogeneity: $I^2 = 75\%$ ; $\tau^2 = 0.107$								

Supplementary Table 52. Bayesian random-effects network meta-analysis after excluding trials at high risk for bias – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.89 [1.09-3.22]	1.46 [0.77-2.83]	1.77 [1.07-3.00]	1.79 [0.61-5.28]
Angio Immediate CR	0.53 [0.31-0.92]		0.77 [0.47-1.31]	0.94 [0.53-1.74]	0.95 [0.29-3.18]
Angio Staged CR	0.68 [0.35-1.30]	1.29 [0.76-2.12]		1.21 [0.59-2.53]	1.22 [0.35-4.25]
Functional Immediate CR	0.57 [0.33-0.94]	1.07 [0.57-1.88]	0.83 [0.40-1.68]		1.01 [0.30-3.28]
Functional Staged CR	0.56 [0.19-1.64]	1.06 [0.31-3.49]	0.82 [0.24-2.88]	0.99 [0.30-3.30]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.01 [1.37-2.97]	1.53 [0.99-2.35]	2.07 [1.38-3.12]	1.38 [0.88-2.16]
Angio Immediate CR	0.50 [0.34-0.73]		0.76 [0.50-1.16]	1.03 [0.67-1.58]	0.68 [0.39-1.19]
Angio Staged CR	0.66 [0.43-1.01]	1.32 [0.86-2.02]		1.36 [0.80-2.32]	0.90 [0.52-1.55]
Functional Immediate CR	0.48 [0.32-0.73]	0.97 [0.63-1.50]	0.74 [0.43-1.26]		0.66 [0.37-1.20]
Functional Staged CR	0.73 [0.46-1.14]	1.46 [0.84-2.56]	1.11 [0.64-1.91]	1.51 [0.83-2.73]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.20 [0.68-2.09]	1.08 [0.58-2.18]	1.28 [0.82-2.29]	0.65 [0.22-1.77]
Angio Immediate CR	0.84 [0.48-1.47]		0.91 [0.49-1.79]	1.07 [0.62-2.12]	0.54 [0.16-1.66]
Angio Staged CR	0.92 [0.46-1.74]	1.10 [0.56-2.02]		1.18 [0.57-2.62]	0.59 [0.18-1.81]
Functional Immediate CR	0.78 [0.44-1.22]	0.93 [0.47-1.61]	0.85 [0.38-1.76]		0.50 [0.14-1.49]
Functional Staged CR	1.55 [0.56-4.59]	1.86 [0.60-6.09]	1.69 [0.55-5.65]	2.00 [0.67-6.96]	
Definite or Probable Stent Thrombos	is				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.87 [0.21-3.83]	0.70 [0.20-2.28]	1.43 [0.48-4.23]	0.17 [0.02-1.73]
Angio Immediate CR	1.16 [0.26-4.75]		0.80 [0.22-2.61]	1.63 [0.39-6.52]	0.20 [0.02-2.01]
Angio Staged CR	1.44 [0.44-5.00]	1.25 [0.38-4.52]		2.04 [0.52-8.81]	0.25 [0.04-1.83]
Functional Immediate CR	0.70 [0.24-2.09]	0.61 [0.15-2.53]	0.49 [0.11-1.93]		0.12 [0.01-1.38]
Functional Staged CR	5.72 [0.58-58.50]	4.98 [0.50-53.37]	3.93 [0.55-28.25]	8.05 [0.73-96.64]	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.83 [1.34-5.76]	2.20 [0.90-5.15]	2.18 [1.09-4.43]	2.86 [0.91-8.78]
Angio Immediate CR	0.35 [0.17-0.75]		0.78 [0.34-1.78]	0.77 [0.36-1.74]	1.01 [0.29-3.53]
Angio Staged CR	0.45 [0.19-1.11]	1.28 [0.56-2.94]		0.99 [0.37-2.79]	1.30 [0.42-4.13]
Functional Immediate CR	0.46 [0.23-0.91]	1.30 [0.57-2.78]	1.01 [0.36-2.73]		1.32 [0.35-4.68]
Functional Staged CR	0.35 [0.11-1.10]	0.99 [0.28-3.41]	0.77 [0.24-2.41]	0.76 [0.21-2.85]	
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR

IRA-Only		2.57 [0.75-7.77]	2.86 [0.86-9.35]	1.97 [0.66-5.81]	3.27 [0.82-12.9]	
Angio Immediate CR	0.39 [0.13-1.34]		1.11 [0.32-4.27]	0.77 [0.22-2.88]	1.28 [0.26-7.01]	
Angio Staged CR	0.35 [0.11-1.16]	0.90 [0.23-3.08]		0.69 [0.15-3.07]	1.14 [0.28-4.67]	
Functional Immediate CR	0.51 [0.17-1.52]	1.31 [0.35-4.52]	1.46 [0.33-6.64]		1.67 [0.31-9.14]	
Functional Staged CR	0.31 [0.08-1.22]	0.78 [0.14-3.87]	0.88 [0.21-3.51]	0.60 [0.11-3.27]		
Major Adverse Cardiac Events						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only	IRA-Only	Angio Immediate CR 1.91 [1.13-3.20]	Angio Staged CR 1.53 [0.82-2.80]	Functional Immediate CR 1.77 [1.10-2.98]	Functional Staged CR 1.63 [0.72-3.67]	
IRA-Only Angio Immediate CR	IRA-Only 0.52 [0.31-0.89]	Angio Immediate CR 1.91 [1.13-3.20]	Angio Staged CR 1.53 [0.82-2.80] 0.80 [0.44-1.44]	Functional Immediate CR   1.77 [1.10-2.98]   0.93 [0.54-1.68]	Functional Staged CR 1.63 [0.72-3.67] 0.85 [0.34-2.09]	
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.52 [0.31-0.89] 0.65 [0.36-1.22]	Angio Immediate CR 1.91 [1.13-3.20] 1.25 [0.69-2.27]	Angio Staged CR 1.53 [0.82-2.80] 0.80 [0.44-1.44]	Functional Immediate CR   1.77 [1.10-2.98]   0.93 [0.54-1.68]   1.15 [0.58-2.44]	Functional Staged CR 1.63 [0.72-3.67] 0.85 [0.34-2.09] 1.06 [0.46-2.45]	
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.52 [0.31-0.89] 0.65 [0.36-1.22] 0.57 [0.34-0.91]	Angio Immediate CR 1.91 [1.13-3.20] 1.25 [0.69-2.27] 1.08 [0.59-1.85]	Angio Staged CR 1.53 [0.82-2.80] 0.80 [0.44-1.44] 0.87 [0.41-1.73]	Functional Immediate CR   1.77 [1.10-2.98]   0.93 [0.54-1.68]   1.15 [0.58-2.44]	Functional Staged CR 1.63 [0.72-3.67] 0.85 [0.34-2.09] 1.06 [0.46-2.45] 0.92 [0.36-2.24]	

Supplementary Table 53. Frequentist random-effects network meta-analysis after excluding trials at high risk for bias – 3-node analysis.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.91 [1.36-2.68]	1.11 [0.82-1.50]
Immediate CR	0.52 [0.37-0.73]		0.58 [0.39-0.87]
Staged CR	0.90 [0.67-1.22]	1.73 [1.15-2.58]	
Heterogeneity: $I^2=33\%$ ; $\tau^2=0.04$	5		
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.54 [1.12-2.12]	1.17 [0.91-1.51]
Immediate CR	0.65 [0.47-0.89]		0.76 [0.53-1.10]
Staged CR	0.85 [0.66-1.10]	1.32 [0.91-1.90]	
Heterogeneity: $I^2=0\%$ ; $\tau^2<0.001$	-		
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.39 [1.10-1.75]	0.99 [0.82-1.20]
Immediate CR	0.72 [0.57-0.91]		0.71 [0.54-0.94]
Staged CR	1.01 [0.83-1.22]	1.40 [1.07-1.84]	
Heterogeneity: $I^2=0\%$ ; $\tau^2<0.001$	-		
Definite or Probable Stent Th	rombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.20 [0.61-2.35]	0.77 [0.45-1.33]
Immediate CR	0.83 [0.42-1.63]		0.64 [0.32-1.31]
Staged CR	1.29 [0.75-2.22]	1.55 [0.76-3.17]	
Heterogeneity: I <sup>2</sup> =0%; $\tau^2$ =0			
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.67 [1.56-4.57]	2.14 [1.20-3.80]
Immediate CR	0.37 [0.22-0.64]		0.80 [0.43-1.50]
Staged CR	0.47 [0.26-0.83]	1.25 [0.67-2.34]	
Heterogeneity: $I^2=87\%$ ; $\tau^2=0.32$	15		
Ischaemia-Driven Revasculari	zation		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.67 [1.56-4.57]	2.14 [1.20-3.80]
Immediate CR	0.37 [0.22-0.64]		0.80 [0.43-1.50]
Staged CR	0.47 [0.26-0.83]	1.25 [0.67-2.34]	
Heterogeneity: $I^2=92\%$ ; $\tau^2=0.44$	1		
Major Adverse Cardiac Event	s		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.99 [1.52-2.61]	1.46 [1.10-1.93]
Immediate CR	0.50 [0.38-0.66]		0.73 [0.53-1.01]
Staged CR	0.68 [0.52-0.91]	1.36 [0.99-1.87]	
Heterogeneity: $I^2=78\%$ ; $\tau^2=0.06$	5		

Values are HRs [95% CIs].

Supplementary Table 54. Bayesian random-effects network meta-analysis after excluding trials at high risk for bias – 3-node analysis.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.65 [1.07-2.75]	1.10 [0.58-1.98]
Immediate CR	0.61 [0.36-0.94]		0.67 [0.33-1.22]
Staged CR	0.91 [0.50-1.71]	1.50 [0.82-3.05]	
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.44 [0.98-2.31]	1.21 [0.75-2.24]
Immediate CR	0.69 [0.43-1.02]		0.84 [0.49-1.50]
Staged CR	0.83 [0.45-1.33]	1.19 [0.67-2.04]	
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.21 [0.88-1.72]	1.00 [0.64-1.55]
Immediate CR	0.82 [0.58-1.14]		0.82 [0.51-1.29]
Staged CR	1.00 [0.64-1.56]	1.21 [0.78-1.95]	
Definite or Probable Stent Th	rombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.22 [0.52-2.90]	0.79 [0.33-1.91]
Immediate CR	0.82 [0.35-1.94]		0.65 [0.25-1.66]
Staged CR	1.27 [0.52-3.03]	1.54 [0.60-3.96]	
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.50 [1.31-4.85]	2.21 [0.93-5.30]
Immediate CR	0.40 [0.21-0.76]		0.88 [0.37-2.10]
Staged CR	0.45 [0.19-1.08]	1.13 [0.48-2.71]	
Ischaemia-Driven Revasculari	zation		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.24 [0.84-5.60]	2.84 [0.95-8.46]
Immediate CR	0.45 [0.18-1.19]		1.27 [0.39-4.35]
Staged CR	0.35 [0.12-1.05]	0.79 [0.23-2.54]	
Major Adverse Cardiac Event	S		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.82 [1.27-2.67]	1.52 [0.94-2.47]
Immediate CR	0.55 [0.37-0.78]		0.84 [0.50-1.34]
Staged CR	0.66 [0.40-1.07]	1.20 [0.75-1.99]	

Values are HRs [95% CrIs].

Supplementary Table 55. Frequentist random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.01 [0.80-5.03]	1.09 [0.38-3.14]	2.01 [0.80-5.04]	0.75 [0.26-2.14]
Angio Immediate CR	0.50 [0.20-1.25]		0.54 [0.27-1.10]	1.00 [0.45-2.23]	0.37 [0.12-1.16]
Angio Staged CR	0.92 [0.32-2.63]	1.84 [0.91-3.73]		1.84 [0.66-5.14]	0.69 [0.23-2.06]
Functional Immediate CR	0.50 [0.20-1.25]	1.00 [0.45-2.23]	0.54 [0.19-1.52]		0.37 [0.11-1.29]
Functional Staged CR	1.33 [0.47-3.79]	2.67 [0.86-8.30]	1.45 [0.49-4.36]	2.68 [0.78-9.23]	
Heterogeneity: $I^2=58\%$ ; $\tau^2=0.285$					
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.29 [0.29-5.71]	1.53 [0.30-7.82]	2.26 [0.51-10.09]	1.39 [0.28-6.86]
Angio Immediate CR	0.77 [0.18-3.42]		1.18 [0.49-2.83]	1.75 [0.38-7.98]	1.08 [0.17-7.02]
Angio Staged CR	0.65 [0.13-3.35]	0.85 [0.35-2.03]		1.48 [0.27-8.16]	0.91 [0.14-6.09]
Functional Immediate CR	0.44 [0.10-1.98]	0.57 [0.13-2.61]	0.68 [0.12-3.73]		0.62 [0.08-4.76]
Functional Staged CR	0.72 [0.15-3.54]	0.93 [0.14-6.06]	1.10 [0.16-7.33]	1.62 [0.21-12.56]	
Heterogeneity: $I^2=59\%$ ; $\tau^2=0.545$					
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.33 [0.51-3.44]	1.59 [0.52-4.83]	1.78 [0.67-4.72]	0.67 [0.21-2.15]
Angio Immediate CR	0.75 [0.29-1.95]		1.20 [0.62-2.30]	1.34 [0.60-3.01]	0.51 [0.13-2.00]
Angio Staged CR	0.63 [0.21-1.91]	0.84 [0.43-1.60]		1.12 [0.40-3.11]	0.42 [0.10-1.76]
Functional Immediate CR	0.56 [0.21-1.49]	0.75 [0.33-1.68]	0.89 [0.32-2.49]		0.38 [0.09-1.58]
Functional Staged CR	1.49 [0.46-4.77]	1.98 [0.50-7.81]	2.37 [0.57-9.90]	2.65 [0.63-11.11]	
Heterogeneity: $I^2=57\%$ ; $\tau^2=0.274$					
Definite or Probable Stent Thrombos	sis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.22 [0.23-6.57]	1.07 [0.17-6.69]	2.17 [0.69-6.81]	0.27 [0.02-3.00]
Angio Immediate CR	0.82 [0.15-4.43]		0.88 [0.42-1.81]	1.79 [0.52-6.17]	0.22 [0.04-1.24]
Angio Staged CR	0.94 [0.15-5.87]	1.14 [0.55-2.36]		2.04 [0.48-8.57]	0.25 [0.05-1.21]
Functional Immediate CR	0.46 [0.15-1.44]	0.56 [0.16-1.93]	0.49 [0.12-2.07]		0.12 [0.01-1.04]
Functional Staged CR	3.75 [0.33-42.13]	4.56 [0.80-25.89]	4.00 [0.83-19.35]	8.15 [0.96-68.79]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$					
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.19 [1.24-3.85]	1.13 [0.59-2.15]	2.20 [1.27-3.84]	2.15[1.11-4.16]
Angio Immediate CR	0.46 [0.26-0.80]		0.52 [0.34-0.77]	1.01 [0.61-1.66]	0.98 [0.48-2.00]

Angio Staged CR	0.88 [0.47-1.68]	1.94 [1.29-2.91]		1.95 [1.05-3.63]	1.90 [0.95-3.81]			
Functional Immediate CR	0.45 [0.26-0.79]	0.99 [0.60-1.64]	0.51 [0.28-0.95]		0.97 [0.45-2.11]			
Functional Staged CR	0.47 [0.24-0.90]	1.02 [0.50-2.07]	0.53 [0.26-1.05]	1.03 [0.47-2.22]				
Heterogeneity: $I^2=49\%$ ; $\tau^2=0.090$								
Ischaemia-Driven Revascularization								
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR			
IRA-Only		2.16 [1.15-4.04]	1.30 [0.63-2.65]	2.04 [1.08-3.86]	2.31 [1.16-4.59]			
Angio Immediate CR	0.46 [0.25-0.87]		0.60 [0.37-0.98]	0.95 [0.48-1.86]	1.07 [0.50-2.28]			
Angio Staged CR	0.77 [0.38-1.58]	1.66 [1.02-2.70]		1.57 [0.71-3.47]	1.78 [0.86-3.69]			
Functional Immediate CR	0.49 [0.26-0.93]	1.06 [0.54-2.08]	0.64 [0.29-1.41]		1.13 [0.48-2.69]			
Functional Staged CR	0.43 [0.22-0.86]	0.93 [0.44-1.99]	0.56 [0.27-1.17]	0.88 [0.37-2.10]				
Heterogeneity: $I^2=70\%$ ; $\tau^2=0.197$								
Major Adverse Cardiac Events								
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR			
IRA-Only		1.87 [1.10-3.17]	1.34 [0.73-2.44]	2.35 [1.36-4.08]	1.55 [0.83-2.88]			
Angio Immediate CR	0.54 [0.32-0.91]		0.72 [0.49-1.04]	1.26 [0.78-2.05]	0.83 [0.42-1.63]			
Angio Staged CR	0.75 [0.41-1.37]	1.40 [0.96-2.04]		1.76 [0.97-3.20]	1.16 [0.59-2.25]			
Functional Immediate CR	0.43 [0.24-0.74]	0.79 [0.49-1.29]	0.57 [0.31-1.03]		0.66 [0.31-1.39]			
Functional Staged CR	0.65 [0.35-1.21]	1.21 [0.61-2.37]	0.86 [0.44-1.68]	1.52 [0.72-3.22]				
Heterogeneity: $I^2=66\%$ ; $\tau^2=0.106$								

Supplementary Table 56. Bayesian random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.00 [0.69-5.92]	1.07 [0.33-3.87]	1.96 [0.69-6.22]	0.76 [0.22-2.56]
Angio Immediate CR	0.50 [0.17-1.44]		0.54 [0.25-1.27]	0.98 [0.40-2.65]	0.38 [0.10-1.40]
Angio Staged CR	0.93 [0.26-3.03]	1.85 [0.79-4.03]		1.83 [0.55-6.11]	0.70 [0.19-2.37]
Functional Immediate CR	0.51 [0.16-1.45]	1.02 [0.38-2.48]	0.55 [0.16-1.82]		0.39 [0.08-1.57]
Functional Staged CR	1.32 [0.39-4.53]	2.64 [0.71-9.92]	1.42 [0.42-5.34]	2.60 [0.64-11.83]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.26 [0.24-7.58]	1.47 [0.24-10.8]	2.20 [0.39-13.72]	1.40 [0.21-8.92]
Angio Immediate CR	0.80 [0.13-4.18]		1.17 [0.42-3.47]	1.76 [0.29-10.18]	1.11 [0.12-8.65]
Angio Staged CR	0.68 [0.09-4.10]	0.86 [0.29-2.38]		1.51 [0.19-10.59]	0.95 [0.10-7.26]
Functional Immediate CR	0.45 [0.07-2.54]	0.57 [0.10-3.45]	0.66 [0.09-5.30]		0.63 [0.05-6.27]
Functional Staged CR	0.72 [0.11-4.80]	0.90 [0.12-8.27]	1.06 [0.14-10.30]	1.58 [0.16-18.78]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.33 [0.42-4.05]	1.57 [0.44-6.15]	1.76 [0.56-5.83]	0.67 [0.17-2.60]
Angio Immediate CR	0.75 [0.25-2.39]		1.18 [0.58-2.79]	1.32 [0.51-3.71]	0.50 [0.11-2.40]
Angio Staged CR	0.64 [0.16-2.25]	0.85 [0.36-1.74]		1.12 [0.32-3.74]	0.43 [0.08-1.99]
Functional Immediate CR	0.57 [0.17-1.78]	0.76 [0.27-1.94]	0.89 [0.27-3.15]		0.38 [0.07-1.94]
Functional Staged CR	1.49 [0.38-5.91]	1.99 [0.42-9.51]	2.35 [0.50-12.33]	2.61 [0.52-14.55]	
Definite or Probable Stent Thrombos	is				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.21 [0.11-14.64]	1.07 [0.08-15.52]	2.20 [0.40-11.92]	0.27 [0.01-7.46]
Angio Immediate CR	0.83 [0.07-9.14]		0.88 [0.33-2.43]	1.81 [0.30-10.12]	0.22 [0.02-2.14]
Angio Staged CR	0.93 [0.06-12.91]	1.14 [0.41-3.04]		2.04 [0.27-14.96]	0.25 [0.03-1.88]
Functional Immediate CR	0.45 [0.08-2.48]	0.55 [0.10-3.31]	0.49 [0.07-3.73]		0.12 [0.01-2.22]
Functional Staged CR	3.70 [0.13-102.12]	4.57 [0.47-41.89]	3.99 [0.53-29.75]	8.23 [0.45-133.63]	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.21 [0.98-4.49]	1.14 [0.49-2.68]	2.21 [1.03-4.85]	2.17 [0.87-5.06]
Angio Immediate CR	0.45 [0.22-1.02]		0.52 [0.31-0.92]	1.00 [0.54-2.10]	0.98 [0.40-2.49]
Angio Staged CR	0.88 [0.37-2.04]	1.94 [1.08-3.18]		1.93 [0.86-4.52]	1.90 [0.75-4.48]
Functional Immediate CR	0.45 [0.21-0.97]	1.00 [0.48-1.85]	0.52 [0.22-1.17]		0.98 [0.33-2.66]
Functional Staged CR	0.46 [0.20-1.16]	1.02 [0.40-2.53]	0.53 [0.22-1.34]	1.02 [0.38-3.01]	
Ischaemia-Driven Revascularization					

	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.15 [0.84-5.42]	1.29 [0.44-3.93]	2.03 [0.74-5.45]	2.32 [0.78-6.33]
Angio Immediate CR	0.46 [0.18-1.19]		0.60 [0.27-1.36]	0.94 [0.34-2.64]	1.08 [0.33-3.22]
Angio Staged CR	0.77 [0.25-2.25]	1.66 [0.73-3.70]		1.57 [0.46-5.40]	1.78 [0.57-4.99]
Functional Immediate CR	0.49 [0.18-1.36]	1.06 [0.38-2.92]	0.64 [0.19-2.17]		1.14 [0.29-4.23]
Functional Staged CR	0.43 [0.16-1.29]	0.93 [0.31-3.02]	0.56 [0.20-1.74]	0.88 [0.24-3.44]	
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.87 [0.94-3.65]	1.33 [0.63-3.00]	2.34 [1.16-4.90]	1.55 [0.70-3.40]
Angio Immediate CR	0.53 [0.27-1.07]		0.71 [0.46-1.21]	1.25 [0.70-2.42]	0.83 [0.36-1.96]
Angio Staged CR	0.75 [0.33-1.58]	1.41 [0.83-2.18]		1.76 [0.81-3.72]	1.16 [0.49-2.59]
Functional Immediate CR	0.43 [0.20-0.86]	0.80 [0.41-1.44]	0.57 [0.27-1.23]		0.66 [0.25-1.66]
Functional Staged CR	0.64 [0.29-1.43]	1.21 [0.51-2.78]	0.86 [0.39-2.02]	1.51 [0.60-3.96]	

Supplementary Table 57. Frequentist random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation -3-node analysis.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.70 [1.14-2.54]	0.82 [0.51-1.32]
Immediate CR	0.59 [0.39-0.88]		0.49 [0.33-0.72]
Staged CR	1.21 [0.76-1.95]	2.06 [1.39-3.07]	
Heterogeneity: $I^2=0\%$ ; $\tau^2<0$ .	.001		
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.70 [1.14-2.54]	0.82 [0.51-1.32]
Immediate CR	0.59 [0.39-0.88]		0.49 [0.33-0.72]
Staged CR	1.21 [0.76-1.95]	2.06 [1.39-3.07]	
Heterogeneity: $I^2=0\%$ ; $\tau^2<0$	.001		
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.16 [0.57-2.36]	1.17 [0.54-2.54]
Immediate CR	0.86 [0.42-1.75]		1.01 [0.57-1.77]
Staged CR	0.85 [0.39-1.86]	0.99 [0.57-1.74]	
Heterogeneity: $I^2=55\%$ ; $\tau^2=$	0.200		
Definite or Probable Stent	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.17 [0.69-6.81]	1.91 [0.49-7.38]
Immediate CR	0.46 [0.15-1.44]		0.88 [0.42-1.81]
Staged CR	0.52 [0.14-2.03]	1.14 [0.55-2.36]	
Heterogeneity: I <sup>2</sup> =0%; $\tau^2$ =0	1		
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.57 [1.38-4.77]	1.50 [0.76-2.99]
Immediate CR	0.39 [0.21-0.72]		0.58 [0.35-0.97]
Staged CR	0.67 [0.33-1.32]	1.71 [1.03-2.85]	
Heterogeneity: $I^2=71\%$ ; $\tau^2=$	0.207		
Ischaemia-Driven Revascu	larization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.41 [1.21-4.80]	1.67 [0.76-3.67]
Immediate CR	0.41 [0.21-0.83]		0.69 [0.36-1.34]
Staged CR	0.60 [0.27-1.31]	1.44 [0.74-2.79]	
Heterogeneity: $I^2=77\%$ ; $\tau^2=$	0.251		
Major Adverse Cardiac Ev	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.16 [1.60-2.92]	1.49 [1.07-2.08]
Immediate CR	0.46 [0.34-0.63]		0.69 [0.54-0.88]
Staged CR	0.67 [0.48-0.94]	1.45 [1.13-1.86]	
Heterogeneity: $I^2=48\%$ ; $\tau^2=$	0.028		

Values are HRs [95% CIs].

Supplementary Table 58. Bayesian random-effects network meta-analysis after excluding trials comparing complete revascularisation with culprit lesion-only revascularisation -3-node analysis.

Myocardial Infarction			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.76 [0.96-3.37]	0.86 [0.44-1.83]
Immediate CR	0.57 [0.30-1.05]		0.49 [0.29-0.89]
Staged CR	1.16 [0.55-2.26]	2.03 [1.13-3.49]	
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.52 [0.57-4.19]	1.64 [0.59-5.09]
Immediate CR	0.66 [0.24-1.75]		1.09 [0.54-2.33]
Staged CR	0.61 [0.20-1.70]	0.92 [0.43-1.87]	
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.17 [0.46-2.88]	1.16 [0.45-3.32]
Immediate CR	0.86 [0.35-2.18]		0.99 [0.52-2.21]
Staged CR	0.86 [0.30-2.21]	1.01 [0.45-1.94]	
Definite or Probable Stent T	hrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.16 [0.52-8.91]	1.91 [0.36-10.19]
Immediate CR	0.46 [0.11-1.93]		0.89 [0.37-2.12]
Staged CR	0.52 [0.10-2.75]	1.13 [0.47-2.73]	
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.57 [1.11-5.70]	1.50 [0.62-3.70]
Immediate CR	0.39 [0.18-0.90]		0.58 [0.31-1.17]
Staged CR	0.67 [0.27-1.62]	1.71 [0.85-3.25]	
Ischaemia-Driven Revascula	rization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.42 [0.95-6.04]	1.68 [0.58-4.81]
Immediate CR	0.41 [0.17-1.05]		0.69 [0.29-1.71]
Staged CR	0.60 [0.21-1.72]	1.45 [0.58-3.47]	
Major Adverse Cardiac Eve	nts		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.15 [1.36-3.32]	1.50 [0.94-2.53]
Immediate CR	0.46 [0.30-0.73]		0.70 [0.51-1.05]
Staged CR	0.67 [0.40-1.06]	1.44 [0.95-1.98]	

Values are HRs [95% CrIs].

Supplementary Table 59. Frequentist random-effects network meta-analysis after excluding trials with mixed revascularisation timing – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.30 [0.92-5.75]	1.23 [0.43-3.56]	2.19 [0.86-5.57]	0.79 [0.27-2.30]
Angio Immediate CR	0.44 [0.17-1.09]		0.54 [0.26-1.10]	0.95 [0.42-2.16]	0.34 [0.11-1.09]
Angio Staged CR	0.81 [0.28-2.35]	1.87 [0.91-3.84]		1.78 [0.63-5.08]	0.64 [0.21-1.96]
Functional Immediate CR	0.46 [0.18-1.16]	1.05 [0.46-2.37]	0.56 [0.20-1.60]		0.36 [0.10-1.28]
Functional Staged CR	1.26 [0.44-3.67]	2.90 [0.92-9.16]	1.56 [0.51-4.74]	2.77 [0.78-9.80]	
Heterogeneity: I <sup>2</sup> =60%; $\tau^2$ =0.303					
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.31 [0.33-5.16]	1.54 [0.33-7.22]	2.27 [0.53-9.81]	1.40 [0.29-6.77]
Angio Immediate CR	0.76 [0.19-3.01]		1.18 [0.49-2.81]	1.74 [0.39-7.64]	1.07 [0.17-6.61]
Angio Staged CR	0.65 [0.14-3.03]	0.85 [0.36-2.02]		1.47 [0.27-7.88]	0.91 [0.14-5.79]
Functional Immediate CR	0.44 [0.10-1.90]	0.58 [0.13-2.54]	0.68 [0.13-3.64]		0.62 [0.08-4.68]
Functional Staged CR	0.72 [0.15-3.46]	0.94 [0.15-5.80]	1.10 [0.17-7.06]	1.63 [0.21-12.37]	
Heterogeneity: $I^2=60\%$ ; $\tau^2=0.533$					
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.31 [0.33-5.16]	1.54 [0.33-7.22]	2.27 [0.53-9.81]	1.40 [0.29-6.77]
Angio Immediate CR	0.76 [0.19-3.01]		1.18 [0.49-2.81]	1.74 [0.39-7.64]	1.07 [0.17-6.61]
Angio Staged CR	0.65 [0.14-3.03]	0.85 [0.36-2.02]		1.47 [0.27-7.88]	0.91 [0.14-5.79]
Functional Immediate CR	0.44 [0.10-1.90]	0.58 [0.13-2.54]	0.68 [0.13-3.64]		0.62 [0.08-4.68]
Functional Staged CR	0.72 [0.15-3.46]	0.94 [0.15-5.80]	1.10 [0.17-7.06]	1.63 [0.21-12.37]	
Heterogeneity: $I^2=54\%$ ; $\tau^2=0.223$					
Definite or Probable Stent Thrombos	sis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.22 [0.23-6.57]	1.07 [0.17-6.69]	2.17 [0.69-6.81]	0.27 [0.02-3.00]
Angio Immediate CR	0.82 [0.15-4.43]		0.88 [0.42-1.81]	1.79 [0.52-6.17]	0.22 [0.04-1.24]
Angio Staged CR	0.94 [0.15-5.87]	1.14 [0.55-2.36]		2.04 [0.48-8.57]	0.25 [0.05-1.21]
Functional Immediate CR	0.46 [0.15-1.44]	0.56 [0.16-1.93]	0.49 [0.12-2.07]		0.12 [0.01-1.04]
Functional Staged CR	3.75 [0.33-42.13]	4.56 [0.80-25.89]	4.00 [0.83-19.35]	8.15 [0.96-68.79]	
Heterogeneity: I <sup>2</sup> =0%; $\tau^2$ =0					
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		3.19 [2.19-4.64]	1.52 [0.98-2.35]	2.56 [1.83-3.58]	2.52 [1.57-4.03]
Angio Immediate CR	0.31 [0.22-0.46]		0.48 [0.36-0.63]	0.80 [0.58-1.12]	0.79 [0.47-1.32]

Angio Staged CR	0.66 [0.43-1.02]	2.10 [1.60-2.77]		1.69 [1.12-2.55]	1.66 [1.00-2.77]
Functional Immediate CR	0.39 [0.28-0.55]	1.25 [0.90-1.73]	0.59 [0.39-0.90]		0.98 [0.58-1.67]
Functional Staged CR	0.40 [0.25-0.64]	1.27 [0.76-2.11]	0.60 [0.36-1.00]	1.02 [0.60-1.73]	
Heterogeneity: $I^2=18\%$ ; $\tau^2=0.007$					
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		3.35 [1.80-6.22]	1.94 [1.04-3.63]	2.42 [1.54-3.80]	2.81 [1.69-4.65]
Angio Immediate CR	0.30 [0.16-0.56]		0.58 [0.44-0.76]	0.72 [0.41-1.26]	0.84 [0.46-1.54]
Angio Staged CR	0.52 [0.28-0.96]	1.73 [1.32-2.25]		1.24 [0.69-2.23]	1.45 [0.80-2.60]
Functional Immediate CR	0.41 [0.26-0.65]	1.39 [0.79-2.42]	0.80 [0.45-1.44]		1.16 [0.64-2.12]
Functional Staged CR	0.36 [0.22-0.59]	1.19 [0.65-2.19]	0.69 [0.38-1.24]	0.86 [0.47-1.57]	
Heterogeneity: $I^2=25\%$ ; $\tau^2=0.008$					
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.33 [1.32-4.08]	1.63 [0.87-3.08]	2.71 [1.52-4.82]	1.68 [0.88-3.21]
Angio Immediate CR	0.43 [0.24-0.76]		0.70 [0.47-1.04]	1.16 [0.70-1.93]	0.72 [0.36-1.46]
Angio Staged CR	0.61 [0.32-1.16]	1.42 [0.96-2.11]		1.66 [0.89-3.08]	1.03 [0.52-2.06]
Functional Immediate CR	0.37 [0.21-0.66]	0.86 [0.52-1.43]	0.60 [0.32-1.12]		0.62 [0.29-1.35]
Functional Staged CR	0.59 [0.31-1.14]	1.38 [0.68-2.79]	0.97 [0.49-1.94]	1.61 [0.74-3.50]	
Heterogeneity: $I^2=67\%$ ; $\tau^2=0.117$					

Supplementary Table 60. Bayesian random-effects network meta-analysis after excluding trials with mixed revascularisation timing – 5-node analysis.

Myocardial Infarction						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		2.29 [0.80-6.84]	1.21 [0.37-4.40]	2.13 [0.75-6.91]	0.80 [0.24-2.80]	
Angio Immediate CR	0.44 [0.15-1.26]		0.53 [0.24-1.26]	0.94 [0.38-2.55]	0.35 [0.09-1.31]	
Angio Staged CR	0.82 [0.23-2.71]	1.88 [0.80-4.09]		1.76 [0.52-6.00]	0.65 [0.18-2.28]	
Functional Immediate CR	0.47 [0.14-1.33]	1.07 [0.39-2.66]	0.57 [0.17-1.91]		0.37 [0.08-1.53]	
Functional Staged CR	1.25 [0.36-4.25]	2.87 [0.76-10.87]	1.53 [0.44-5.69]	2.69 [0.65-12.20]		
Cardiac Death						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		1.31 [0.26-6.83]	1.52 [0.25-10.17]	2.24 [0.40-13.46]	1.41 [0.21-8.84]	
Angio Immediate CR	0.76 [0.15-3.84]		1.16 [0.42-3.55]	1.72 [0.30-9.94]	1.09 [0.12-8.17]	
Angio Staged CR	0.66 [0.10-3.92]	0.86 [0.28-2.39]		1.49 [0.19-10.32]	0.93 [0.10-6.83]	
Functional Immediate CR	0.45 [0.07-2.50]	0.58 [0.10-3.33]	0.67 [0.10-5.18]		0.63 [0.05-6.27]	
Functional Staged CR	0.71 [0.11-4.85]	0.92 [0.12-8.35]	1.08 [0.15-9.92]	1.59 [0.16-18.66]		
Death						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		1.12 [0.37-3.27]	1.31 [0.39-4.86]	1.57 [0.52-5.06]	0.65 [0.17-2.38]	
Angio Immediate CR	0.89 [0.31-2.71]		1.18 [0.59-2.71]	1.40 [0.57-3.81]	0.58 [0.13-2.66]	
Angio Staged CR	0.76 [0.21-2.56]	0.85 [0.37-1.70]		1.19 [0.35-3.85]	0.49 [0.09-2.21]	
Functional Immediate CR	0.64 [0.20-1.93]	0.71 [0.26-1.75]	0.84 [0.26-2.84]		0.41 [0.08-2.00]	
Functional Staged CR	1.54 [0.42-5.95]	1.73 [0.38-7.89]	2.03 [0.45-10.55]	2.43 [0.50-13.01]		
Definite or Probable Stent Thrombos	sis					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		1.20 [0.10-14.02]	1.06 [0.08-15.22]	2.15 [0.39-12.19]	0.27 [0.01-7.17]	
Angio Immediate CR	0.83 [0.07-9.77]		0.88 [0.33-2.43]	1.80 [0.30-10.71]	0.22 [0.02-2.15]	
Angio Staged CR	0.94 [0.07-13.22]	1.13 [0.41-3.08]		2.02 [0.27-15.74]	0.25 [0.03-1.83]	
Functional Immediate CR	0.46 [0.08-2.54]	0.56 [0.09-3.31]	0.49 [0.06-3.74]		0.12 [0.01-2.12]	
Functional Staged CR	3.70 [0.14-104.57]	4.52 [0.47-41.69]	3.99 [0.55-29.38]	8.09 [0.47-138.25]		
Any Revascularization						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		3.19 [1.79-5.70]	1.55 [0.82-3.11]	2.65 [1.53-5.02]	2.51[1.25-4.99]	
Angio Immediate CR	0.31 [0.18-0.56]		0.49 [0.33-0.77]	0.83 [0.51-1.49]	0.78[0.38-1.62]	
Angio Staged CR	0.64 [0.32-1.23]	2.05 [1.30-3.07]		1.71 [0.91-3.37]	1.61[0.75-3.24]	
Functional Immediate CR	0.38 [0.20-0.65]	1.20 [0.67-1.95]	0.59 [0.30-1.10]		0.94 [0.40-2.01]	
Functional Staged CR	0.40 [0.20-0.80]	1.27 [0.62-2.65]	0.62 [0.31-1.32]	1.06 [0.50-2.53]		
Ischaemia-Driven Revascularization						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	

IRA-Only		3.41 [0.99-12.55]	1.93 [0.54-6.90]	2.47 [0.89-7.07]	2.76 [0.93-7.77]
Angio Immediate CR	0.29 [0.08-1.01]		0.57 [0.25-1.19]	0.72 [0.24-2.09]	0.81 [0.23-2.59]
Angio Staged CR	0.52 [0.14-1.84]	1.76 [0.84-3.94]		1.27 [0.39-4.32]	1.43 [0.47-4.19]
Functional Immediate CR	0.41 [0.14-1.13]	1.38 [0.48-4.09]	0.78 [0.23-2.56]		1.12 [0.30-3.74]
Functional Staged CR	0.36 [0.13-1.07]	1.23 [0.39-4.39]	0.70 [0.24-2.15]	0.89 [0.27-3.32]	
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only	IRA-Only	Angio Immediate CR 2.32 [1.09-4.90]	Angio Staged CR 1.63 [0.72-3.95]	Functional Immediate CR 2.67 [1.25-6.04]	Functional Staged CR 1.68 [0.70-4.01]
IRA-Only Angio Immediate CR	IRA-Only 0.43 [0.20-0.92]	Angio Immediate CR 2.32 [1.09-4.90]	Angio Staged CR 1.63 [0.72-3.95] 0.70 [0.43-1.25]	Functional Immediate CR   2.67 [1.25-6.04]   1.15 [0.61-2.36]	Functional Staged CR 1.68 [0.70-4.01] 0.72 [0.29-1.85]
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.43 [0.20-0.92] 0.61 [0.25-1.39]	Angio Immediate CR 2.32 [1.09-4.90] 1.43 [0.80-2.31]	Angio Staged CR 1.63 [0.72-3.95] 0.70 [0.43-1.25]	Functional Immediate CR   2.67 [1.25-6.04]   1.15 [0.61-2.36]   1.65 [0.72-3.74]	Functional Staged CR 1.68 [0.70-4.01] 0.72 [0.29-1.85] 1.03 [0.41-2.47]
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.43 [0.20-0.92] 0.61 [0.25-1.39] 0.37 [0.17-0.80]	Angio Immediate CR 2.32 [1.09-4.90] 1.43 [0.80-2.31] 0.87 [0.42-1.65]	Angio Staged CR 1.63 [0.72-3.95] 0.70 [0.43-1.25] 0.61 [0.27-1.39]	Functional Immediate CR   2.67 [1.25-6.04]   1.15 [0.61-2.36]   1.65 [0.72-3.74]	Functional Staged CR 1.68 [0.70-4.01] 0.72 [0.29-1.85] 1.03 [0.41-2.47] 0.63 [0.22-1.74]

Supplementary Table 61. Frequentist random-effects network meta-analysis after excluding trials with mixed revascularisation timing – 3-node analysis.

Myocardial Infarction			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.87 [1.21-2.90]	0.89 [0.53-1.49]
Immediate CR	0.53 [0.34-0.83]		0.48 [0.31-0.73]
Staged CR	1.12 [0.67-1.88]	2.11 [1.37-3.24]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$ .	023		
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.57 [0.75-3.27]	1.67 [0.75-3.70]
Immediate CR	0.64 [0.31-1.33]		1.06 [0.62-1.83]
Staged CR	0.60 [0.27-1.32]	0.94 [0.55-1.62]	
Heterogeneity: I <sup>2</sup> =18%; $\tau^2$ =	0.069		
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.04 [0.56-1.96]	1.05 [0.52-2.12]
Immediate CR	0.96 [0.51-1.80]		1.01 [0.60-1.68]
Staged CR	0.95 [0.47-1.91]	0.99 [0.60-1.65]	
Heterogeneity: $I^2=48\%$ ; $\tau^2=$	0.137		
Definite or Probable Stent	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.17 [0.69-6.81]	1.91 [0.49-7.38]
Immediate CR	0.46 [0.15-1.44]		0.88 [0.42-1.81]
Staged CR	0.52 [0.14-2.03]	1.14 [0.55-2.36]	
Heterogeneity: $I^2=0\%$ ; $\tau^2=0$			
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		3.39 [2.09-5.49]	1.84 [1.07-3.16]
Immediate CR	0.30 [0.18-0.48]		0.54 [0.36-0.81]
Staged CR	0.54 [0.32-0.94]	1.85 [1.23-2.77]	
Heterogeneity: $I^2=59\%$ ; $\tau^2=$	0.106		
Ischaemia-Driven Revascu	larization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		3.28 [1.56-6.89]	2.07 [0.97-4.39]
Immediate CR	0.31 [0.15-0.64]		0.63 [0.35-1.14]
Staged CR	0.48 [0.23-1.03]	1.59 [0.88-2.87]	
Heterogeneity: $I^2=74\%$ ; $\tau^2=$	0.181		
Major Adverse Cardiac Ev	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.49 [1.87-3.32]	1.65 [1.21-2.26]
Immediate CR	0.40 [0.30-0.53]		0.66 [0.53-0.83]
Staged CR	0.60 [0.44-0.83]	1.51 [1.20-1.89]	
Heterogeneity: $I^2=42\%$ ; $\tau^2=$	0.018		

Values are HRs [95% CIs].

Supplementary Table 62. Bayesian random-effects network meta-analysis after excluding trials with mixed revascularisation timing – 3-node analysis.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.91 [1.02-3.90]	0.92 [0.46-2.10]
Immediate CR	0.52 [0.26-0.98]		0.48 [0.27-0.90]
Staged CR	1.08 [0.48-2.16]	2.07 [1.12-3.66]	
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.55 [0.63-3.87]	1.68 [0.64-4.50]
Immediate CR	0.64 [0.26-1.60]		1.08 [0.55-2.19]
Staged CR	0.60 [0.22-1.57]	0.93 [0.46-1.82]	
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.05 [0.44-2.37]	1.05 [0.43-2.85]
Immediate CR	0.96 [0.42-2.28]		1.01 [0.55-2.18]
Staged CR	0.95 [0.35-2.30]	0.99 [0.46-1.82]	
Definite or Probable Stent	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.15 [0.52-9.06]	1.89 [0.36-10.10]
Immediate CR	0.46 [0.11-1.93]		0.88 [0.37-2.12]
Staged CR	0.53 [0.10-2.77]	1.14 [0.47-2.71]	
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		3.36 [1.73-6.72]	1.82 [0.90-4.03]
Immediate CR	0.30 [0.15-0.58]		0.54 [0.32-0.97]
Staged CR	0.55 [0.25-1.11]	1.84 [1.03-3.13]	
Ischaemia-Driven Revascu	larization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		3.25 [1.08-10.29]	2.05 [0.67-6.39]
Immediate CR	0.31 [0.10-0.92]		0.63 [0.26-1.56]
Staged CR	0.49 [0.16-1.49]	1.59 [0.64-3.91]	
Major Adverse Cardiac Ev	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.49 [1.57-3.95]	1.68 [1.05-2.92]
Immediate CR	0.40 [0.25-0.64]		0.67 [0.49-1.02]
Staged CR	0.60 [0.34-0.95]	1.49 [0.98-2.05]	

Values are HRs [95% CrIs].

Supplementary Table 63. Frequentist random-effects network meta-analysis after excluding the FRAME-AMI trial – 5-node analysis.

Myocardial Infarction						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		2.98 [2.09-4.25]	1.46 [1.17-1.82]	1.56 [1.15-2.12]	0.91 [0.67-1.23]	
Angio Immediate CR	0.34 [0.24-0.48]		0.49 [0.34-0.69]	0.52 [0.35-0.79]	0.30 [0.19-0.48]	
Angio Staged CR	0.69 [0.55-0.86]	2.05 [1.45-2.90]		1.07 [0.74-1.54]	0.62 [0.43-0.90]	
Functional Immediate CR	0.64 [0.47-0.87]	1.91 [1.27-2.88]	0.93 [0.65-1.35]		0.58 [0.38-0.90]	
Functional Staged CR	1.10 [0.81-1.49]	3.28 [2.07-5.20]	1.60 [1.12-2.30]	1.72 [1.11-2.64]		
Heterogeneity: $I^2=0\%$ ; $\tau^2<0.001$						
Cardiac Death						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		1.72 [0.89-3.30]	1.45 [0.84-2.53]	1.34 [0.73-2.44]	1.24 [0.68-2.27]	
Angio Immediate CR	0.58 [0.30-1.12]		0.85 [0.50-1.43]	0.78 [0.32-1.89]	0.72 [0.30-1.73]	
Angio Staged CR	0.69 [0.40-1.20]	1.18 [0.70-2.00]		0.92 [0.41-2.08]	0.86 [0.39-1.89]	
Functional Immediate CR	0.75 [0.41-1.37]	1.29 [0.53-3.13]	1.09 [0.48-2.47]		0.93 [0.40-2.18]	
Functional Staged CR	0.80 [0.44-1.47]	1.38 [0.58-3.30]	1.17 [0.53-2.58]	1.07 [0.46-2.51]		
Heterogeneity: $I^2=16\%$ ; $\tau^2=0.078$						
Death						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		1.32 [0.96-1.81]	1.17 [0.91-1.50]	1.38 [1.06-1.81]	0.83 [0.62-1.12]	
Angio Immediate CR	0.76 [0.55-1.05]		0.89 [0.65-1.22]	1.05 [0.73-1.51]	0.63 [0.41-0.98]	
Angio Staged CR	0.85 [0.67-1.10]	1.12 [0.82-1.54]		1.18 [0.83-1.67]	0.71 [0.49-1.04]	
Functional Immediate CR	0.72 [0.55-0.95]	0.95 [0.66-1.37]	0.85 [0.60-1.20]		0.60 [0.40-0.90]	
Functional Staged CR	1.20 [0.89-1.61]	1.58 [1.02-2.43]	1.40 [0.96-2.06]	1.66 [1.11-2.47]		
Heterogeneity: I <sup>2</sup> =15%; $\tau^2 < 0.001$						
Definite or Probable Stent Thrombos	sis					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		0.81 [0.37-1.79]	0.72 [0.41-1.26]	1.39 [0.67-2.87]	0.18 [0.03-0.96]	
Angio Immediate CR	1.24 [0.56-2.74]		0.89 [0.46-1.72]	1.72 [0.71-4.14]	0.22 [0.04-1.23]	
Angio Staged CR	1.39 [0.80-2.43]	1.13 [0.58-2.18]		1.93 [0.84-4.43]	0.25 [0.05-1.21]	
Functional Immediate CR	0.72 [0.35-1.49]	0.58 [0.24-1.40]	0.52 [0.23-1.18]		0.13 [0.02-0.77]	
Functional Staged CR	5.57 [1.05-29.66]	4.50 [0.81-24.89]	4.00 [0.83-19.35]	7.73 [1.30-45.89]		
Heterogeneity: I <sup>2</sup> =0%; $\tau^2$ =0						
Any Revascularization						
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR	
IRA-Only		3.32 [1.88-5.87]	2.12 [1.15-3.90]	2.09 [1.11-3.93]	2.31 [1.20-4.42]	
Angio Immediate CR	0.30 [0.17-0.53]		0.64 [0.38-1.07]	0.63 [0.31-1.28]	0.69 [0.32-1.53]	
Angio Staged CR	0.47 [0.26-0.87]	1.57 [0.94-2.63]		0.99 [0.45-2.18]	1.09 [0.51-2.34]	

Functional Immediate CR	0.48 [0.25-0.90]	1.59 [0.78-3.24]	1.01 [0.46-2.24]		1.10 [0.46-2.67]
Functional Staged CR	0.43 [0.23-0.83]	1.44 [0.65-3.17]	0.92 [0.43-1.97]	0.91 [0.37-2.19]	
Heterogeneity: $I^2=80\%$ ; $\tau^2=0.241$					
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		3.00 [1.36-6.64]	2.42 [1.10-5.36]	2.06 [0.97-4.39]	3.02 [1.13-8.08]
Angio Immediate CR	0.33 [0.15-0.74]		0.81 [0.39-1.67]	0.69 [0.28-1.69]	1.01 [0.33-3.08]
Angio Staged CR	0.41 [0.19-0.91]	1.24 [0.60-2.56]		0.85 [0.32-2.29]	1.25 [0.46-3.39]
Functional Immediate CR	0.49 [0.23-1.03]	1.46 [0.59-3.59]	1.18 [0.44-3.16]		1.47 [0.44-4.85]
Functional Staged CR	0.33 [0.12-0.88]	0.99 [0.32-3.04]	0.80 [0.29-2.18]	0.68 [0.21-2.26]	
Heterogeneity: $I^2=84\%$ ; $\tau^2=0.331$					
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.32 [1.70-3.17]	1.64 [1.19-2.26]	1.76 [1.26-2.45]	1.37 [0.97-1.95]
Angio Immediate CR	0.43 [0.32-0.59]		0.71 [0.54-0.93]	0.76 [0.51-1.12]	0.59 [0.38-0.92]
Angio Staged CR	0.61 [0.44-0.84]	1.42 [1.07-1.87]		1.08 [0.70-1.64]	0.84 [0.55-1.29]
Functional Immediate CR	0.57 [0.41-0.79]	1.32 [0.89-1.95]	0.93 [0.61-1.42]		0.78 [0.49-1.25]
Functional Staged CR	0.73 [0.51-1.03]	1.69 [1.09-2.62]	1.19 [0.78-1.83]	1.28 [0.80-2.06]	
Heterogeneity: $I^2 = 64\%$ ; $\tau^2 = 0.053$					

Supplementary Table 64. Bayesian random-effects network meta-analysis after excluding the FRAME-AMI trial – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.79 [1.76-4.38]	1.43 [0.93-2.17]	1.28 [0.91-1.88]	0.87 [0.43-1.70]
Angio Immediate CR	0.36 [0.23-0.57]		0.51 [0.33-0.79]	0.46 [0.28-0.78]	0.31 [0.14-0.68]
Angio Staged CR	0.70 [0.46-1.07]	1.96 [1.26-3.04]		0.90 [0.55-1.55]	0.61 [0.30-1.22]
Functional Immediate CR	0.78 [0.53-1.10]	2.18 [1.27-3.55]	1.11 [0.64-1.82]		0.68 [0.31-1.42]
Functional Staged CR	1.15 [0.59-2.31]	3.21 [1.48-6.95]	1.64 [0.82-3.32]	1.47 [0.70-3.24]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.73 [0.85-4.35]	1.45 [0.81-3.85]	1.26 [0.64-2.24]	1.52 [0.44-5.09]
Angio Immediate CR	0.58 [0.23-1.18]		0.85 [0.48-1.66]	0.73 [0.22-1.77]	0.87 [0.20-3.29]
Angio Staged CR	0.69 [0.26-1.23]	1.17 [0.60-2.09]		0.87 [0.24-1.87]	1.03 [0.23-3.52]
Functional Immediate CR	0.80 [0.45-1.57]	1.37 [0.56-4.60]	1.15 [0.53-4.12]		1.22 [0.31-4.91]
Functional Staged CR	0.66 [0.20-2.27]	1.15 [0.30-5.06]	0.97 [0.28-4.28]	0.82 [0.20-3.21]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.27 [0.77-2.15]	1.25 [0.78-2.41]	1.16 [0.74-1.84]	0.66 [0.25-1.71]
Angio Immediate CR	0.79 [0.47-1.30]		0.99 [0.64-1.71]	0.91 [0.50-1.64]	0.52 [0.18-1.47]
Angio Staged CR	0.80 [0.41-1.27]	1.01 [0.58-1.56]		0.92 [0.44-1.67]	0.52 [0.17-1.41]
Functional Immediate CR	0.86 [0.54-1.34]	1.09 [0.61-2.00]	1.08 [0.60-2.28]		0.57 [0.20-1.61]
Functional Staged CR	1.51 [0.59-3.98]	1.92 [0.68-5.66]	1.91 [0.71-5.91]	1.75 [0.62-5.11]	
Definite or Probable Stent Thrombosi	is				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.80 [0.24-2.57]	0.71 [0.25-1.99]	1.37 [0.51-3.59]	0.18 [0.02-1.48]
Angio Immediate CR	1.25 [0.39-4.20]		0.89 [0.38-2.08]	1.72 [0.52-5.92]	0.23 [0.03-1.73]
Angio Staged CR	1.41 [0.50-4.00]	1.12 [0.48-2.63]		1.94 [0.57-6.47]	0.25 [0.04-1.61]
Functional Immediate CR	0.73 [0.28-1.95]	0.58 [0.17-1.93]	0.52 [0.15-1.75]		0.13 [0.01-1.16]
Functional Staged CR	5.58 [0.68-48.23]	4.43 [0.58-34.37]	3.94 [0.62-25.97]	7.58 [0.86-71.9]	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		3.39 [1.69-6.51]	2.22 [1.03-4.61]	1.98 [1.03-3.74]	2.89 [1.04-7.87]
Angio Immediate CR	0.29 [0.15-0.59]		0.65 [0.36-1.22]	0.58 [0.27-1.35]	0.85 [0.29-2.53]
Angio Staged CR	0.45 [0.22-0.97]	1.53 [0.82-2.80]		0.89 [0.37-2.23]	1.30 [0.47-3.58]
Functional Immediate CR	0.50 [0.27-0.97]	1.71 [0.74-3.77]	1.12 [0.45-2.73]		1.45 [0.45-4.63]
Functional Staged CR	0.35 [0.13-0.96]	1.17 [0.39-3.44]	0.77 [0.28-2.14]	0.69 [0.22-2.22]	
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR

IRA-Only		3.02 [0.96-8.73]	2.42 [0.78-7.38]	2.07 [0.72-5.90]	3.02 [0.76-11.73]
Angio Immediate CR	0.33 [0.11-1.04]		0.81 [0.29-2.30]	0.69 [0.20-2.44]	1.00 [0.22-4.87]
Angio Staged CR	0.41 [0.14-1.28]	1.24 [0.43-3.42]		0.85 [0.22-3.52]	1.24 [0.32-4.97]
Functional Immediate CR	0.48 [0.17-1.39]	1.45 [0.41-4.89]	1.18 [0.28-4.62]		1.46 [0.28-7.76]
Functional Staged CR	0.33 [0.09-1.32]	1.00 [0.21-4.60]	0.81 [0.20-3.14]	0.69 [0.13-3.62]	
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only	IRA-Only	Angio Immediate CR 2.29 [1.51-3.36]	Angio Staged CR 1.67 [1.09-2.60]	Functional Immediate CR 1.52 [1.06-2.26]	Functional Staged CR 1.70 [0.93-3.14]
IRA-Only Angio Immediate CR	IRA-Only 0.44 [0.30-0.66]	Angio Immediate CR 2.29 [1.51-3.36]	Angio Staged CR 1.67 [1.09-2.60] 0.73 [0.52-1.07]	Functional Immediate CR   1.52 [1.06-2.26]   0.67 [0.42-1.10]	Functional Staged CR 1.70 [0.93-3.14] 0.75 [0.39-1.46]
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.44 [0.30-0.66] 0.60 [0.39-0.92]	Angio Immediate CR 2.29 [1.51-3.36] 1.36 [0.94-1.92]	Angio Staged CR 1.67 [1.09-2.60] 0.73 [0.52-1.07]	Functional Immediate CR   1.52 [1.06-2.26]   0.67 [0.42-1.10]   0.91 [0.54-1.56]	Functional Staged CR 1.70 [0.93-3.14] 0.75 [0.39-1.46] 1.02 [0.54-1.90]
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.44 [0.30-0.66] 0.60 [0.39-0.92] 0.66 [0.44-0.94]	Angio Immediate CR 2.29 [1.51-3.36] 1.36 [0.94-1.92] 1.50 [0.91-2.36]	Angio Staged CR 1.67 [1.09-2.60] 0.73 [0.52-1.07] 1.10 [0.64-1.85]	Functional Immediate CR   1.52 [1.06-2.26]   0.67 [0.42-1.10]   0.91 [0.54-1.56]	Functional Staged CR 1.70 [0.93-3.14] 0.75 [0.39-1.46] 1.02 [0.54-1.90] 1.12 [0.54-2.24]

## Supplementary Table 65. Random-effects network meta-regression for diabetes – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.16 [1.08-4.17]	1.27 [0.58-2.66]	1.58 [0.90-3.05]	0.84 [0.27-2.41]
Angio Immediate CR	0.46 [0.24-0.92]		0.58 [0.30-1.14]	0.73 [0.38-1.58]	0.39 [0.12-1.17]
Angio Staged CR	0.79 [0.38-1.71]	1.71 [0.88-3.28]		1.25 [0.56-3.14]	0.66 [0.22-1.89]
Functional Immediate CR	0.63 [0.33-1.11]	1.36 [0.63-2.63]	0.80 [0.32-1.77]		0.53 [0.15-1.62]
Functional Staged CR	1.19 [0.42-3.67]	2.58 [0.85-8.04]	1.51 [0.53-4.46]	1.89 [0.62-6.61]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.27 [0.51-3.40]	1.30 [0.53-3.95]	1.55 [0.73-3.84]	1.40 [0.26-6.77]
Angio Immediate CR	0.79 [0.29-1.96]		1.03 [0.49-2.35]	1.23 [0.41-3.80]	1.10 [0.18-5.48]
Angio Staged CR	0.77 [0.25-1.90]	0.97 [0.43-2.04]		1.20 [0.35-3.81]	1.06 [0.18-4.98]
Functional Immediate CR	0.65 [0.26-1.37]	0.81 [0.26-2.42]	0.83 [0.26-2.87]		0.90 [0.13-4.79]
Functional Staged CR	0.72 [0.15-3.89]	0.91 [0.18-5.43]	0.94 [0.20-5.58]	1.12 [0.21-7.64]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.13 [0.61-2.04]	1.21 [0.65-2.54]	1.27 [0.77-2.33]	0.68 [0.20-2.10]
Angio Immediate CR	0.88 [0.49-1.64]		1.08 [0.65-2.04]	1.13 [0.63-2.29]	0.61 [0.17-1.98]
Angio Staged CR	0.83 [0.39-1.54]	0.93 [0.49-1.53]		1.04 [0.48-2.23]	0.56 [0.15-1.76]
Functional Immediate CR	0.79 [0.43-1.30]	0.89 [0.44-1.58]	0.96 [0.45-2.06]		0.54 [0.14-1.75]
Functional Staged CR	1.46 [0.48-5.00]	1.65 [0.50-5.81]	1.79 [0.57-6.69]	1.86 [0.57-7.34]	
Definite or Probable Stent Thrombos	sis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.75 [0.23-2.48]	0.66 [0.23-1.91]	1.37 [0.52-3.57]	0.17 [0.02-1.39]
Angio Immediate CR	1.33 [0.40-4.31]		0.87 [0.38-2.05]	1.82 [0.55-6.06]	0.22 [0.03-1.71]
Angio Staged CR	1.53 [0.52-4.26]	1.14 [0.49-2.65]		2.09 [0.63-7.03]	0.25 [0.04-1.61]
Functional Immediate CR	0.73 [0.28-1.92]	0.55 [0.17-1.83]	0.48 [0.14-1.60]		0.12 [0.01-1.11]
Functional Staged CR	6.00 [0.72-51.68]	4.48 [0.59-35.90]	3.94 [0.62-26.17]	8.16 [0.90-75.74]	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.96 [1.39-6.09]	2.03 [0.86-4.62]	2.21 [1.11-4.44]	2.77 [0.81-9.04]
Angio Immediate CR	0.34 [0.16-0.72]		0.69 [0.35-1.34]	0.75 [0.35-1.66]	0.93 [0.29-3.13]
Angio Staged CR	0.49 [0.22-1.16]	1.46 [0.75-2.82]		1.09 [0.44-2.80]	1.36 [0.44-4.28]
Functional Immediate CR	0.45 [0.23-0.90]	1.34 [0.60-2.86]	0.92 [0.36-2.27]		1.25 [0.34-4.52]
Functional Staged CR	0.36 [0.11-1.23]	1.07 [0.32-3.49]	0.74 [0.23-2.26]	0.80 [0.22-2.98]	
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR

IRA-Only		2.97 [0.86-9.71]	2.40 [0.69-8.08]	2.02 [0.57-7.38]	3.05 [0.65-13.74]
Angio Immediate CR	0.34 [0.10-1.17]		0.81 [0.26-2.54]	0.68 [0.17-3.04]	1.03 [0.18-5.83]
Angio Staged CR	0.42 [0.12-1.45]	1.24 [0.39-3.80]		0.84 [0.17-4.33]	1.26 [0.27-6.00]
Functional Immediate CR	0.49 [0.14-1.76]	1.46 [0.33-6.05]	1.19 [0.23-5.81]		1.51 [0.20-10.83]
Functional Staged CR	0.33 [0.07-1.53]	0.97 [0.17-5.46]	0.79 [0.17-3.66]	0.66 [0.09-5.01]	
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only	IRA-Only	Angio Immediate CR 1.89 [1.07-3.23]	Angio Staged CR 1.48 [0.80-2.77]	Functional Immediate CR 1.77 [1.07-3.02]	Functional Staged CR 1.57 [0.64-3.79]
IRA-Only Angio Immediate CR	IRA-Only 0.53 [0.31-0.93]	Angio Immediate CR 1.89 [1.07-3.23]	Angio Staged CR 1.48 [0.80-2.77] 0.78 [0.49-1.31]	Functional Immediate CR 1.77 [1.07-3.02] 0.94 [0.53-1.73]	Functional Staged CR 1.57 [0.64-3.79] 0.83 [0.34-2.07]
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.53 [0.31-0.93] 0.67 [0.36-1.24]	Angio Immediate CR 1.89 [1.07-3.23] 1.28 [0.76-2.04]	Angio Staged CR 1.48 [0.80-2.77] 0.78 [0.49-1.31]	Functional Immediate CR   1.77 [1.07-3.02]   0.94 [0.53-1.73]   1.19 [0.60-2.39]	Functional Staged CR 1.57 [0.64-3.79] 0.83 [0.34-2.07] 1.06 [0.45-2.49]
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.53 [0.31-0.93] 0.67 [0.36-1.24] 0.57 [0.33-0.93]	Angio Immediate CR 1.89 [1.07-3.23] 1.28 [0.76-2.04] 1.07 [0.58-1.87]	Angio Staged CR 1.48 [0.80-2.77] 0.78 [0.49-1.31] 0.84 [0.42-1.67]	Functional Immediate CR 1.77 [1.07-3.02] 0.94 [0.53-1.73] 1.19 [0.60-2.39]	Functional Staged CR 1.57 [0.64-3.79] 0.83 [0.34-2.07] 1.06 [0.45-2.49] 0.89 [0.33-2.33]

## Supplementary Table 66. Random-effects network meta-regression for 3-vessel disease – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.38 [1.20-4.52]	1.26 [0.61-2.67]	2.02 [1.00-4.31]	0.84 [0.30-2.26]
Angio Immediate CR	0.42 [0.22-0.83]		0.53 [0.27-1.10]	0.85 [0.42-1.86]	0.35 [0.12-1.06]
Angio Staged CR	0.79 [0.37-1.63]	1.89 [0.91-3.72]		1.60 [0.64-4.17]	0.67 [0.23-1.85]
Functional Immediate CR	0.50 [0.23-1.00]	1.17 [0.54-2.35]	0.62 [0.24-1.56]		0.42 [0.12-1.28]
Functional Staged CR	1.19 [0.44-3.35]	2.83 [0.94-8.46]	1.49 [0.54-4.42]	2.39 [0.78-8.26]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.25 [0.47-3.86]	1.51 [0.52-5.51]	1.82 [0.62-6.61]	1.43 [0.27-7.42]
Angio Immediate CR	0.80 [0.26-2.13]		1.22 [0.45-3.44]	1.48 [0.38-5.78]	1.14 [0.16-6.78]
Angio Staged CR	0.66 [0.18-1.92]	0.82 [0.29-2.20]		1.22 [0.25-5.83]	0.94 [0.14-5.31]
Functional Immediate CR	0.55 [0.15-1.61]	0.67 [0.17-2.62]	0.82 [0.17-4.07]		0.77 [0.10-5.00]
Functional Staged CR	0.70 [0.13-3.64]	0.88 [0.15-6.14]	1.07 [0.19-7.29]	1.29 [0.20-10.10]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.08 [0.63-1.91]	1.39 [0.79-2.96]	1.42 [0.81-2.82]	0.65 [0.23-1.88]
Angio Immediate CR	0.93 [0.52-1.60]		1.29 [0.73-2.58]	1.32 [0.73-2.59]	0.61 [0.19-1.93]
Angio Staged CR	0.72 [0.34-1.26]	0.77 [0.39-1.37]		1.03 [0.43-2.28]	0.47 [0.13-1.49]
Functional Immediate CR	0.70 [0.35-1.23]	0.76 [0.39-1.38]	0.98 [0.44-2.31]		0.46 [0.14-1.42]
Functional Staged CR	1.53 [0.53-4.29]	1.65 [0.52-5.22]	2.14 [0.67-7.44]	2.19 [0.70-7.15]	
Definite or Probable Stent Thrombos	sis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.76 [0.21-2.70]	0.75 [0.24-2.31]	1.29 [0.39-3.99]	0.19 [0.02-1.81]
Angio Immediate CR	1.31 [0.37-4.77]		0.98 [0.38-2.63]	1.68 [0.42-6.89]	0.25 [0.03-2.22]
Angio Staged CR	1.33 [0.43-4.15]	1.02 [0.38-2.64]		1.72 [0.37-7.54]	0.25 [0.04-1.75]
Functional Immediate CR	0.78 [0.25-2.53]	0.59 [0.15-2.40]	0.58 [0.13-2.73]		0.15 [0.01-1.76]
Functional Staged CR	5.30 [0.55-50.48]	4.04 [0.45-33.98]	3.97 [0.57-27.39]	6.86 [0.57-77.54]	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		3.02 [1.29-6.65]	2.15 [0.84-5.46]	2.54 [0.98-6.51]	2.94 [0.82-9.99]
Angio Immediate CR	0.33 [0.15-0.78]		0.71 [0.31-1.72]	0.84 [0.34-2.22]	0.97 [0.26-3.79]
Angio Staged CR	0.47 [0.18-1.20]	1.41 [0.58-3.23]		1.18 [0.36-3.88]	1.36 [0.38-4.80]
Functional Immediate CR	0.39 [0.15-1.02]	1.19 [0.45-2.92]	0.85 [0.26-2.75]		1.15 [0.27-4.94]
Functional Staged CR	0.34 [0.10-1.22]	1.03 [0.26-3.89]	0.73 [0.21-2.65]	0.87 [0.20-3.77]	
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR

IRA-Only		2.94 [0.88-9.15]	2.36 [0.70-7.70]	2.14 [0.64-6.98]	3.08 [0.72-12.90]
Angio Immediate CR	0.34 [0.11-1.13]		0.80 [0.27-2.43]	0.73 [0.18-3.06]	1.05 [0.20-5.48]
Angio Staged CR	0.42 [0.13-1.43]	1.24 [0.41-3.67]		0.91 [0.18-4.46]	1.31 [0.29-5.84]
Functional Immediate CR	0.47 [0.14-1.56]	1.37 [0.33-5.62]	1.10 [0.22-5.48]		1.43 [0.25-8.34]
Functional Staged CR	0.32 [0.08-1.40]	0.95 [0.18-4.98]	0.76 [0.17-3.46]	0.70 [0.12-4.03]	
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only	IRA-Only	Angio Immediate CR 1.99 [1.14-3.37]	Angio Staged CR 1.68 [0.91-3.14]	Functional Immediate CR 2.06 [1.12-3.92]	Functional Staged CR 1.69 [0.73-3.96]
IRA-Only Angio Immediate CR	IRA-Only 0.50 [0.30-0.88]	Angio Immediate CR 1.99 [1.14-3.37]	Angio Staged CR 1.68 [0.91-3.14] 0.84 [0.50-1.51]	Functional Immediate CR   2.06 [1.12-3.92]   1.04 [0.57-2.00]	Functional Staged CR 1.69 [0.73-3.96] 0.85 [0.35-2.13]
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.50 [0.30-0.88] 0.60 [0.32-1.10]	Angio Immediate CR 1.99 [1.14-3.37] 1.19 [0.66-2.02]	Angio Staged CR 1.68 [0.91-3.14] 0.84 [0.50-1.51]	Functional Immediate CR   2.06 [1.12-3.92]   1.04 [0.57-2.00]   1.23 [0.57-2.67]	Functional Staged CR 1.69 [0.73-3.96] 0.85 [0.35-2.13] 1.01 [0.41-2.37]
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.50 [0.30-0.88] 0.60 [0.32-1.10] 0.48 [0.26-0.89]	Angio Immediate CR 1.99 [1.14-3.37] 1.19 [0.66-2.02] 0.96 [0.50-1.75]	Angio Staged CR 1.68 [0.91-3.14] 0.84 [0.50-1.51] 0.81 [0.37-1.77]	Functional Immediate CR   2.06 [1.12-3.92]   1.04 [0.57-2.00]   1.23 [0.57-2.67]	Functional Staged CR 1.69 [0.73-3.96] 0.85 [0.35-2.13] 1.01 [0.41-2.37] 0.82 [0.30-2.16]

## Supplementary Table 67. Random-effects network meta-regression for the year of publication – 5-node analysis.

Myocardial Infarction					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.98 [1.01-3.66]	1.17 [0.57-2.27]	1.69 [0.98-3.08]	0.68 [0.24-1.80]
Angio Immediate CR	0.51 [0.27-0.99]		0.59 [0.32-1.08]	0.86 [0.44-1.87]	0.34 [0.12-0.99]
Angio Staged CR	0.85 [0.44-1.75]	1.69 [0.92-3.10]		1.44 [0.67-3.45]	0.58 [0.22-1.56]
Functional Immediate CR	0.59 [0.33-1.02]	1.17 [0.54-2.30]	0.69 [0.29-1.50]		0.40 [0.12-1.24]
Functional Staged CR	1.47 [0.56-4.10]	2.91 [1.01-8.05]	1.72 [0.64-4.59]	2.48 [0.81-8.20]	
Cardiac Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.08 [0.48-2.48]	1.13 [0.53-2.75]	2.08 [0.97-4.39]	1.02 [0.24-4.05]
Angio Immediate CR	0.93 [0.40-2.07]		1.06 [0.56-2.12]	1.94 [0.62-5.73]	0.95 [0.21-4.02]
Angio Staged CR	0.88 [0.36-1.87]	0.94 [0.47-1.79]		1.83 [0.56-5.18]	0.89 [0.20-3.57]
Functional Immediate CR	0.48 [0.23-1.04]	0.52 [0.17-1.60]	0.55 [0.19-1.78]		0.49 [0.09-2.62]
Functional Staged CR	0.98 [0.25-4.09]	1.06 [0.25-4.73]	1.13 [0.28-5.02]	2.04 [0.38-11.45]	
Death					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		1.05 [0.58-1.82]	1.14 [0.64-2.25]	1.42 [0.84-2.43]	0.54 [0.17-1.61]
Angio Immediate CR	0.95 [0.55-1.73]		1.08 [0.68-1.96]	1.34 [0.71-2.76]	0.51 [0.16-1.67]
Angio Staged CR	0.88 [0.44-1.57]	0.92 [0.51-1.48]		1.24 [0.56-2.58]	0.47 [0.14-1.45]
Functional Immediate CR	0.71 [0.41-1.19]	0.74 [0.36-1.41]	0.81 [0.39-1.78]		0.38 [0.11-1.32]
Functional Staged CR	1.87 [0.62-5.75]	1.97 [0.60-6.22]	2.14 [0.69-7.17]	2.65 [0.76-9.51]	
Definite or Probable Stent Thrombos	sis				
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		0.77 [0.24-2.54]	0.68 [0.24-1.95]	1.39 [0.52-3.71]	0.17 [0.02-1.43]
Angio Immediate CR	1.29 [0.39-4.16]		0.88 [0.38-2.08]	1.79 [0.54-6.16]	0.22 [0.03-1.67]
Angio Staged CR	1.46 [0.51-4.17]	1.14 [0.48-2.67]		2.04 [0.61-6.90]	0.25 [0.04-1.58]
Functional Immediate CR	0.72 [0.27-1.92]	0.56 [0.16-1.86]	0.49 [0.14-1.64]		0.12 [0.01-1.12]
Functional Staged CR	5.85 [0.7-49.15]	4.51 [0.60-34.91]	4.02 [0.63-25.62]	8.10 [0.90-75.37]	
Any Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only		2.89 [1.32-5.98]	1.98 [0.84-4.48]	2.24 [1.15-4.45]	2.64 [0.80-8.58]
Angio Immediate CR	0.35 [0.17-0.76]		0.69 [0.35-1.34]	0.78 [0.34-1.86]	0.92 [0.28-3.00]
Angio Staged CR	0.50 [0.22-1.19]	1.46 [0.75-2.82]		1.13 [0.43-3.08]	1.34 [0.44-4.11]
Functional Immediate CR	0.45 [0.22-0.87]	1.29 [0.54-2.94]	0.89 [0.32-2.31]		1.18 [0.30-4.49]
Functional Staged CR	0.38 [0.12-1.25]	1.09 [0.33-3.52]	0.75 [0.24-2.30]	0.85 [0.22-3.30]	
Ischaemia-Driven Revascularization					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR

IRA-Only		3.14 [0.86-10.69]	2.53 [0.69-8.81]	2.06 [0.65-6.41]	3.29 [0.63-16.91]
Angio Immediate CR	0.32 [0.09-1.16]		0.80 [0.27-2.49]	0.65 [0.16-2.85]	1.05 [0.20-5.82]
Angio Staged CR	0.40 [0.11-1.44]	1.24 [0.40-3.77]		0.81 [0.17-3.92]	1.30 [0.29-6.00]
Functional Immediate CR	0.49 [0.16-1.53]	1.53 [0.35-6.08]	1.23 [0.26-5.79]		1.61 [0.23-10.99]
Functional Staged CR	0.30 [0.06-1.59]	0.95 [0.17-5.10]	0.77 [0.17-3.46]	0.62 [0.09-4.35]	
Major Adverse Cardiac Events					
	IRA-Only	Angio Immediate CR	Angio Staged CR	Functional Immediate CR	Functional Staged CR
IRA-Only	IRA-Only	Angio Immediate CR 1.72 [1.04-2.73]	Angio Staged CR 1.36 [0.81-2.27]	Functional Immediate CR 1.88 [1.23-2.94]	Functional Staged CR 1.31 [0.62-2.80]
IRA-Only Angio Immediate CR	IRA-Only 0.58 [0.37-0.96]	Angio Immediate CR 1.72 [1.04-2.73]	Angio Staged CR 1.36 [0.81-2.27] 0.79 [0.53-1.22]	Functional Immediate CR   1.88 [1.23-2.94]   1.10 [0.65-1.96]	Functional Staged CR 1.31 [0.62-2.80] 0.77 [0.37-1.67]
IRA-Only Angio Immediate CR Angio Staged CR	IRA-Only 0.58 [0.37-0.96] 0.74 [0.44-1.24]	Angio Immediate CR 1.72 [1.04-2.73] 1.27 [0.82-1.90]	Angio Staged CR 1.36 [0.81-2.27] 0.79 [0.53-1.22]	Functional Immediate CR   1.88 [1.23-2.94]   1.10 [0.65-1.96]   1.39 [0.76-2.62]	Functional Staged CR 1.31 [0.62-2.80] 0.77 [0.37-1.67] 0.97 [0.47-2.02]
IRA-Only Angio Immediate CR Angio Staged CR Functional Immediate CR	IRA-Only 0.58 [0.37-0.96] 0.74 [0.44-1.24] 0.53 [0.34-0.81]	Angio Immediate CR 1.72 [1.04-2.73] 1.27 [0.82-1.90] 0.91 [0.51-1.53]	Angio Staged CR 1.36 [0.81-2.27] 0.79 [0.53-1.22] 0.72 [0.38-1.32]	Functional Immediate CR   1.88 [1.23-2.94]   1.10 [0.65-1.96]   1.39 [0.76-2.62]	Functional Staged CR 1.31 [0.62-2.80] 0.77 [0.37-1.67] 0.97 [0.47-2.02] 0.70 [0.29-1.65]

Supplementary Table 68. Random-effects network meta-regression for diabetes – 3-node analysis.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.73 [1.08-2.90]	1.06 [0.57-1.94]
Immediate CR	0.58 [0.34-0.92]		0.61 [0.33-1.04]
Staged CR	0.94 [0.52-1.77]	1.64 [0.96-3.01]	
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.39 [0.93-2.24]	1.31 [0.82-2.46]
Immediate CR	0.72 [0.45-1.08]		0.94 [0.59-1.63]
Staged CR	0.76 [0.41-1.22]	1.06 [0.61-1.70]	
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.18 [0.82-1.73]	1.15 [0.74-1.94]
Immediate CR	0.85 [0.58-1.23]		0.98 [0.65-1.57]
Staged CR	0.87 [0.51-1.34]	1.02 [0.64-1.55]	
<b>Definite or Probable Stent</b>	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.05 [0.46-2.44]	0.77 [0.34-1.92]
Immediate CR	0.96 [0.41-2.15]		0.74 [0.36-1.57]
Staged CR	1.29 [0.52-2.95]	1.35 [0.64-2.77]	
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.55 [1.30-4.98]	1.92 [0.82-4.41]
Immediate CR	0.39 [0.20-0.77]		0.75 [0.37-1.52]
Staged CR	0.52 [0.23-1.23]	1.33 [0.66-2.71]	
Ischaemia-Driven Revascu	larization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.56 [0.94-6.81]	2.33 [0.74-7.09]
Immediate CR	0.39 [0.15-1.07]		0.91 [0.30-2.78]
Staged CR	0.43 [0.14-1.34]	1.10 [0.36-3.34]	
Major Adverse Cardiac Ev	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.82 [1.21-2.75]	1.45 [0.89-2.45]
Immediate CR	0.55 [0.36-0.83]		0.80 [0.52-1.24]
Staged CR	0.69 [0.41-1.13]	1.25 [0.81-1.91]	

Values are HRs [95% CrIs].

Supplementary Table 69. Random-effects network meta-regression for 3-vessel disease – 3-node analysis.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.36 [1.43-3.72]	1.18 [0.72-1.83]
Immediate CR	0.42 [0.27-0.70]		0.50 [0.30-0.83]
Staged CR	0.85 [0.55-1.39]	2.00 [1.20-3.30]	
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.33 [0.73-2.87]	1.45 [0.82-3.28]
Immediate CR	0.75 [0.35-1.37]		1.09 [0.56-2.24]
Staged CR	0.69 [0.30-1.21]	0.91 [0.45-1.80]	
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.22 [0.70-2.06]	1.26 [0.78-2.40]
Immediate CR	0.82 [0.48-1.44]		1.04 [0.62-2.00]
Staged CR	0.79 [0.42-1.28]	0.96 [0.50-1.62]	
<b>Definite or Probable Stent</b>	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		0.94 [0.36-2.38]	0.83 [0.38-1.93]
Immediate CR	1.06 [0.42-2.77]		0.89 [0.39-2.06]
Staged CR	1.21 [0.52-2.65]	1.13 [0.49-2.56]	
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.99 [1.16-7.43]	2.32 [0.84-6.21]
Immediate CR	0.33 [0.13-0.87]		0.77 [0.31-1.93]
Staged CR	0.43 [0.16-1.19]	1.29 [0.52-3.18]	
Ischaemia-Driven Revascu	larization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.71 [0.91-7.96]	2.45 [0.77-7.43]
Immediate CR	0.37 [0.13-1.10]		0.90 [0.30-2.76]
Staged CR	0.41 [0.13-1.29]	1.11 [0.36-3.30]	
Major Adverse Cardiac Ev	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.01 [1.24-3.20]	1.67 [1.03-2.78]
Immediate CR	0.50 [0.31-0.81]		0.83 [0.53-1.36]
Staged CR	0.60 [0.36-0.97]	1.21 [0.74-1.88]	

Values are HRs [95% CrIs].

Supplementary Table 70. Random-effects network meta-regression for the year of publication – 3-node analysis.

<b>Myocardial Infarction</b>			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.74 [1.16-2.63]	1.03 [0.59-1.66]
Immediate CR	0.57 [0.38-0.86]		0.59 [0.34-0.95]
Staged CR	0.97 [0.60-1.69]	1.70 [1.05-2.93]	
Cardiac Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.01 [1.24-3.20]	1.67 [1.03-2.78]
Immediate CR	0.50 [0.31-0.81]		0.83 [0.53-1.36]
Staged CR	0.60 [0.36-0.97]	1.21 [0.74-1.88]	
Death			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.18 [0.78-1.72]	1.11 [0.70-1.88]
Immediate CR	0.85 [0.58-1.28]		0.94 [0.61-1.58]
Staged CR	0.90 [0.53-1.42]	1.06 [0.63-1.63]	
Definite or Probable Stent	Thrombosis		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		1.07 [0.49-2.44]	0.80 [0.37-1.87]
Immediate CR	0.93 [0.41-2.05]		0.75 [0.37-1.57]
Staged CR	1.25 [0.54-2.68]	1.33 [0.64-2.74]	
Any Revascularization			
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.57 [1.37-4.72]	1.91 [0.88-4.11]
Immediate CR	0.39 [0.21-0.73]		0.74 [0.37-1.49]
Staged CR	0.52 [0.24-1.13]	1.35 [0.67-2.68]	
Ischaemia-Driven Revascu	larization		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.51 [0.88-6.95]	2.31 [0.70-7.48]
Immediate CR	0.40 [0.14-1.14]		0.92 [0.31-2.77]
Staged CR	0.43 [0.13-1.42]	1.09 [0.36-3.26]	
Major Adverse Cardiac Ev	vents		
	IRA-Only	Immediate CR	Staged CR
IRA-Only		2.51 [0.88-6.95]	2.31 [0.70-7.48]
Immediate CR	0.40 [0.14-1.14]		0.92 [0.31-2.77]
Staged CR	0.43 [0.13-1.42]	1.09 [0.36-3.26]	

Values are HRs [95% CrIs].

Supplementary Table 71. Frequentist random-effects pairwise metaanalysis for complete versus IRA-only revascularisation.

Endpoint	HR [95% CI]	$\mathbf{I}^2$	$ au^2$
Myocardial Infarction	0.72 [0.56-0.91]	43%	0.038
Cardiac Death	0.76 [0.61-0.97]	13%	0.072
Death	0.88 [0.72-1.09]	25%	0.021
Definite or Probable Stent Thrombosis	1.04 [0.55–1.94]	29%	0.099
Any Revascularization	0.41 [0.28-0.60]	82%	0.205
Ischaemia-Driven Revascularization	0.41 [0.24–0.68]	84%	0.278
Major Adverse Cardiac Events	0.58 [0.46-0.73]	78%	0.070

CI = Confidence Interval; HR = Hazard Ratio.

Supplementary Table 72. Bayesian random-effects pairwise metaanalysis for complete versus IRA-only revascularisation.

Endpoint	HR [95% CrI]	$\mathbf{I}^2$	$\tau^2$
Myocardial Infarction	0.71 [0.48-0.97]	43%	0.038
Cardiac Death	0.74 [0.46–1.04]	13%	0.072
Death	0.88 [0.66-1.16]	25%	0.021
Definite or Probable Stent Thrombosis	1.04 [0.47-2.07]	29%	0.099
Any Revascularization	0.41 [0.25-0.70]	82%	0.205
Ischaemia-Driven Revascularization	0.41 [0.19-0.89]	84%	0.278
Major Adverse Cardiac Events	0.58 [0.42-0.79]	78%	0.070

CrI = credible interval; HR = Hazard Ratio.

Supplementary Table 73. Frequentist random-effects pairwise metaanalysis for periprocedural outcomes for complete versus IRA-only revascularisation.

Endpoint	OR [95% CI]	$\mathbf{I}^2$	$\tau^2$
Stroke	1.27 [0.92–1.75]	0%	0.000
Contrast-Induced Acute Kidney Injury	1.15 [0.93–1.41]	0%	0.000
Major Bleeding	1.08 [0.84–1.38]	0%	0.000

CI = Confidence Interval; OR = Odds Ratio.
Supplementary Table 74. Bayesian random-effects pairwise metaanalysis for periprocedural outcomes for complete versus IRA-only revascularisation.

Endpoint	OR [95% CrI]	$\mathbf{I}^2$	$\tau^2$
Stroke	1.29 [0.70 – 2.71]	0%	< 0.001
Contrast-Induced Acute Kidney Injury	1.15 [0.63 – 1.85]	0%	0.000
Major Bleeding	1.02 [0.61 - 1.45]	0%	0.010

CrI = Credibile Interval; OR = Odds Ratio.

## Supplementary Figure 1. Screening and selection process.



## Supplementary Figure 2. Individual trial risk of bias.

<u>Unique ID</u>	<u>Study ID</u>	<u>Weight</u>	<u>D1</u>	<u>D2</u>	<u>D3</u>	<u>D4</u>	<u>D5</u>	<u>Overall</u>		
1	BIOVASC	1	+	!	+	•	+	!	•	Low risk
2	COCUA	1	+	!	+	•	+	•	!	Some concerns
3	COMPARE-ACUTE	1	!	+	+	+	+	!	•	High risk
4	COMPLETE	1	+	!	+	+	+	!		
5	CROSS-AMI	1	!	!	+	+	+	!	D1	Randomisation process
6	CvLPRIT	1	+	+	+	+	+	!	D2	Deviations from the intended interventions
7	DANAMI-3 PRIMU	Ľ 1	+	!	+	+	+	!	D3	Missing outcome data
8	FIRE	1	+	!	+	+	+	!	D4	Measurement of the outcome
9	FLOWER-MI	1	+	!	+	+	+	!	D5	Selection of the reported result
10	FRAME-AMI	1	+	+	+	+	+	+		
11	MULTISTARS AMI	1	+	+	+	•	+	•		
12	PRAMI	1	+	!	+	+	+	!		
13	SMILE	1	!	+	+	+	+	!		
14	FULL REVASC	1	+	!	+	+	+	!		

Supplementary Figure 3. Cumulative risk of bias.



## Summary of RoB 2.0 assessments